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You can travel the world
But you can’t run away
From the person you are in your heart
You can be who you want to be
Make us believe in you
Keep all your light in the dark
If you’re searching for truth
You must look in the mirror
And make sense of what you can see
Just be
Just be
They say learning to love yourself
Is the ﬁrst step
That you take when you want to be real
Flying on plains to exotic locations
Won’t teach you
How you really feel
Face up to the fact
That you are who you are 
And nothing can change that believe
Just be
Just be
Cause now I know
Is not so far
To were I go
There’s not this spot
Since this I feel
I need
To just be
Just be
I was lost
And I’m still lost
But I feel so much better
Tiesto featuring Kirsty Hawkshaw – Just Be
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ABP  actin binding protein
acc.nr.  accession number
ALP  alpha-actinin-associated LIM protein
APC   adenomatous polyposis coli
AR  androgen receptor
Arg   arginine 
ARVCF   armadillo repeat gene deleted in velo-cardio-facial syndrome
Asn  aspartate 
BP75   bromodomain-containing protein 75
BSA   bovine serum albumin
CaMKII  calcium/calmodulin-dependent protein kinase II
CASK   calcium/calmodulin-dependent serine protein kinase
CDK2   cyclin-dependent kinase 2
CFTR  cystic ﬁbrosis transmembrane conductance regulator
CKI  casein kinase I
CLSM  confocal laser scanning microscopy
CRIB   CDC42/Rac1 interactive binding
CRIP2   cysteine-rich protein 2
CSI   chemical shift index
CSK   c-terminal Src kinase
C-terminal  carboxyl terminal
Cys   cysteine 
DEAE   diethylaminoethyl 
DNA   deoxyribonucleic acid
DTT   dithiothreitol 
Dvl-1   dishevelled 1
EBFP   enhanced blue ﬂuorescent protein
EBP50   ERM-binding phosphoprotein of 50 kDa
EDTA   ethylenediaminetetraacetic acid
EGFP   enhanced green ﬂuorescent protein 
ephrin   eph family receptor interacting
ER   endoplasmic reticulum
Erbin  Erb-interacting
FACS  ﬂuorescence activated cell sorting
FCS  fetal calf serum
FERM  acronym of band 4.1, ezrin, radixin and moesin
GFP  green ﬂuorescent protein
Gly  glycine 
GRIP1  glutamate receptor interacting protein 1
GSK-3β  glycogen synthase-3β
GST   glutathione-S-transferase
H2O2  hydrogen peroxide
HeLa   Henrietta Lack
HPV   human papilloma virus
HSQC   heteronuclear single quantum coherence
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IKEPP  intestinal and kidney epithelial-enriched PDZ protein
IL5R  interleukin-5 receptor
Ile   isoleucine 
InaD  inactivation no afterpotential D
IPTG  isopropyl-beta-D-thiogalactopyranoside
KD   apparent dissociation constant
KIF1C   kinesin-like protein
KIND   kinase non-catalytic C-lobe
Kir2.3   inward rectiﬁer potassium channel
Kpm   kinase phosphorylated during mitosis
L27   heterodimerization domain found in receptor targeting proteins 
  Lin-2 and Lin-7
Lats   large tumour suppressor
Leu   leucine 
LIM   acronym of Lin-11, Isl-1 and Mec-3
LIMK1   LIM-kinase 1
MAGI-3  membrane-associated guanylate kinase-related
NDR   nuclear Dbf2-related
NHERF  Na+/ H+ exchanger regulatory factor
NMDA   N-methyl-D-aspartate 
NMR   nuclear magnetic resonance 
nNOS   neuronal nitric oxide synthase
NOESY  nuclear Overhauser enhancement spectroscopy
NorpA   no receptor potential A
NR2A   NMDA receptor 2A
N-terminal  amino terminal
p55   protein of 55 kDa
p75NTR  p75 neurotrophin receptor
Pals1   protein associated with lin seven-1
PAPIN   plakophilin-related armadillo repeat protein-interacting PDZ protein
Par-6   partitioning defective 6
PARG   PTPL1-associated Rho-GAP
PBS   phosphate buffered saline
PCR   polymerase chain reaction
PDB   protein database bank
PDZ   acronym of PSD-95/SAP90, Discs-large and ZO-1
PFA   paraformaldehyde
PH   pleckstrin homology
PHEM   Pipes, HEPES, EGTA, MgCl2
PI   propidium iodide
PIP2   phospholipidphosphatidylinositol 3,4-biphosphate
PKC   protein kinase C
PMSF   phenyl methyl sulfonyl ﬂuoride
PRK2   protein kinase C-related kinase 2
PSD-95   post synaptic density 95
PTB   phosphotyrosine binding
PTP  protein tyrosine phosphatase
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PTP-BAS  protein tyrosine phosphatase-basophile
PTP-BL  protein tyrosine phosphatase BAS-like 
pTyr   phosphotyrosine
PX   Phox homology
Redox   reducing and oxidizing  
RIL   reversion-induced LIM gene 
RNA   ribonucleic acid
ROS   reactive oxygen species
SA   streptavidin
SAP97   synapse associated protein 97kd
SDS  sodium dodecyl sulfate
SDS-PAGE  SDS-polyacrylamide gel electrophoresis
SEM   standard error of the mean
Ser   serine
SFKs   Src family kinases
SH2   Src homology region 2
SMART  simple modular architecture research tool
SPBS   saponine in PBS
SPR   surface plasmon resonance
TBS   tris buffered saline
TBS-T   TBS with Tween
Thr   threonine 
TRIP6   thyroid receptor interacting protein 6
Trp   tryptophan
Val   valine 
VSV   vesicular stomatitis virus
WT   wild type
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Chapter 1
General Introduction
General  introduction
Proper interpretation of external and internal stimuli, tight regulation of biochemical 
reactions and control of cellular dynamics in living organisms all require a precise 
spatial and temporal organization of the involved compounds into multi-molecular 
machines. It will therefore come as no surprise that abnormal assembly and dis-
assembly of such biocomplexes can lead to improper cell functioning, eventually 
resulting in pathologies like oncogenesis (1,2). Detailed knowledge on protein inter-
action characteristics is therefore essential in order to understand the cellular proc-
esses occurring in health and disease. In this thesis, focus will be on the interaction 
capacities as displayed by ﬁve so-called PDZ protein domains within PTP-BL, a 
large intracellular enzyme with protein tyrosine phosphatase activity. Results ob-
tained provide insight into the binding preferences of the PTP-BL PDZ domains and 
reveal cooperative and regulatory effects on PDZ-target binding. Before presenting 
an outline of this thesis, relevant protein interaction domains – most notably the PDZ 
domain – and cell biological data on the phosphatase PTP-BL will be discussed. 
Protein signalling complexes
Research over the past decade has identiﬁed many types of protein-protein interac-
tions that participate in intracellular signalling pathways (3). A common feature of 
these pathways is the involvement of several types of small protein domains (<100 
residues) whose sole function is to recognize sequence motifs presented by other 
members of the signalling cascade (4). Single proteins may contain, in addition to 
enzymatically active domains, multiple copies of distinct protein interaction mod-
ules, permitting the formation of large multi-subunit signal transducing complexes. 
There are even proteins that solely consist of protein interaction modules and may 
be considered adapters or scaffolds on which other active components of a signalling 
pathway are brought into proximity (5). In Figure 1, examples of such modulatory 
proteins are depicted, including some that will reappear in this thesis later on.
 Importantly, several of the protein interaction modules are themselves sub-
ject to protein posttranslational modiﬁcations or act as recognition modules for small 
molecules that act as second messengers. The paradigm example is the Src homol-
ogy region 2 (SH2) domain that, like the phosphotyrosine binding (PTB) domain (6), 
interacts with phosphotyrosine (pTyr) sites formed by the actions of tyrosine kinase 
enzymes (7). Likewise, pleckstrin homology (PH), Phox homology (PX), and FYVE 
domains can target proteins to speciﬁc cellular sites upon production of the appropri-
ate phospholipid by phosphoinositide kinases (8-10).
 Protein domains can also be important in directing the entire protein to its 
proper location within the cell. For instance, FERM domains (originally found in 
the members of the band 4.1 and ERM (ezrin, radixin, moesin) family cytoskel-
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etal proteins) are involved in the localization of proteins to the plasma membrane 
(11). Likewise,  ERM domains associate with membrane-spanning molecules such 
as CD44 and thereby mediate linkage between the plasma membrane and the actin 
cytoskeleton (12). Not all domains of one given class behave similarly, however, as 
exempliﬁed by the FERM domain of PTPD1, which associates with the microtubule 
motor protein KIF1C and thereby localizes to ER-golgi like subcellular structures 
(13). This preludes on the variability in binding properties that FERM domains may 
display. 
Figure 1: Schematic overview of some representative interaction domain-containing proteins. 
The protein domain build-up of various proteins, as extracted from the SMART database, is 
depicted. Protein entries used are; GRIP1, Q6GQT7; Syntenin, O08992; DLG3, O88910; 
PSD-95, Q62108; PTP-BL, Q64512; CASK, O70589; RIL, P70271; TYK2, Q9R117; HCK, 
P08103 and Lats2, Q7TSJ6. PDZ domains are depicted by grey octagonals. The SH3 and 
SH2 domains are indicated by light and dark grey triangles. Gyanylate kinase, tyrosine/ser-
ine/threonine kinase, serine/threonine kinase, tyrosine kinase domains are depicted by white, 
light grey, dark grey and black pentagonals respectively. Additional domains include L27 
(grey ellipsoid), KIND (grey oval), FERM (white rectangle), PTP (white octagonal), LIM 
(black rectangle) and kinase extension domain (grey rectangle).
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 Another recently identiﬁed module that will be discussed in this thesis, is the 
kinase non-catalytic C-lobe (KIND) domain, which shows homology to the regula-
tory C-lobe of protein kinases (14). Its presence at the N-terminus of signalling pro-
teins and the absence of the active-site residues in the catalytic and activation loops 
suggest that it folds independently and is likely to be non-catalytic. The function of 
this domain is currently unknown but a role in mediating protein-protein interactions 
has been suggested.
 Currently, altogether close to ﬁfty different protein interaction domains have 
been identiﬁed (http://www.mshri.on.ca/pawson/domains.html) but, given the cur-
rent efforts to reveal the complete coding potential of genomes of a wide variety 
of species this number will undoubtedly rise in the coming decades. Also the stud-
ies of the composition of cellular protein complexes using proteomics and mass 
spectrometric techniques will contribute to our knowledge on the structure-function 
relationship of protein domains. Among this plethora of protein-interaction domains, 
the PDZ protein module is amongst the most common encountered in sequenced 
genomes (http://smart.embl.de (15)).
PDZ domains
PDZ domains are protein modules of about 90 amino acids and are named after 
the three proteins in which they were ﬁrst recognized (the synapse-associated pro-
tein PSD-95/SAP90 (16), the septate junction protein Discs-large (17), and the tight 
junction protein ZO-1 (18); for review see (19)). Database searches identify PDZ 
domain-containing proteins in organisms ranging from bacteria (5 in E.coli) to hu-
mans (1163 occurrences in 484 proteins). They are mostly found in membrane-asso-
ciated proteins but mitochondrial, nuclear and extracellular examples have also been 
reported. PDZ domains contribute to the speciﬁcity of cellular signalling events by 
selectively interacting with C-terminal polypeptides.
 The common structure of PDZ domains comprises six β-strands (denoted 
as βA-βF) and two α-helices (denoted as αA and αB), which fold in an overall six-
stranded β sandwich (Figure 2) (20,21). The N- and C-terminus of a PDZ domain are 
positioned in close proximity of each other at the opposite side of the peptide-bind-
ing cavity, an ideal setting for a globular protein interaction domain. Three structural 
elements make up the peptide binding groove, i.e. the two secondary structure ele-
ments αB and βB, and the carboxylate binding loop (GLGF motif) located between 
βA and βB (20). While the carboxylate binding loop is important for binding to the 
C-terminal carboxylate group of the target peptide, amino acids from αB and βB are 
known to make contacts at positions P-1 to P-3 of the target peptide. As a result, the 
target peptide is bound and stabilized in an antiparallel β-sheet conformation (20). 
Mutations that localize to any of these structural elements alter the C-terminal target 
speciﬁcity of PDZ domains (22). 
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Peptide recognition
Peptide library studies indicate that most of the recognition determinants are located 
within the ﬁnal four amino acids, and that termination with a speciﬁc C-terminal 
residue (P0 position) is required for recognition (23). This carboxylate amino acid 
residue is oriented in such a way that its side chain is projected into the hydrophobic 
pocket of the PDZ domain. Most PDZ domains show a preference for a hydrophobic 
residue at this position, and variations in amino acid content of the PDZ binding 
pocket probably determines distinct preferences for valine, leucine of isoleucine at 
the extreme end of the peptide ligand. In contrast, PDZ-interacting peptides ending 
with a negatively charged acidic (aspartic or glutamic acid) residue (24) or with the 
polar cysteine residue (25,26) have also been described. Apart from the carboxyl 
residue, the binding speciﬁcity of the PDZ domain is also crucially dependent on the 
nature of the amino acid residue at the P-2 position. The side chain of this residue 
interacts with the ﬁrst residue of the αB helix (αB1). This speciﬁc interaction is gen-
erally used in the classiﬁcation of PDZ domains and their cognate ligands (discussed 
below). 
 The crystal structure of the third PDZ domain of PSD-95/SAP90 in complex 
with a peptide ligand showed that the side chain of the residue at the P-1 position is 
Figure 2: The topology of a PDZ domain. The secondary structures are labelled sequentially 
according to their position relative to the N-terminus. Rectangular cubes represent β-strands 
while cylinders represent α-helices. Ligands (white arrow) canonically bind in between the 
βB strand and αB helix. The L1 and carboxyl loops are also indicated (courtesy of Tine 
Walma). 
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exposed from the binding surface and does not participate in the formation of hydro-
gen bonds (20). Recent experiments, however, do show involvement of this residue 
in determining speciﬁcity of PDZ domains. For instance, PDZ domains of both LIN-
2 and p55 bind peptides of which all three terminal residues are hydrophobic, includ-
ing aromatic side chains at both P-1 and P-2 (23). Phage display techniques revealed 
that the second PDZ domain of MAGI-3 selects peptides containing a Trp residue 
at the P-1 position and that its side chain is critical for high afﬁnity binding (27). A 
completely different function for the P-1 residue is revealed in the crystal structure of 
the InaD N-terminal PDZ domain in complex with its ligand (28). In this particular 
case, the interaction between both proteins is not reﬂecting canonical, non-covalent 
peptide-PDZ binding but rather involves an intermolecular disulﬁde bond formation 
between a cysteine residue at P-1 within the peptide and a cysteine residue within the 
βB element of the PDZ domain. 
 Residues downstream of the P-2 position are also described to be involved in 
PDZ domain interactions (23). For instance, the phenolic ring of the tyrosine residue 
at the P-7 position within the ErbB2 C-terminus enters into a pocket formed by the 
extended βB-βC loop (L1; Figure 2) of the Erbin PDZ domain (29). Several PDZ 
domains of PSD-95 and - of relevance for this thesis - the second PDZ domain of 
PTP-BL also show such an extended βB-βC loop that is involved in ligand interac-
tions (30-33). 
 The apparent requirement for a ligand with a free terminal carboxylate group 
has led to the proposal that electrostatic interactions of residues within the PDZ car-
boxylate binding loop with the ligand C-terminus play a signiﬁcant role in recogni-
tion. However, this model has been called into question by the more recent ﬁnding 
that PDZ domains can recognize some internal peptide motifs that occur within a 
speciﬁc structural context (34,35). Although these internal peptide motifs obviously 
lack the negatively charged terminal carboxylate, they do bind to the same PDZ 
interface with comparable binding afﬁnities (34). Moreover, a structural study sug-
gests that direct electrostatic interactions do not play a signiﬁcant energetic role in 
binding to the carboxyl-terminus (36). The current understanding therefore includes 
that steric- and hydrogen bonding-complementarities are the main determinants for 
PDZ domain speciﬁcity.
Peptide classiﬁcation
In an attempt to classify PDZ preferences for individual C-terminal target peptides, 
four different peptide-classes were introduced (Table I (adapted from (37)). In this 
manner, PDZ domains were grouped on the basis of the nature of the residues at the 
P0 and P-2 position in the target peptide. The majority of the PDZ domains recognize 
ligands that have either a serine or threonine residue at the P-2 position (class I). 
These PDZ domains posses a hydrophilic pocket, where residues of the βB strand 
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and αB helix (in particular a highly conserved histidine at position αB1) are in-
volved in contacting the P-2 residue of the peptide ligand. Most of the remaining 
PDZ domains recognize a varied class of ligand peptides characterized by aromatic 
or hydrophobic residues at position P-2 (class II). Again, the side chain of the P-2 
residue exhibits hydrogen bond formation with the αB1 residue of the PDZ domain, 
whereas the main chain forms hydrogen bonds with the βB strand of the PDZ do-
main. Only a few PDZ domains bind to yet another group of peptide ligands that 
expose a negatively charged amino acid residue at the P-2 position (class III). Equally 
rare is the binding of PDZ domains to ligands of class IV that have the peculiarity of 
carrying a negatively charged residue at the P0 position instead of the almost invari-
ant hydrophobic residue. 
 Initially, almost all C-terminal peptides known to associate with PDZ do-
mains could be grouped within these four classes, but the number of PDZ target 
peptides that do not ﬁt the above classiﬁcation is steadily growing (25). Therefore, 
a second method to classify PDZ domains was proposed, this time based upon the 
type of residue present in two contact positions of the binding pocket, βB5 and αB1 
(38). The importance of these two positions in PDZ domain ligand recognition had 
arisen from the crystal structure of the CASK PDZ domain in complex with its class 
II-type peptide ligand (39). This structure revealed the presence of a second hydro-
phobic pocket that had not been observed in structures of PDZ domains complexed 
with class I ligands. In total, 25 groups of PDZ domains were deﬁned and correlated 
to experimentally determined ligands.
 Both classiﬁcation methods have their advantages and disadvantages (as dis-
cussed in (37,40)). The ﬁrst method is deﬁnitely a safe approach, but unfortunately 
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Table I: Classiﬁcation of PDZ domains.
Pos.  Consensus
    [S/T]XФ*     [Ф/ψ]XФ*     [D/E]XV*     Xψ[D/E]*
    class I       class II      class III     class IV
P0   HYDROPHOBIC/AROMATIC  HYDROPHOBIC/AROMATIC  HYDROPHOBIC/AROMATIC   NEGATIVE OR #
P-1  ANY (Trp or Asp)      ANY (Trp or Asp)      ANY                    AROMATIC
P-2  Ser or Thr            HYDROPHOBIC/AROMATIC  NEGATIVE               ANY
P-3  ANY (Glu)             ANY (Glu)             Gly or Glu             ANY
PDZ domain ligands can be distinguished on the basis of residues at position P-2 (classes I to 
III) or position P0 (class IV). Residues in brackets are the most abundant at that position. Ф: 
hydrophobic; ψ: aromatic; *: COOH-terminus; #: any residue different from Ф/ψ. Classiﬁca-
tion is according to (37).
every newly identiﬁed peptide target that does not ﬁt the existing proﬁles would 
require expansion, or at least revision, of the classiﬁcation scheme. Furthermore, the 
method does not have any predictive power: the speciﬁcity of a given PDZ domain 
must ﬁrst be identiﬁed experimentally. The second method does allow the prediction 
of binding speciﬁcity but, being solely based on the chemical properties of just two 
crucial residues within the PDZ domain, it will probably not sufﬁce to describe the 
complex and sometimes promiscuous binding characteristics of PDZ domain fam-
ily members. Ultimately, the gradual expansion of domain/ligands structural and 
biochemical information will lead to a better understanding of PDZ domain - target 
interaction modes and concomitantly to the further improvement of classiﬁcation 
and prediction schemes.
Non-canonical binding modes
A growing number of manuscripts report on PDZ domain binding to internal motifs 
that are markedly different from the canonical carboxyl terminal peptides. One of the 
ﬁrst cases dealt with an apparent hetero-dimerization capacity of PDZ domains, but 
later on this turned out to reﬂect the binding of a PDZ domain to a so-called β-ﬁnger 
immediately following the heterologous PDZ domain (35,41). In addition, interac-
tions that appear distinct from both the canonical and the apparent PDZ/PDZ binding 
mode have been reported. For instance, an N-terminal PDZ target sequence has been 
identiﬁed in Kv1 potassium channels (42). Furthermore, the PDZ domain of mDvl-
1 shows a preference for the internal sequence motif KTXXXφ (where φ stands for 
any hydrophobic residue) (43,44). Other proteins bind PDZ domains by mechanisms 
that are not yet understood. For instance, the PDZ domain of the actinin-associated 
LIM protein, ALP, binds to the internal spectrin repeats of α-actinins (45,46) and the 
ﬁrst PDZ domain in human PTP-BL binds to ankyrin repeats within the transcription 
factor-inhibitory protein IκBα (47).
 All the above-mentioned binding modes have in common that the ligands 
appear to be bound by the hydrophobic binding groove formed by αB and βB on the 
PDZ domain. The participation of additional PDZ domain surface areas in protein 
interactions, however, has also been reported. One of the PDZ domains in GRIP1 
uses a large solvent-exposed hydrophobic surface located between αB and βE to in-
teract with its ligand (48). The corresponding PDZ domain structure reveals a closed 
carboxyl group-binding pocket and a narrow αB/βB-groove that is unlikely to bind 
classical ligands. Similarly, a novel surface outside the binding-groove is shown to 
mediate self-dimerization of another PDZ domain (49). The dimeric interface be-
tween the two PDZ domains involves the βA strand and the αA/βD loop from each 
protomer (see Figure 2). The crystal structure of this PDZ domain revealed that it 
is capable of dimer formation both in its free and in its ligand-bound state. Further-
more, the canonical peptide binding pockets are located at the distal sides of the 
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dimeric interface, situated in anti-parallel fashion, facilitating independent binding 
of peptide ligands for both PDZ monomers.
Phosphorylation-dependent interactions of PDZ domains
Interaction of C-terminal targets with PDZ domains can also be inﬂuenced by the 
phosphorylation status of certain residues within the C-terminal peptide. Phospho-
rylation of a serine residue at the P-2 position in both Kir2.3 and β2-adrenergic re-
ceptor is described to disrupt the interaction between this residue and the histidine 
residue within the αB helix of the interacting PDZ domain in SAP97 and EBP50, re-
spectively (50-52). In contrast, phosphorylation of a serine residue at the P-3 position 
was found not to abolish but rather enhance the binding of the C-terminal tail of the 
ABC protein MRP2 to PDZ domains in IKEPP and EBP50 (53). This phenomenon 
is reminiscent of the ﬁnding that a negatively charged residue at P-3 stabilizes the 
interaction by a salt bridge with a positively charged, conserved amino acid within 
the PDZ domain (20,54). 
 This regulation of PDZ-mediated associations through reversible phospho-
rylation does not exclusively reﬂect the posttranslational modiﬁcation of the PDZ-
ligands; also examples of phosphorylation of PDZ domains themselves have been 
encountered. In the case of NHERF, simultaneous binding of both PDZ domains 
to the CFTR channel increases the channel’s open probability (Po). Interestingly, 
phosphorylation of Ser-162 in the PDZ2 domain of NHERF by PKC disrupts this 
stimulatory effect on CFTR channel Po (55). Another example is the direct interac-
tion between SAP97 PDZ1 and the NR2A NMDA subunit. The dynamic association/
dissociation of this complex is modulated via CaMKII-dependent phosphorylation 
of Ser-232 in the SAP97 PDZ1 domain (56). 
Promiscuity of PDZ domains
In the previous sections I already preluded on the current notion that PDZ domain 
interactions reach beyond the canonical C-terminal targets. Their binding character-
istics are further complexed by the discovery that some PDZ domains show multiple 
speciﬁcities, and as yet there is no general model that can account for this. Probably 
one of the best examples is the syntenin protein, since its PDZ domains bind to at 
least 10 different protein partners, including class I (57), class II (58) and even class 
III peptides (59). Furthermore, also the phospholipid PIP2 ﬁts their binding groove 
(60). Such a diversity of interactions could reﬂect degenerate speciﬁcity, but in this 
case it implies cooperative effects between the two PDZ domains.
 Initially puzzled by the observed PDZ binding promiscuity, Kang et al. pro-
posed that perhaps a more structural epitope rather than a sequence motif is important 
in PDZ interactions (61). Their hypothesis originated from the following observa-
tions. Syndecan binds the syntenin-PDZ domain mainly by residues at the P-1 and P-2 
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position, while IL5Rα interacts through residues at the P0 and P-1 position (Figure 
3A and B). Then, there is the situation of the β-hairpin ﬁnger just following the PDZ 
domain of the neuronal nitric oxide synthase isoform nNOS, that essentially mimics 
a canonical C-terminal PDZ-binding motif (35) and is bound by the PDZ domains of 
PSD-95 and α1-syntrophin (41) (Figure 3C). Yet another intriguing binding strategy 
is displayed by the syntenin PDZ2-PDZ2 interaction where the residues at the P0 and 
P-3 positions in the C-terminus of one domain dock into the peptide binding groove 
of the other (Figure 3D). It should be noted, however, that the latter interaction re-
ﬂects the binding of a non-physiological, experimentally imposed syntenin PDZ2 C-
22
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Figure 3: Schematics of the various PDZ domain interactions. Normally, C-terminal targets 
bind to residues of the PDZ domain present at the S0 and S-2 positions. However, exceptions 
do exist in which (A) C-terminal binding depends on the binding at S-1 and S-2 of the PDZ 
domain as seen in PDZ2-syndecan-4 peptide complex or (B) C-terminal binding depends on 
the binding to residues present at the S0 and S-1 position as seen in syntenin PDZ2-interleukin 
5 receptor α-subunit peptide complex. (C) Other types of binding involve binding of PDZ 
domains to internal protein domains as observed for syntrophin PDZ which binds to residues 
from β-ﬁnger conformation of nNOS. (D) Alternatively, PDZ binding can depend on an in-
ternal residue that binds to the residue present at the S-2 position of the PDZ domain, while 
C-terminal residues of the target binds the PDZ domain at the S0 position, as seen in syntenin 
PDZ2-PDZ2 interaction. Adapted from (61).
terminus. New structures of PDZ domains in complex with bona-ﬁde targets, crucial 
for broadening our understanding of PDZ domain binding capabilities, are therefore 
eagerly awaited. Most notably, structural studies on PDZ-target complexes that do 
not reﬂect the canonical binding mode, i.e. C-terminus recognition, but rather con-
tain alternative interactions will be of great interest.
The protein tyrosine phosphatase PTP-BL
Multiple PDZ domains that display conspicuous promiscuity in their associative ca-
pacity can be found in the protein tyrosine phosphatase PTP-BL. Before embarking 
upon the multitude of interactions that have been reported for these ﬁve PTP-BL 
PDZ domains, the composition and function of PTP-BL will be discussed ﬁrst. 
 Together with protein kinases, the protein phosphatases determine the phos-
phoprotein levels within the cell and, as a consequence, virtually all cellular proc-
esses (62). PTP-BL (Protein Tyrosine Phosphatase BAS-Like, the mouse orthologue 
of human PTP-BAS) is a member of the cytosolic PTP subfamily (63,64). The enzy-
matic activity of the C-terminal PTP domain of PTP-BL has been demonstrated for 
several substrates thus far. These proteins include IκBα and EphrinB, which have 
been shown to serve as in vivo substrates using transfected cell lines (47,65). Fur-
thermore, β-catenin, RIL and c-Src have been shown to be dephosphorylated by the 
PTP-BL phosphatase domain in vitro (65-67). Additionally, in this thesis in Chapter 
5 it is shown that also the Lats2 kinase can serve as an in vitro substrate for PTP-BL. 
In addition to its carboxyl-terminal catalytic phosphotyrosine phosphatase domain, 
PTP-BL consists of an intriguing collection of protein interaction domains (Figure 
1). The N-terminal two hundred amino acids represent a KIND domain, which is 
presumed to be involved in protein-protein interactions (14) although experimental 
evidence is as yet lacking. The following three hundred amino acids of PTP-BL can-
not be matched to any currently identiﬁed protein domain but this part is essential for 
its targeting to the midbody and centrosomes during cell cycle progression, probably 
through association with microtubular structures (68). The FERM domain is located 
C-terminal of the KIND domain and is responsible for the proper localization of 
PTP-BL to the apical membrane in polarized epithelial cells (69) and submembra-
nous localisation in neuronal cells (70). In mitotic cells the PTP-BL FERM domain 
mediates the localisation at the contractile ring during cytokinesis, through direct 
or indirect binding to the actin microﬁlaments (68). In the human orthologue, PTP-
BAS, the FERM domain was also shown to be a crucial determinant in the intracel-
lular targeting of PTP-BAS to the plasma membrane and it was suggested that this 
association is driven by the interaction of the PTP-BAS FERM domain with PIP2 
(71). However, this is disputed by others who failed to demonstrate a signiﬁcant 
interaction of PTP-BAS with PIP2, but rather demonstrated that a PDZ-mediated 
interaction with the PIP2-binding adaptor protein TAPP1 may be responsible for the 
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localization of PTP-BAS (72).
 Finally, in the more than thousand amino acid residues in between the FERM 
domain and the phosphotyrosine phosphatase (PTP) domain of PTP-BL, ﬁve PDZ 
domains have been identiﬁed. Intriguingly, PDZ domains 2 and 3 as well as PDZ 
domains 4 and 5 in PTP-BL are clustered as head-to-tail tandems, a grouping that 
is frequently observed in multi-PDZ proteins (Figure 1). The numerous interactions 
that have been documented for these ﬁve PTP-BL PDZ domains are listed in Table 
II and will be discussed in detail later on.
PTP-BL function
Initially, a possible role for PTP-BL was suggested on the basis of its tissue-speciﬁc 
and subcellular expression pattern (73), but the list of functional implications has 
expanded as a consequence of the growing number of candidate interacting proteins 
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Table II: PTP-BL PDZ interactions.
PDZ  ligand   motif/domain   classiﬁcation    reference
1     BP75     -PDAS*           unclassiﬁed       (82)
      IκBα     ankyrin repeat   internal domain   (47)
2     p75NTR   -TSPV*           class I           (84)
      hFAS     -QSLV*           class I           (85)
      TRIP6    -TTDC*           class I           (87,89)
      APC      -VTSV*           class I           (66)
      RIL      -VELV*           class III         (67)
      PIP2              unclassiﬁed       (60)
3     PRK2     -ADWC*           class III         (26)
      PIP2           unclassiﬁed       (60)
4     EphrinB  -YYKV*           class II          (83)
      Lats2    -PVYV*           class II          (91)
      RIL      -VELV*           class III         (67)
      CRIP2    LIM domain       internal domain   (88)
      PARG     -PQFV*           unclassiﬁed       (86)
5     PIP2            unclassiﬁed       (60)
PDZ numbers in PTP-BL are indicated on the left. PDZ ligands are listed according to their 
names and their interacting motifs are indicated as sequence motifs using single amino acid 
numbering (* COOH tail) or as entire protein domain name. Classiﬁcation, when possible, is 
according to (37) and references are indicated on the right. 
(summarized in (74)) and currently contains contributions to cellular processes rang-
ing from proliferation (68), differentiation (73), and cell death (75,76). The latter 
was coined on the basis of a direct interaction with the human Fas receptor, but this 
could not be conﬁrmed in mouse. Still, PTP-BAS is thought to play a negative role 
in the regulation of the cell surface expression of the human Fas receptor, a member 
of the tumour necrosis factor receptor superfamily (77,78). Also, a possible role for 
PTP-BAS/PTP-BL in regulation of cytokinesis, the last step of mitosis dividing the 
cell into two parts after chromosome segregation, has been reported (68). In cells 
overexpressing PTP-BAS/PTP-BL, an accumulation of PTP-BAS/PTP-BL at the 
spindle midzone and contractile ring is observed during anaphase, interfering with 
its contraction and eventually leading to multinucleated cells. Additionally, involve-
ment of PTP-BL in the control of the meiotic cell cycle has been demonstrated by 
speciﬁc RNA interference in Xenopus (79). Downregulation of the PTP-BL mRNA 
produces a meiotic blockade, which can be overcome by cdc25. 
 The dynamic pattern of expression of the PTP-BL gene during the develop-
ment of the peripheral nervous system, combined with the localization pattern of 
transgenic PTP-BL β-galactosidase fusion protein, suggested that it may function in 
the regulation of the cytoskeleton during neurite outgrowth (73). These in situ data 
(73,80), together with coexpression studies in growth cones (65), support the idea 
that PTP-BL and ephrinB ligands act in concert in guiding peripheral axons during 
development. Binding of ephrinB to its receptor (EphB) causes rapid recruitment of 
Src family kinases (SFKs) to ephrinB expressing domains and transient SFK activa-
tion. Interestingly, PTP-BL is able to dephosphorylate ephrinB and inactivate SFKs, 
causing a switch in downstream signalling (65). 
 Intriguingly, mice that carry a mutant PTP-BL gene that encodes a protein 
that lacks phosphatase activity but has retained its anchoring and scaffolding poten-
tial, appeared normal in their overall morphology, behaviour, fertility, and life span 
(81). However, a small but signiﬁcant impairment of sciatic motor nerve function 
recovery was observed in these PTP-BL∆P/∆P animals following nerve lesioning. 
This suggests that the enzymatic function of PTP-BL can be compensated for by 
other PTPs in these mice, and that the more unique biological function of PTP-BL 
may address its anchoring potential. It is of relevance, therefore, to review the list of 
proteins that up to now have been reported to be potential targets of PTP-BL PDZ 
domains. 
PTP-BL PDZ domain interactions
The proteins known to interact with one or more PDZ domains of PTP-BL are listed 
in Table II. PDZ1 of PTP-BL is able to interact with both the bromodomain-con-
taining protein BP75 and the transcription regulator IκBα. The ﬁrst interaction is 
dependent on an intact C-terminal tail, although the tail alone is not sufﬁcient for 
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binding (82). The second interaction is mediated via the ankyrin repeats of IκBα, 
and is therefore an excellent example of a non-canonical binding (47). PDZ2 and 4 
of PTP-BL predominantly engage in canonical types of interaction with C-terminal 
peptides belonging to either of the four classes, like APC, EphrinB, p75NTR and the 
Fas receptor (66,83-85), or with C-terminal peptides that form the exceptions to the 
rules of classiﬁcation, like PARG (86). Both PDZ2 and 4 also display interactions 
with internal LIM domains present within the TRIP6 and CRIP2 protein (87-89). 
The RIL protein is the only known PDZ-target of PTP-BL that binds to two PDZ 
domains of PTP-BL (67). Although this binding is dominated by the RIL C-terminal 
tail, the LIM domain within RIL appears to be involved in stabilizing the interaction 
(90). Thus far, only one PDZ ligand, which ﬁts the consensus for class III peptides, 
has been reported for the PDZ3 domain of PTP-BL (26). To date no interaction part-
ners have been described for PTP-BL PDZ5, although, like PDZ domains 2 and 3, it 
was shown to bind the phospholipid PIP2 (60).
Scope and rationale of the work described in this thesis
As will be clear from the above, PDZ domains of PTP-BL interact with a wide va-
riety of proteins and do this in multiple ways. In order to classify all PDZ domains 
of PTP-BL according to rules shown in Table I, we performed an unbiased screen 
for potential ligands using a peptide library expressing random 9-mer peptides by 
exploiting the phage display technique. As described in Chapter 2, the results ob-
tained are consistent with previous reported data describing potential in vivo binding 
partners of PTP-BL. While PDZ1 showed a clear preference for class I targets with a 
unanimous selection of a tryptophan residue at the P-1 position, PDZ2 and 4 showed 
a more diverse preference towards C-terminal peptides. Most interestingly, we ob-
served that the PTP-BL PDZ2 peptide binding groove is altered as a consequence 
of an allosteric interaction with PDZ1, thereby hampering PDZ2 binding to class III 
but not class II C-terminal targets. Thus, instead of synergistic effects between two 
PDZ domains, also obstructing effects on binding of a speciﬁc subset of C-terminal 
targets may occur.
 Thus far, only one interaction partner of PTP-BL PDZ3 has been described, 
which contains an unusual cysteine residue instead of the more common valine resi-
due at the P0 position. As described in Chapter 3, our screening of a random 9-mer 
C-terminal peptide library in fact revealed that the third PDZ domain of PTP-BL 
displays a preference for peptides that contain two cysteine residues. Additional data 
suggest that recognition of these carboxyl terminal peptides by PDZ3 is regulated 
by the formation of intramolecular disulﬁde bridges within the ligand, implicating a 
redox-condition sensitive preference of PDZ3 for cyclic peptides. 
 Previous yeast two-hybrid studies suggested that the interaction of PTP-BL 
with the RIL protein is mediated through the LIM domain of RIL. Chapter 4 de-
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scribes studies aimed to unravel the mode of binding of PTP-BL PDZ domains 2 and 
4 to the RIL protein in a more physiological setting. Immunoprecipitations on lysates 
of transfected mammalian cells revealed that this interaction is in fact a canonical 
type of interaction, dominated by the C-terminal tail of RIL, with the LIM domain 
of RIL playing an important role in stabilization and thereby enhancement of the 
interaction.
 Yeast two-hybrid experiments had put forward the tumour suppressor Lats2 
as a potential binding partner for PTP-BL PDZ4 (91). Interestingly, Drosophila Lats 
is phosphorylated on tyrosine within the C-terminal PDZ-binding motif (92). This 
prompted us to study in detail the binding of PTP-BL PDZ4 to the Lats2 protein ki-
nase. In Chapter 5 it is reported that the association with PTP-BL is indeed regulated 
through reversible phosphorylation of the tyrosine residue present at the P-1 position 
(Y1041) in the Lats2 C-terminus. Intriguingly, PTP-BL is able to dephosphorylate 
this phosphotyrosine residue, thereby regulating its own binding as reﬂected by the 
extent of co-localization of the two proteins in transfected cells. Overexpression of 
Lats2 in HeLa cells leads to a cell cycle block in the G1 phase. Inhibition of cell divi-
sion does not require Lats2 C-terminal phosphorylation as demonstrated by the use 
of a Lats2 Y1041F mutant. Interestingly, a mild reduction in cell cycle inhibition at 
the G1/S transition was noted upon removal of the carboxyl terminal PDZ binding 
site of Lats2, suggesting a cooperative role for PTP-BL and Lats2 in the regulation 
of the cell cycle.
 Finally, in Chapter 6 I summarise and discuss the obtained results in relation 
to current data in the literature. Based on our ﬁndings we propose three novel roles 
for PTP-BL, i.e. in catenin/cadherin-based signalling, redox sensing, and cell cycle 
regulation.
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Abstract
PDZ domains are abundant small globular protein interaction domains that mainly 
recognize the carboxyl termini of their target proteins. Detailed knowledge on PDZ 
domain binding speciﬁcity is a prerequisite for understanding the interaction net-
works they establish. Here, we describe the binding preference of the PDZ domains 
in the protein tyrosine phosphatase PTP-BL, as determined by screening a random 
C-terminal nonapeptide λ phage display library. PTP-BL PDZ domains 2 and 4 ap-
pear the most promiscuous, displaying interactions with a rather diverse set of pep-
tides. Interestingly, the potential of PDZ2 to interact with class III-type ligands is 
attenuated by the presence of PDZ1. Structural studies revealed a direct and speciﬁc 
interaction of PDZ1 with a surface on PDZ2 that is opposite of the peptide binding 
groove. Long-range allosteric effects causing structural changes in the PDZ2 peptide 
binding groove thus explain the altered PDZ2 binding preference. Our results indi-
cate that the molecular embedding of PDZ domains is an important determinant of 
their ligand-binding speciﬁcity.
Introduction
In cellular signalling networks, dynamic protein-protein interactions form the back-
bone of information ﬂow, and the large number of specialized protein domains that 
mediate these contacts highlights their importance in signal transduction (1). The 
PDZ1 domain (acronym of the synapse-associated protein PSD-95/SAP90, the sep-
tate junction protein Discs-large, and the tight junction protein ZO-1) is one of the 
most common protein interaction modules in metazoan genomes. They participate in 
a wide variety of signalling pathways and also contribute to the protein sorting and 
transport machinery (2,3). 
 PDZ domains typically bind to short carboxyl terminal peptide sequences 
in target proteins. For this canonical PDZ binding mode it is well documented that 
amino acids at the P0 and P-2 position of the target C-terminus are of crucial impor-
tance in determining PDZ domain afﬁnity. Based on the kind of residue present at 
position P-2 in the PDZ ligands, three PDZ binding classes are discerned (4). Class 
I peptides end with -(S/T)xΦ sequences, class II C-termini read -(Φ/Ψ)xΦ, and -
G(D/E)xV protein tails comprise class III PDZ binding sites (where x denotes any 
amino acid, Φ hydrophobic residues and Ψ aromatic residues). These three classes 
all posses a hydrophobic residue at the P0 position. A fourth ligand type (class IV), 
however, ends in -XΨ(D/E), thus is characterized by a negatively charged residue at 
the P0 position (5,6).
 Many PDZ domain-containing proteins harbour multiple PDZ domains, of-
ten arranged in closely linked groups. This renders the proteins capable of binding 
to several different transmembrane or intracellular partners at the same time, thus 
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organizing multimeric complexes. For example, the large intracellular phosphotyro-
sine-speciﬁc phosphatase PTP-BL contains ﬁve PDZ domains, of which the second 
and third as well as the fourth and ﬁfth are tandemly linked (7). Interestingly, syner-
gistic effects on target peptide binding have been noted for the ﬁve PTP-BL PDZ do-
mains (8,9). Also for other proteins it has been reported that tandemly occurring PDZ 
domains display target-binding properties that are distinct from that of the individual 
PDZ domains in isolation (10-12) but the molecular basis of such supramodular ef-
fects remains mostly unresolved.
 Here, we have studied the binding preferences of the ﬁve PTP-BL PDZ do-
mains individually as well as in clusters, and encountered an allosteric regulation of 
PTP-BL PDZ2 binding preference by the PDZ1 domain. The interaction of PDZ2 
with class III peptides, as displayed by the PDZ2 domain alone, was lost when PDZ1 
was present, while PDZ2 binding to class I peptides remained unaffected. The direct 
binding of PDZ1 to a PDZ2 surface area opposite of its C-terminal binding pocket 
caused this change in binding speciﬁcity. These ﬁndings disclose a new method of 
regulating PDZ-binding speciﬁcity and urge for a cautious interpretation of PDZ 
binding characteristics when these domains are studied in isolation.
Materials and Methods
Expression plasmids
Bacterial expression plasmids pGEX-PDZ1, pGEX-PDZ2, pGEX-PDZ3, pGEX-
PDZ4, pGEX-PDZ5, pGEX-PDZ1+2, pGEX-PDZ4+5 and pGEX-PDZ2-5 were 
constructed by subcloning PCR-generated PTP-BL cDNA fragments (spanning resi-
due numbers 1078-1171, 1353-1449, 1489-1601, 1756-1855, 1853-1946, 1064-1501, 
1661-2021 and 1285-1978 respectively; numbering according to acc.nr. Q64512) in-
frame into appropriate pGEX vectors. Primer and construction details are available 
from the authors upon request.
GST fusion protein production and puriﬁcation
GST fusion proteins were expressed in E.coli DH5α following transformation with 
pGEX-based constructs. Cultures were grown to mid-log phase (A600 ~ 0.7) in LB 
medium at 37 °C and, following addition of 1.0 mM IPTG, grown for an additional 
three hours. Bacteria were pelleted by centrifugation at 5000 rpm for 5 min and re-
suspended in ice-cold PBS including 1 mM of PMSF. After three soniﬁcation steps 
of 10 sec with an interval of 1 minute on ice between each step, 1/100 volume of 
Triton-X 100 was added. Cell debris was pelleted by centrifugation at 9500 rpm for 
15 min, and supernatant containing GST-fusion proteins was incubated with Glu-
tathione–Sepharose 4B beads (Amersham Biosciences, England) for 3 hours at room 
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temperature. After three successive washing steps with PBS, fusion protein-loaded 
beads were stored at 4 °C or further processed. 
 For SPR purposes, GST-fusion proteins were eluted from the beads using 
10 mM of reduced glutathione in 50 mM Tris-HCl, pH 8.0, and subsequently dia-
lyzed against HBS (10 mM Hepes, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% 
surfactant P20; BR-1000–54, Biacore AB, Switzerland).
 For structural studies, GST-PDZ1 fusion protein was expressed in Es-
cherichia coli BL21 Codon Plus (DE3) RIL cells (Stratagene, CA, USA). Bacte-
rial pellet was resuspended in PBS in the presence of 1 mM PMSF and complete 
protease inhibitor (Roche, Mannheim, Germany), and soniﬁed. Lysed bacteria were 
then centrifuged twice at 10,000 rpm at 4 ºC for 30 min to remove cell debris. The 
supernatant was bound to Glutathione-Sepharose 4B beads and washed with 0.1 M 
NaCl in 20 mM Tris-HCl, pH 8.0. Elution from the column was performed with 15 
mM reduced glutathione in 50 mM Tris-HCl, pH 7.7. To remove the GST tag, 35 
units thrombin per ml was added for ± 18 h at 25 °C. The mixture was passed over a 
Sephadex G75 size exclusion column at room temperature, and appropriate fractions 
were collected, pooled and dialyzed against excess water overnight at 4 °C. Result-
ing PDZ1 protein was freeze-dried and stored at -80 °C until further use. Production 
and puriﬁcation of 15N-labelled His-tagged PDZ2 protein in E. coli BL21(DE3) cells 
has been described previously (13).
Phage Display Library Screening
Phage display experiments were performed as described before (5). In brief, a car-
boxyl terminal peptide library (with a complexity of 107 independent clones) dis-
played as capsid protein D fusions on bacteriophage λ (5) was screened by afﬁn-
ity selection over Glutathione–Sepharose 4B beads coated with GST-PDZ fusion 
protein. Following extensive washes, the adsorbed phages were propagated on BB4 
bacteria by plate lysate, eluted, concentrated and subjected to another panning cycle. 
After three successive panning cycles, individual phage clones were plaque-puriﬁed, 
and PCR-ampliﬁed λDsplay1 inserts were sequenced.
Surface Plasmon Resonance
A Biacore 2000 system (Biacore AB, Uppsala, Sweden) was used for surface plas-
mon resonance (SPR) analysis. The N-terminally biotinylated peptides APC and 
RIL (KRHSGSYLVTSVCOOH and VAVYPNAKVELVCOOH, respectively; Ansynth 
Service B.V., Roosendaal, the Netherlands) were loaded onto streptavidin-coated 
(SA) sensor chips at a ﬂow rate of 5 μl/min using the manufacturer’s instructions. 
Puriﬁed GST fusion proteins, or GST alone as control, were dialyzed against running 
buffer (10 mM Hepes, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% surfactant P20) 
and diluted to the concentrations indicated. Perfusion was at a ﬂow rate of 25 - 50 
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μl/min, ﬁrst over a control ﬂow cell coated with biotin (Fc1) and then over capture 
ﬂow cells coated with the biotinylated peptides (Fc2-4). After 6-8 min of association, 
the sample solution was replaced by running buffer alone, allowing the complex to 
dissociate. Binding was measured as the difference between the Fc1 and Fc2-Fc4 
curves. The binding surface was regenerated with two 60 s pulses of Glycine, pH 2.0. 
Experiments were performed at 25 °C. Association and dissociation kinetics were 
ﬁtted using a two independent site model as implemented in the program GraphPad 
Prism (version 4.0, GraphPad Software, Inc.). Binding curves consisted of a fast 
and a slow process, of which the latter appeared concentration independent and may 
reﬂect GST dimerization or other modulating effects. Dissociation constants were 
derived from a concentration dependant series.
NMR measurements
The NMR samples contained ~1 mM uniformly labelled 15N/13C PDZ2 protein in a 
buffer consisting of 50 mM KH2PO4/K2HPO4 and 50 mM KCl, pH 6.8, H2O/D2O 
(95%/5%) and trace amount of NaN3 (13). Unlabeled peptides corresponding to the 
APC (KRHSGSYLVTSV) and RIL (VAVYPNAKVELV) C-termini, were titrated 
into the PDZ2 domain-containing samples until the 15N-HSQC spectra of PDZ2 
showed little further changes, with ﬁnal peptide concentrations of 2.4 and 3.2 mM, 
respectively. All NMR experiments were recorded at 25 °C. The sequential assign-
ments were completed using 3D HNCA and CCH-TOCSY experiments recorded on 
either Varian Inova 500 or 600 spectrometers. All spectra were processed using the 
NMRPipe program suite (14) and assigned using XEASY (15). The APC and RIL 
assignments have been deposited in the BioMagResBank under accession numbers 
6060 and 6091, respectively. 
 Freeze-dried, unlabeled PDZ1 was added to a 0.5 mM solution of uniformly 
15N-labeled PDZ2 in phosphate buffer, as described above. Relative concentrations 
of PDZ1 and PDZ2 were checked by 1D 15N-edited/ﬁltered experiments. 15N-HSQC 
spectra of PDZ2 were recorded at PDZ1:PDZ2 ratios of 0:1, 0.6:1, 1:1, 1.2:1 and 
1.6:1.
Results
Identiﬁcation of PTP-BL PDZ interacting C-terminal peptides
Previous studies have shown that PTP-BL is engaged in several protein-protein in-
teractions mediated by its ﬁve PDZ domains (summarized in (16)). To expand our 
knowledge on the carboxyl terminal target speciﬁcity of the PDZ domains of PTP-
BL, we screened a random C-terminal nonapeptide λ phage display library using 
GST-tagged PTP-BL PDZ domains bound to Glutathione-Sepharose 4B beads as 
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an afﬁnity matrix. The phages obtained after three successive selection cycles were 
plaque-puriﬁed and DNA sequencing revealed the amino acid sequence of the ex-
posed peptides. Alignment of obtained sequences with respect to their carboxyl ter-
minus enabled determination of a consensus motif reﬂecting the binding preference 
of the different PTP-BL PDZ domains (Figure 1). The results obtained for PTP-BL 
PDZ3 will be described elsewhere. In agreement with previous data (16), PDZ5 did 
not selectively bind peptide-displaying phages.
Figure 1: C-terminal peptides selected by PTP-BL PDZ domains. (A) On top a schemat-
ic representation of the relevant segment of PTP-BL (pos. 1000-2020; acc.nr. Q64512) is 
shown, comprising its ﬁve PDZ domains. Below, the C-terminal sequence encoded by each 
phage clone selected by the indicated PDZ domain is shown. PDZ5 of PTP-BL did not yield 
speciﬁcally selected phage clones, and results for PTP-BL PDZ3 will be published else-
where. Clone numbers are depicted in bold on the left and peptides are classiﬁed according 
to Vaccaro et al. (6). Conserved residues (deﬁned as appearing in more than 50% of the 
peptides) are depicted in bold and are represented in the consensus that is shown in bold and 
italic. The single letter code for amino acids is used, Φ represents residues with hydrophobic 
side chains and x represents any amino acid. In panel (B), the currently reported interacting 
proteins for the individual PTP-BL PDZ domains are listed. Their four C-terminal amino acid 
residues are shown and peptide classiﬁcation (6) is indicated on the right. The PDZ target se-
quences in IκBα and CRIP2 are non-canonical, being the ankyrin repeats and LIM domains, 
respectively (23,24).
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 PTP-BL PDZ2 and PDZ4 both selected phages that express peptides belong-
ing to classes I, II as well as III, indeed reﬂecting the C-termini of reported inter-
acting proteins (Figure 1). Reported targets for PDZ2 include the class I termini of 
p75NTR (17), FAS (18), TRIP6 (19), and APC (20), and the RIL class III C-terminus 
(8,9). PDZ2 also binds the phospholipidphosphatidylinositol 3,4-biphosphate (21). 
PDZ4 interacts with EphrinB (class II), RIL (class III) and PARG1 C-termini, and 
also binds internal peptide stretches in CRIP2 (8,9,22,23). PDZ1 interacts with a 
stretch of N-terminal ankyrin repeats in IκBα (24) and with the C-terminal half of 
BP75 (25), although the exact PDZ-binding motif within these proteins has not been 
deﬁned. We now ﬁnd that PDZ1 displays an exclusive preference for class I peptides 
carrying a tryptophan residue at the P-1 position (Figure 1).
Structural analysis of PTP-BL PDZ2 in complex with speciﬁc C-terminal tar-
gets
The observed PTP-BL PDZ2 binding promiscuity towards C-terminal targets ((16) 
and Figure 1) raises the question whether binding of C-terminal targets from dif-
ferent peptide-classes involves similar residues in the binding pocket of this PDZ 
domain. To investigate this, we selected two peptides, representing a class-I (APC) 
and a class-III (RIL) PDZ2 ligand, for NMR studies in complex with the second 
PDZ domain of PTP-BL. The 15N-HSQC spectrum of PTP-BL PDZ2 without ligand 
has been assigned previously (13). For the comparison of the complexed and free 
PDZ2 domain, both the backbone chemical shift, as expressed in the chemical shift 
index (CSI), as well as side chain chemical shifts were used as monitors (26). These 
two measures indicate the effect of peptide binding and highlight potential structural 
changes that occur upon complex formation. 
 For each complex, the largest shifts occurred for residues located in the βB 
strand and αB helix (Figure 2A), implying that both peptides bind in the canonical 
binding pocket. Other residues outside the direct binding site also show signiﬁcant 
changes upon complex formation. For example, residues within the αA helix dis-
play signiﬁcant effects (i.e residues 53 and 54; numbering according to (13)). We 
attribute these variations to a structural change occurring upon complex formation 
due to the close proximity of helix αA to the carboxylate binding loop in the binding 
pocket. In addition, Asn-69 also shows large chemical shift changes for both com-
plexes. Examination of the native structure of PDZ2 (13) shows that this residue is 
located on the βD-βF face, opposite to the binding pocket. The CSI indicates that the 
conformation of this region of the protein adopts a more uniform β-sheet structure 
while in a peptide-bound form. The CSI patterns also suggest that the binding of the 
ligand along the βB strand promotes more β-strand character of the βB-βC sheet. The 
interaction of the carboxylate binding loop with the peptide also appears to affect 
the conformation of the αA helix, as indicated by the changes in CSI for the class I 
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peptide, APC.
 Monitoring the resonance positions of selected peaks as a function of in-
creasing peptide concentration yielded the dissociation constants for the two PDZ2-
ligand complexes. In Figure 2B the changes in chemical shift of Gly-26, a key resi-
due in the carboxylate binding loop, at different peptide:PDZ2 ratios are depicted. 
Dissociation constants of 190 µM and 1400 µM were obtained for the APC and RIL 
Figure 2: Chemical shift changes in PDZ2 upon complex formation. (A) The two bottom 
panels display the weighted absolute changes in 1H and 15N backbone chemical shifts, cal-
culated as |∆δHN|+0.2|∆δN|, observed in PDZ2 upon complex formation with APC and RIL 
C-terminal ligands, respectively. Structural informative chemical shifts of Hα, Cα and Cβ 
are translated into CSI values (26) and displayed as horizontal bars for helical regions and 
triangles for β-sheet regions, respectively, in the top three panels for the native PDZ2, the 
PDZ2-APC complex, and the PDZ2-RIL complex. Atop, the secondary structure elements, as 
present in the native PDZ2 domain (13). (B) The change in chemical shift (y-axis) of Gly-26, 
a key residue in the PDZ2 carboxylate binding loop, upon complex formation with the APC 
(■) and RIL (▲) peptide ligands at various ligand:PDZ ratios (x-axis). 
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complexes, respectively. This difference in afﬁnity is also reﬂected in the pattern 
of chemical shift differences, as displayed in Figure 2A, where the interaction with 
APC results in larger overall effects when compared to RIL.
Quantitative analysis of PTP-BL PDZ - C-terminal target afﬁnities
We also determined the binding constants for the peptide-PDZ complexes in surface 
plasmon resonance (SPR) measurements using biotinylated APC and RIL C-termi-
nal peptides on streptavidin-coated sensor chips. As expected (8,20), PTP-BL PDZ2 
bound to the APC peptide (class I) as well as the RIL peptide (class III), whereas 
PDZ4 only interacted with the RIL peptide (Figure 3). The use of different concen-
trations of GST-PDZ fusion protein allowed the determination of the apparent dis-
sociation constants (KD) for the APC and RIL peptides towards PDZ2; 27 µM and 
45 µM, respectively. This conﬁrmed the suggested higher binding afﬁnity of PDZ2 
for the APC peptide as compared to RIL. PDZ4, however, displayed a higher afﬁnity 
for the RIL C-terminal tail (KD = 21 µM) than that of PDZ2. The apparent dissocia-
tion constants determined here are within the typical range observed for other PDZ 
domain interactions (20,27-29).
PDZ1 alters PDZ2 binding speciﬁcity
Thus far, the binding preference of the PDZ2 domain in PTP-BL was studied outside 
the context of the whole molecule. Evidence is accumulating that intramolecular 
synergistic or allosteric effects may regulate PDZ domain binding potential (30-32). 
To investigate whether a similar situation exists for PTP-BL PDZ domains, we tested 
different PDZ domain combinations in phage display and SPR experiments. Intrigu-
ingly, a protein segment spanning the ﬁrst two PDZ domains of PTP-BL (PDZ1+2) 
failed to select phage clones expressing class III peptides while class I peptide-dis-
playing phages were readily obtained (Figure 4A), which is in sharp contrast to re-
sults obtained for PDZ2 alone (Figure 1). SPR experiments conﬁrmed these results: 
PDZ1+2 readily bound to the class I peptide (Figure 4B) while an interaction with a 
class III peptide was hardly detectable (Figure 4C).
 The modulation of speciﬁcity is speciﬁc for PDZ1+2 because a segment 
spanning PTP-BL PDZ domains 4 and 5 (PDZ4+5) did not reveal an altered binding 
preference for PDZ4 in phage display and SPR experiments. Phage display screen-
ing using the PDZ4+5 fusion construct yielded phages expressing peptide classes II 
and III (Figure 4A), much like for PDZ4 alone. Likewise, the PDZ4+5 combination 
was still capable of binding to the class III RIL peptide in SPR experiments (Figure 
4C). 
PDZ1 binds directly to PDZ2
The observed difference in binding speciﬁcity of PDZ1+2 in comparison to PDZ2 
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Figure 3:  Biosensor analysis of 
PTP-BL PDZ domain interactions 
with APC and RIL C-termini. The 
binding of GST fusions of PTP-BL 
PDZ2 (A,B) or PDZ4 (C), at differ-
ent concentrations (indicated on the 
right in µM), to the APC C-terminal 
peptide (A) or the RIL C-terminus 
(B,C) immobilized on the surface 
of a sensor chip was detected by 
changes in resonance units (RU) 
over time (sec). The sensorgrams 
shown were obtained by subtract-
ing the blank sensorgram of a con-
trol non-peptide ﬂow cell from the 
sensorgrams of the peptide-loaded 
cells.
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Figure 4:  Peptide binding speciﬁcity of two PTP-BL PDZ domain combinations. (A) Top: 
Schematic representation of the relevant segment of PTP-BL, comprising the PDZ domain 
combinations PDZ1+2 and PDZ4+5. Below: C-terminal sequence encoded by each phage 
clone selected by the respective combination is shown. Clone numbers are depicted in bold 
on the left. Peptides were classiﬁed according to Vaccaro et al. (6). Conserved residues (de-
ﬁned as appearing in more than 50% of the peptides) are depicted in bold and are represented 
in the consensus that is shown in bold and italic. The single letter code for amino acids is 
used, Φ represents residues with hydrophobic side chains and x represents any amino acid. 
(B,C) Different combinations of PTP-BL PDZ domains were screened for interaction using 
SPR. N-terminally biotinylated APC (B) and RIL (C) C-terminal peptides were loaded onto 
streptavidin-coated sensor chips and tested for interaction with the GST-PDZ fusion proteins 
indicated on the right. The response (in resonance units; RU) to each fusion protein is de-
picted (on the y-axis) against time (in seconds; x-axis). 
alone suggests either a direct interaction between the two PDZ domains or an effect 
caused by the ~200 amino acid long spacer-region separating these domains. Several 
examples of PDZ-PDZ interactions have previously been reported (33-36). Hence, 
we tested the possibility of a direct interaction between the PTP-BL PDZ domains by 
titrating unlabelled PDZ1 into a sample containing 15N-labelled PDZ2 for which the 
15N-HSQC spectrum has been assigned (13). This allowed the direct mapping of the 
PDZ1-PDZ2 interaction interface on the PDZ2 structure. Upon addition of PDZ1, 
major shifts were observed for signals of PDZ2-residues present in αA and βA and 
the C-terminal tip of βF, jointly forming a surface opposite to the C-terminal peptide 
binding groove (Figure 5). Changes were also observed for Gly-26 and Arg-86, two 
residues present at the top of the canonical binding groove that play a crucial role 
in PDZ target binding, indicating that long-range allosteric effects caused by PDZ1 
binding to the opposite side of the PDZ2 domain alter the binding preference of 
PDZ2.
Discussion
Over the past decade, attempts to understand, classify and predict PDZ domain 
binding preferences have resulted in numerous studies in which the target selection 
speciﬁcity for PDZ domains was determined by testing individual PDZ domains in 
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Figure 5: Structural aspects of the PDZ1-PDZ2 interaction. PDZ2 residues affected by 
PDZ1 are mapped onto the structure of PDZ2 (13) in surface representation (PDZ1-2 inter-
face region) and CPK representation (peptide-binding groove), respectively. Relevant amino 
acid residues, numbered according to (13), are indicated. 
isolation. More recent studies, however, raise the concern that these results may be 
compromised due to this reductionistic approach. Indeed, our current study illus-
trates that the binding characteristics of one of the ﬁve PDZ domains in PTP-BL, 
PDZ2, is allosterically modulated by PTP-BL PDZ1, underscoring the notion that 
for a full appreciation of PDZ functioning long range interactions should be taken 
into account. 
 As a start, we performed an unbiased determination of the PTP-BL PDZ 
domain binding preferences by screening a random C-terminal nonapeptide λ phage 
display library using the individual, GST-tagged, PDZ domains. In general, the bind-
ing consensus that was obtained for domains PDZ2 and PDZ4 nicely ﬁtted with 
current knowledge on potential binding partners of PTP-BL (reviewed in (16)). In 
contrast, we noted a clear preference of PTP-BL PDZ1 for class I peptides that carry 
a penultimate tryptophan residue, whereas reported PDZ1 interactions rather reﬂect 
binding to an internal protein domain (ankyrin repeats within IκBα (24)) or to the 
carboxyl terminal portion of bromodomain-containing protein BP75 (25). For the 
latter interaction, the BP75 C-terminus (-PDASCOOH) appeared necessary but not 
sufﬁcient for strong binding (25), reminiscent of the interaction between PTP-BL 
PDZ domains and the RIL C-terminus (8). 
 Interestingly, no speciﬁc peptide-displaying phages were selected by PTP-
BL PDZ5. Alternative strategies also did not result in the identiﬁcation of target pro-
teins for PDZ5 (16). The only reported PDZ5 interaction thus far is with phosphati-
dylinositol 3,4-biphosphate, a phosphoinositide that also binds to PTP-BL PDZ2 
and PDZ3 (21). Perhaps PTP-BL PDZ5 is not involved in target peptide binding but 
rather serves in modulating the structure of the neighbouring PDZ4 domain. Such 
a situation is encountered for the fourth PDZ domain in the glutamate receptor-in-
teracting protein GRIP. This domain itself is not able to bind C-terminal targets but 
it allows functioning of PDZ5 by stabilizing this closely-linked domain (30). We 
tested whether PTP-BL PDZ5 perhaps inﬂuenced the binding characteristics of the 
neighbouring PDZ4 domain, but we could not detect any signiﬁcant difference for 
the GST-PDZ4+5 fusion protein relative to GST-PDZ4 (compare Figures 1 and 4). 
 PTP-BL PDZ domains 2 and 4 are the most promiscuous, displaying interac-
tions with a rather diverse set of peptides (Figure 1). Structural analysis of the PDZ2 
interaction with C-terminal ligands that represent class I (APC) and class III (RIL) 
peptide targets revealed that the observed difference in afﬁnity correlates well with 
the observed range of chemical shift differences (Figure 2B). The high-afﬁnity ligand 
(APC) displayed larger chemical shift differences for identical residues compared to 
that of the low-afﬁnity ligand (RIL). Furthermore, the APC peptide interacted with a 
greater number of PDZ2 residues than the RIL ligand. This was particularly notice-
able in the lower portions of βB and the αB helix, which showed signiﬁcant effects 
by the APC peptide but were untouched by the RIL peptide. These differential effects 
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were to be expected, since APC and RIL are members of two different classes. In 
addition, the lower number of PDZ2 residues that interacted with the RIL C-terminus 
provides an explanation for the requirement of the RIL LIM domain to elicit efﬁcient 
in vivo binding (8). Previously, it has been reported that PDZ2 binds with very high 
afﬁnity (KD = 8.1 nM) to the carboxyl terminal tail of the APC protein (20). This 
afﬁnity differs considerably from the afﬁnities determined here using NMR (190 
µM) and SPR (27 µM) analyses. This may either reﬂect differences in experimental 
setup, most notably the difference in length of the APC-peptide used (19 versus 12 
residues, resp.), or be related to more subtle effects originating from differences in 
protein constructs that potentially could (de-)stabilize the high-afﬁnity conformation 
of this protein domain (vide infra). 
 In proteins that harbour multiple PDZ domains, such as PTP-BL, a conspic-
uous clustered appearance of these domains is apparent. For example, the six PDZ 
domains in the GRIP and ABP protein families show conserved clustering of the ﬁrst 
three (PDZ123) and the second three (PDZ456) PDZ domains (35,37,38). Recently, 
the three-dimensional structures for three different PDZ tandems (as present in PSD-
95, syntenin and GRIP) were solved (30-32). These studies revealed that the PDZ 
domain orientation in such tandems could vary considerably. For instance, the two 
PSD-95 PDZ domains had limited rotational freedom and their respective C-ter-
minal peptide-binding grooves appeared aligned, which explains their tendency to 
interact with dimeric ligands (32). The syntenin PDZ domain tandem, on the other 
hand, displayed independent and fully solvent-accessible peptide binding pockets 
(31). Quite opposite, as mentioned previously, the GRIP PDZ domains 4 and 5 were 
tightly packed together, which stabilized the structure of PDZ5 but caused a distorted 
peptide binding groove within PDZ4 that may no longer allow the binding of C-ter-
minal peptides (30). 
 In view of the above, we examined the target speciﬁcity of PTP-BL PDZ 
domain clusters in both phage display and SPR experiments and found that the bind-
ing speciﬁcity of PDZ2 as observed in isolation is altered upon the presence of PDZ1 
(Figure 4). Subsequent structural studies revealed a direct and speciﬁc interaction 
of PDZ1 with the αA-βA interface on PDZ2 (Figure 5). Importantly, the binding of 
PDZ1 also affected crucial residues in the PDZ2 peptide-binding groove, consistent 
with effects observed for residues in helix αA of PDZ2, when binding the APC pep-
tide. Moreover, structural coupling between these two parts of PDZ domains has also 
been inferred from theoretical calculations (39). We hypothesize that PDZ1 binding 
induces a conformational change in PDZ2 in such a way that it speciﬁcally loses 
interaction with class III-type ligands without having a major inﬂuence on class I 
peptide binding. This change likely involves alterations in the positioning of βB 
and αB, reminiscent of changes in the binding pocket observed for the alternatively 
spliced PTP-BL PDZ2 (40).
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 The PDZ1-PDZ2 effect in PTP-BL also resembles the allosteric interaction 
observed within Par-6 (41). The Par-6 protein contains a single PDZ domain that is 
preceded by a CRIB (Cdc42/Rac interactive binding) domain. In fact, these domains 
were found to be structurally coupled; the CRIB domain forms an extension of the 
central PDZ domain β-sheet (41,42). The structure of the free Par-6 PDZ domain 
was found to deviate from the canonical PDZ conformation, explaining its low af-
ﬁnity towards ligands (41). Cdc42 binding to the Par-6 CRIB domain signiﬁcantly 
increases the afﬁnity of the ﬂanking PDZ domain for its carboxyl terminal ligand by 
inducing a canonical, high afﬁnity PDZ conformation (41,42). Interestingly, the resi-
dues in the Par-6 PDZ domain that interact with the CRIB domain are structurally 
similar to the ones in PTP-BL PDZ2 that are affected by PDZ1. This suggests that 
the conformation of PDZ2, as induced by PDZ1, may also reﬂect a more canonical, 
high afﬁnity conformation. PDZ-PDZ interactions thus provide an excellent means 
to regulate their own ligand-binding speciﬁcity. In Par-6 the allosteric transition is 
regulated by Cdc42, and our results strongly suggest that comparable regulatory 
principles also hold true for PTP-BL.
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Abstract
PDZ domains are protein–protein interaction modules that are crucial for the assem-
bly of structural and signalling complexes. They speciﬁcally bind to short C-termi-
nal peptides and occasionally to internal sequences that structurally resemble such 
peptide termini. The binding of PDZ domains is dominated by the residues at the P0 
and P-2 position within these C-terminal targets, but other residues are also important 
in determining speciﬁcity. In this study, we analyzed the binding speciﬁcity of the 
third PDZ domain of protein tyrosine phosphatase BAS-like (PTP-BL) using a C-
terminal combinatorial peptide phage library. Binding of PDZ3 to C-termini is pref-
erentially governed by two cysteine residues at the P-1 and P-4 position and a valine 
residue at the P0 position. Interestingly, we found that this binding is lost upon addi-
tion of the reducing agent dithiothrietol, indicating that the interaction is disulﬁde-
bridge-dependent. Site-directed mutagenesis of the single cysteine residue in PDZ3 
revealed that this bridge formation does not occur intermolecularly, between peptide 
and PDZ3 domain, but rather is intramolecular. These data point to a preference of 
PTP-BL PDZ3 for cyclic C-terminal targets, which may suggest a redox state-sens-
ing role at the cell cortex.
Introduction
The reversible assembly and activation of (large) protein complexes, or ‘protein ma-
chines’, is a crucial determinant in the regulation of processes within the living cell. 
Understanding the rules that govern protein machine (dis-)assembly would, there-
fore, greatly enhance our ability to infer and interpret cell physiology (1). Protein 
complex formation is exerted by specialized interaction domains, of which the PDZ 
protein recognition module is one of the most abundant and best characterized (2). 
PDZ domains, named after the ﬁrst three proteins in which they were noted (PSD95/
SAP90, Discs large, and ZO-1 (3)), have rather diverse binding properties resulting 
from the variability of their approximately 90-amino acid primary sequences (4). 
Ligand preferences range from C-terminal targets (5,6) to protein-internal peptide 
stretches (7-9) and even phosphoinositides (10). This astonishing diversity impinges 
on both the classiﬁcation of PDZ domains or their binding targets and on the predic-
tion of PDZ binding preferences (11-14). 
 For the canonical C-terminal peptide binding by PDZ domains, it is well 
documented that amino acids at the P0 and P-2 position of the target peptide are of 
crucial importance in determining PDZ domain afﬁnity. Three PDZ binding classes 
can be discerned based on the kind of residue present at position P-2 in the PDZ 
ligands (11). Class I, II and III peptides end with -(S/T)XΦ, -(Φ/Ψ)XΦ, and -G(E/
D)XV carboxyl terminal sequences, respectively (where X denotes any amino acid, 
Φ a hydrophobic residue and Ψ an aromatic residue). These former classes all have 
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a hydrophobic residue at the P0 position. In contrast, a fourth ligand type (class IV) 
ends in -XΨ(E/D), thus containing a negatively charged residue at the P0 position. 
Additional class deﬁnitions seem to be required to allow incorporation of novel PDZ 
target sequences like those that bear a cysteine residue at P0 (i.e. -YTEC and the 
PTP-BL PDZ3 target -ADWC (15,16)).
 In addition to those at P0 and P-2, other residues in canonical PDZ bind-
ing targets may contribute as well. Although at ﬁrst the side-chains of P-1 residues 
were found to be exposed from the PDZ binding surface, and therefore regarded as 
unimportant, recent data show that in some cases the P-1 residue does play a role 
and even may be a decisive factor in discriminating between low- and high-afﬁnity 
binding (17,18). Residues further upstream from the C-terminus are also described 
to be involved in PDZ domain interactions (19). For instance, the phenolic ring of 
tyrosine P-7 of the ErbB2 protein enters into a pocket formed by the extended β2-β3 
loop of the Erbin PDZ domain (20). Several other PDZ domains, including PDZ2 of 
PTP-BL, also contain an extended β2-β3 loop that is involved in ligand interactions 
(21-24). 
 PTP-BL is a large intracellular phosphotyrosine-speciﬁc phosphatase that 
contains ﬁve PDZ domains (denoted PDZ1 to PDZ5 from here on). Domains PDZ2 
and PDZ4 display afﬁnities for canonical, C-terminal targets (25-27) as well as pro-
tein-internal structures (8,28), and PDZ2 even binds phospholipids (10). For the 
other three PDZ domains only a few interaction partners have been described. An 
interaction of PDZ1 with the bromodomain containing protein BP75 and with the 
transcription regulator IκBα has been shown (29,30). Interestingly, no proteins are 
known to interact with the PDZ5 domain, but it is able, like PDZ2 and PDZ3, to 
interact with phospholipids (10). Finally, the only protein known, thus far, to interact 
with PTP-BL PDZ3 is the cytosolic serine threonine kinase PRK2 (16), which is 
implicated in the modulation of the actin cytoskeleton (31). 
 Interestingly, PTP-BL PDZ3 binding to PRK2 occurs via an unusual C-ter-
minal motif, -ADWCCOOH (16), that cannot be classiﬁed according to the abovemen-
tioned schemes. Here, we utilized phage-displayed combinatorial peptide libraries to 
obtain an unbiased view on the binding preferences of PTP-BL PDZ3. Our studies 
reveal a unique binding consensus, containing two cysteine residues at the P-4 and 
P-1 position. Importantly, the afﬁnity of PDZ3 for these selected peptides was found 
to depend on intramolecular disulﬁde bridge formation.
Materials and Methods
Expression Plasmids
Plasmid VSV-BL-PDZ-I-V has been described elsewhere (29). Bacterial expres-
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sion plasmid pGEX-PDZ3 was constructed by subcloning a PCR-generated PTP-BL 
cDNA fragment (spanning residue numbers 1489–1601; accession no. NP_035334) 
in-frame into the BamHI- and XhoI-digested pGEX2T-XhoI vector. The 5’- and 3’ 
PDZ3-speciﬁc primers that were used contained additional nucleotides that entailed 
BglII and XhoI restriction sites, respectively, allowing unidirectional cloning fol-
lowing use of the indicated restriction enzymes. pGEX2T-XhoI was generated by 
introducing an oligonucleotide linker carrying a XhoI restriction site into the EcoRI 
site of pGEX-2T. pGEXPDZ3(C1575S) was created exploiting the QuickChange 
Mutagenesis protocol (Strategene Inc., La Jolla, CA) utilizing two complemen-
tary primers (5’-GTGTCCTTGCTTCTCAGCAGACCGGCACCTGG-3’ and 5’-
CCAGGTGCCGGTCTGCTGAGAAGCAAGGACAC-3’; mutated nucleotides are 
in bold) and the wild-type pGEX-PDZ3 plasmid according to the manufacturer’s in-
structions. Bacterial expression plasmids pGEX-PDZ2, pGEX-PDZ4, pGEX-PDZ5 
and pGEX-PDZ2-5 were constructed by subcloning PCR-generated PTP-BL cDNA 
fragments (spanning residues 1353–1449, 1756–1855, 1853–1946 and 1285–1978, 
respectively; accession no. NP_035334) in-frame into the appropriate pGEX vec-
tor. 
 Mammalian GST-fusion expression plasmids were constructed by adding 
appropriate PCR-generated cDNA fragments, ﬂanked by BamHI or BglII sites, into 
the pEBG vector (32). For mouse Slit1 a full-length cDNA clone obtained from the 
RZPD (http://www.rzpd.de) served as a template. For the generation of E7 protein 
expression constructs the genomic DNAs of HPV8, HPV10 and HPV16 were used 
as templates (kindly provided by W. Melchers, Radboud University Nijmegen Medi-
cal Centre, Nijmegen, the Netherlands). The BamHI or BglII site-containing primers 
resulted in the ampliﬁcation of nucleotide regions 653-964, 524-784, 562-858, and 
3675-5069 for HPV8 (NC_001532), HPV10 (NC_001576), HPV16 (NC_001526), 
and Slit1 (Q80TR4), respectively. In the database, the derived protein sequence for 
mouse Slit1 displays Ala and Val as alternative ﬁnal C-terminal residues, which may 
reﬂect a polymorphism. Using appropriate antisense primers in the above cloning 
strategy we constructed both the Ala and Val variants for this protein. 
 All expression constructs that were generated by PCR were veriﬁed by au-
tomated sequence analysis to exclude undesired mutations. Primer sequences are 
available from the authors upon request.
GST Protein Production and Puriﬁcation
GST-fusion proteins were expressed in Escherichia coli DH5α following transfor-
mation with appropriate pGEX-PDZ expression constructs. Cultures were grown 
to mid-log phase (A600 ~ 0.7) in Luria–Bertani medium at 37 °C, induced with 1.0 
mM isopropyl thio-β-D-galactoside, and grown for an additional 3 h. Bacteria were 
pelleted by centrifugation at 4000 g for 5 min and resuspended in ice-cold NaCl /Pi. 
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After three soniﬁcation steps of 10 s with an interval of 1 min on ice between each 
step, 1% (v/v) Triton X-100 was added. Cell debris was pelleted by centrifugation 
at 9500 r.p.m. for 15 min, and the supernatant containing the GST-fusion proteins 
was incubated with glutathione–Sepharose 4B beads for 3 h at room temperature. 
Subsequently, beads with adherent GST-fusion proteins were washed extensively 
with NaCl /Pi and stored at 4 °C until further use. For microwell coating and SPR 
purposes, GST-fusion proteins were eluted from the beads using 10 mm of reduced 
glutathione in 50 mm Tris/HCl pH 8.0.
Phage Display Library Screening
Phage display experiments were performed as described previously (6). In brief, a C-
terminal peptide library (with a complexity of 107 independent clones) displayed as 
capsid protein D fusions on bacteriophage λ was screened by afﬁnity selection (pan-
ning) over glutathione–Sepharose 4B beads coated with GST–PDZ fusion protein. 
The heterogeneity of the displayed peptides within the library has been previously 
veriﬁed by sequencing the inserts of randomly isolated phage clones (6). Following 
extensive washes, the adsorbed phage were propagated on BB4 bacteria by plate 
lysate, eluted, concentrated and subjected to another panning cycle. After three suc-
cessive panning cycles, individual phage clones were plaque puriﬁed and used for 
further studies, including sequence analysis of PCR-ampliﬁed λDsplay1 inserts. 
Micropanning Assay
Micropanning assays were performed directly on Glutathione-Sepharose 4B beads 
or on microtiter plate wells coated overnight with GST fusion proteins. The assay 
consists of a ‘one-step’ afﬁnity selection that is applied to individual clones. After 
washing out the excess of coated protein, equal amounts (109 phage particles) of 
each selected clone were added. Following 2 h incubation at 4 °C, unbound phages 
were removed by repeated washing, and adsorbed phage particles were titred by 
infecting BB4 bacteria.  
Tissue Culture and Transient Cell Transfection
COS-1 cells (ATCC # CRL-1650) were cultured in Dulbecco’s modiﬁed Eagle’s 
medium (Gibco  BRL, Gaithersburg, MD) supplemented with 10% (v /v) fetal bo-
vine serum. Transfections were performed as described previously (28) using the 
DEAE-Dextran method. Following a 24–48 h incubation at 37 °C and 7.5% (v/v) 
CO2, cells were washed twice with ice-cold NaCl/Pi and lysed with 500 μL ice-cold 
lysis buffer [0.5% (v/v) Triton X-100 (Merck, Rahway, NJ), 1mm phenylmethylsul-
fonyl ﬂuoride and protease inhibitor cocktail (Boehringer, Mannheim, Germany) in 
NaCl/Pi)]. After 30 min incubation on ice, lysates were cleared by centrifugation for 
20 min at 10.000 g and 4 °C. 
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 GST pull-down experiments were performed by incubating glutathione–
Sepharose 4B beads (Amersham Biosciences AB) with lysates of transfected COS-1 
cells expressing GST- and VSV-tagged proteins, essentially as described (27). Occa-
sionally, GST pull-down experiments were performed using glutathione–Sepharose 
4B-bound recombinant GST–PDZ3 protein that was produced in E. coli (28). After 
overnight incubation at 4 °C, beads were washed thoroughly ﬁve times with NaCl/
Pi, through repeated pelleting by centrifugation, before being transferred into a new 
tube and resuspended in 40 μL sample buffer [100 mm Tris/HCl, pH 6.8; 200 mm 
DTT; 4% (w/v) SDS; 20% (v/v) glycerol, 0.2% (w/v) bromophenol blue].
Western Blotting
Protein samples were boiled for 5 min and loaded onto a 15% polyacrylamide gel 
for size separation. Subsequently, proteins were transferred to nitrocellulose mem-
branes (Hybond ECL, Amersham Pharmacia Biotech, Piscataway, NJ) by electrob-
lotting. Blots were blocked for 30 min using 5% non-fat dry milk in TBS-T [10 
mm Tris/HCl, pH 8.0; 150 mm NaCl; 0.05% (v/v) Tween-20 (Sigma, St. Louis, 
MO)]. Monoclonal antibody P5D4 (33) [dilution 1 : 5.000 in TBS-T containing 5% 
(w/v) not-fat dry milk] was used to detect VSV-tagged proteins on blot. Polyclonal 
antiserum α-GFP (dilution 1 : 5.000) was raised in rabbits against a GST–EBFP fu-
sion protein (8) and has been successfully exploited to detect GST- as well as green 
ﬂuorescent protein-tagged proteins (27). Antibodies were incubated for at least 1 h 
at room temperature. Blots were washed three times with TBS-T to remove unbound 
antibody. Subsequently peroxidase-conjugated goat antimouse IgG or goat anti-rab-
bit IgG (dilution 1:20.000; Pierce, Rockford, IL) were applied as secondary antibod-
ies. Following three successive washes with TBS-T, the lumi-light Western blotting 
substrate kit (Roche Diagnostics, Lewes, UK) was used to visualize immunoreactive 
bands through exposure to Kodak X-omat autoradiography ﬁlms.
Sequence Alignments and Homology Modelling 
Amino acid sequences were analysed and aligned using Vector NTI Suite 5.5 soft-
ware (Informax, Oxford, UK), with similarity scores according to the BLOSUM62 
matrix. Homology modelling of PTP-BL PDZ3 was performed on the basis of the 
coordinates of PTP-BL PDZ2 solved by NMR (Brookhaven Protein Data Bank entry 
code 1GM1) (24), using the SWISS PDB VIEWER software. Molecular mechan-
ics calculations to energy-minimize the model were performed using the SWISS 
MODEL server (34).
Surface Plasmon Resonance 
A Biacore 2000 system (Biacore AB, Uppsala, Sweden) was used for SPR analy-
sis. N-Terminally biotinylated peptides (PRK2; DFDYIADWCCOOH, and ‘CxxCV’; 
56
Chapter 3
WQGRCEVCVCOOH; Ansynth Service B.V., Roosendaal, the Netherlands) were 
bound to streptavidin-coated sensor chips (SA) using the manufacturer’s instructions 
at a ﬂow rate of 5 μL•min-1. Puriﬁed GST-tagged PDZ domains, or GST alone as 
control, were dialysed against running buffer (10 mm Hepes pH 7.4, 150 mm NaCl, 
3 mm EDTA, 0.005% surfactant P20; BR-1000-54, Biacore AB) and diluted to the 
concentrations indicated. Besides the normal buffer conditions, also different redox 
conditions were tested by including 0.1 mm DTT or 1 mm H2O2 in the standard run-
ning buffer, respectively. Perfusion was at a ﬂow rate of 25 μL•min-1, ﬁrst over a 
control ﬂow cell (Fc1) and then over capture ﬂow cells coated with the biotinylated 
peptides (Fc2–4). After 13 min of association, the sample solution was replaced by 
running buffer alone, allowing the complex to dissociate. Binding was measured as 
the difference between the Fc1 and Fc2–4 curves. Experiments were performed at 
25 °C.
Results
Identiﬁcation of PDZ3 interacting C-terminal peptides
To disclose the C-terminal target speciﬁcity of the third PDZ domain in PTP-BL we 
screened a random C-terminal nonapeptide λ phage display library (6) using glu-
tathione S-transferase (GST)-tagged PTP-BL PDZ3 bound to glutathione–Sepharose 
4B beads as an afﬁnity matrix. After three successive selection cycles the obtained 
phage were plaque-puriﬁed and DNA sequencing revealed the amino acid sequence 
of the exposed peptides. The resulting sequences were aligned with respect to their 
C-terminus, and a consensus motif was derived reﬂecting the binding preference of 
PTP-BL PDZ3 (Table 1). No peptide-displaying phage were isolated that are remi-
niscent of the PRK2 C-terminus (-ADWCCOOH), the sole reported protein target for 
PTP-BL PDZ3 (16), suggesting that, under the conditions used for the selection, it 
may not represent the most optimal target for this PDZ domain. A majority of select-
ed peptides belongs to class II PDZ binding motifs, having hydrophobic or aromatic 
residues at the P-2 and P0 position (6,19,35). Remarkably, within this class II-type 
consensus sequence for PDZ3 two cysteine residues occupy the P-4 and P-1 positions, 
and valine is found as the P0 residue (-CxxCVCOOH, - where x is for any amino acid). 
The derived consensus sequence CxxCVCOOH represents a unique feature of putative 
PDZ3 ligands, because other PDZ domains analysed using the same approach never 
selected such peptides (6). Exceptions to this consensus are two sequences (clones 6 
and 23) that belong to the canonical class II PDZ target peptides, and one sequence 
(represented in clones 1, 3 and 4) harbouring two cysteine residues at the adjacent 
positions P-3 and P-2. 
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Cross-reactivity with other PDZ domains
The selected -CxxCVCOOH-encoding clones were tested for their suitability as PDZ-
binding interfaces for other PDZ domains using a micropanning assay. Two repre-
sentative phage clones (displaying –CssCV and -CdmCV C-terminal peptides) that 
had been selected by GST–PDZ2-5 or GST–PDZ3, respectively, were applied to 
PTP-BL PDZ domains (or combinations thereof) immobilized on multiwell plates. 
Bacterial expression of a GST-fusion protein containing all ﬁve PTP-BL PDZ do-
mains proved difﬁcult, probably due to the sheer size of the recombinant protein, and 
could not, therefore, be included in this study. In parallel, a more classical class II 
peptide-displaying phage, ending with -TWVCOOH, was included in the experiment. 
Figure 1 clearly shows that the -CxxCVCOOH peptides preferably bind to PDZ3; 
some 500-fold above background level (GST) and at least 20-fold better than to 
established class II binders like PDZ2 and PDZ4 of PTP-BL. A GST-fusion protein 
containing PTP-BL PDZ domains 2–5, thus including PDZ3, displays adsorption of 
the -CxxCVCOOH peptide-bearing phage that compares well with that of GST–PDZ3 
Table I: PTP-BL PDZ3-binding peptides selected by phage display
Clones             Sequences           Class
  6                 R Q E N S Q V Y V           II
  23                S G S M L I L F F           II
 1,3,4              V L S E G C C R V 
  2,8               V Q Q S C D M C V           II
  7,24              W Q G R C E V C V           II
  9                 L R T M C P V C V           II
  6*                A L H P C S A C V           II
  5                 L H Y G C F T C V            I
  5*                G F Q A C S S C V            I
  25                G G Y L C W T C V            I
  10                G I G Y C T N C V
consensus                 - C x x C V
Phage clones numbers, representing independent isolates (i.e. with different insert 
sequences), are indicated on the left. Clones marked by * were selected by PDZ 
domains 2-5, including PDZ3. Selected peptide sequences are depicted in single-
letter amino acid code and P0 and cysteine residues are shown in bold. The PDZ 
peptide binding class (11), when appropriate, is indicated on the right. The peptide 
consensus is shown. 
58
Chapter 3
alone. Taken together, these ﬁndings corroborate the unique preference of PDZ3 for 
-CxxCVCOOH peptides.
Candidate targets do not bind to PTP-BL PDZ3 in vivo
To identify cellular proteins that bear the PDZ3 binding consensus -CxxCVCOOH, 
and thus may represent physiological binding partners of PTP-BL, a ScanProsite 
database search (http://www.expasy.org/tools/scanprosite) was performed, which 
yielded eight hits (Figure 2A). We selected two candidates for in vivo binding stud-
ies, based on possible functional links with PTP-BL. 
 The human papilloma virus E7 protein interferes with NFκB signalling via 
attenuating the IκBα kinase complex (36). PTP-BL can bind to and dephosphorylate 
IκBα, and thus is implicated in regulating NFκB transcriptional activity (30,37). 
We therefore tested PDZ3-mediated binding of PTP-BL to the HPV10 E7 protein 
(-CprCVCOOH) by GST pull-down experiments. Glutathione–Sepharose 4B beads 
loaded with bacterially produced GST–PDZ3 fusion protein were incubated with 
lysates of COS-1 cells transfected with a vesicular stomatitis virus (VSV)-tagged 
HPV10 E7 construct. As a control we included the E7 protein of either the related 
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Figure 1: Binding preference of PTP-BL PDZ domains for class II versus CxxCV peptides. 
The speciﬁcity of the different GST-tagged PDZ domains (depicted by different shades of 
grey as indicated by the key) for three different peptides (peptide names are given below the 
bars) was investigated by performing a solid-phase immunoassay. Phage encoding -CDMCV 
and - CSSCV peptides, selected speciﬁcally by PDZ3 and PDZ2–5, respectively (Table I), 
were used. In addition, a phage displaying a class I peptide (ending with -TWV) was includ-
ed. On the vertical axis the number of phage binding to the PDZ domains following stringent 
washing steps is displayed.
HPV8 or HPV16, which do contain a CxxC motif but not at their extreme C-ter-
minus (which reads -KHGGS or -CSQKP, respectively; see also Figure 2B). In ad-
dition, GST pull-down experiments were also performed with PTP-BL PDZ2 and 
PDZ5 as controls. In western blot analyses, VSV-tagged E7 proteins could be readily 
detected in the cell lysates, but no afﬁnity precipitation of HPV10 E7 was evidenced 
for PDZ3 (data not shown). Bearing in mind that a PTP-BL protein segment con-
taining all of its ﬁve PDZ domains has revealed synergistic effects on PDZ target 
binding (27,38), we also performed the reverse experiment on lysates of transfected 
COS-1 cells coexpressing VSV-tagged PTP-BL PDZ domains 1–5 and GST-tagged 
E7 proteins. However, also in this set-up no signiﬁcant binding of HPV10 E7 protein 
to PTP-BL PDZ domains was detected (data not shown). 
 Mouse Slit1 protein has been reported to contain a C-terminal end that reads 
either –CAQCACOOH or –CAQCVCOOH, reﬂecting a possible polymorphism (acc.no. 
Q80TR4). Slit proteins play a key role in axon guidance, a process involving mul-
tiple signalling components among which the ephrins and ephrin receptors (39,40). 
PTP-BL, together with Src kinases, has been reported to regulate phosphorylation 
and reverse signalling of EphrinB (41). Furthermore, protein expression patterns in 
mice carrying a gene trap insertion within the PTP-BL gene support a role in neurite 
Figure 2: Testing of potential PTP-BL PDZ3 cellular targets that carry a CxxCV type C-
terminus. (A) Selection of proteins identiﬁed by a SCANPROSITE database search for the 
‘CxxCVCOOH’ motif. Proteins shown in bold were subsequently tested for interaction with 
PTP-BL PDZ3. (B) Sequence alignment of E7 proteins of HPV types 8, 10 and 16. Identities 
are in bold, and similar residues are on a grey background. The CxxCV-type C-terminus of 
HPV10 E7 is boxed.
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outgrowth (42). Indeed, using a sciatic nerve lesioning model, we recently dem-
onstrated a mild but signiﬁcant delay in motor neuron outgrowth in mice that lack 
PTP-BL phosphatase activity (43). We therefore tested whether PTP-BL PDZ3 could 
bind Slit1 isoforms using the afﬁnity puriﬁcation assays on transfected cell lysates 
described above. As was found for the HPV10 E7 protein, we did not observe a sig-
niﬁcant interaction using either GST-PDZ fusion proteins to afﬁnity-purify epitope-
tagged Slit proteins or using GST-Slit fusions to precipitate the VSV-tagged PDZ 
moiety of PTP-BL (data not shown).
Inﬂuence of redox conditions on PDZ3 binding to CxxCV targets
The above ﬁndings in mammalian cell lysates strongly oppose the results obtained 
in the phage display experiments. An obvious difference between these two experi-
mental approaches is the redox state. Panning experiments with phage occur under 
conditions that allow the formation of disulﬁde links between cysteine residues. Af-
ﬁnity puriﬁcation from transfected cell lysates is under conditions that prevent di-
sulﬁde bridge formation. To investigate directly whether the redox state inﬂuences 
PDZ3 binding to -CxxCV peptides, we performed phage display experiments under 
reducing conditions, by including dithiothrietol (DTT) at different concentrations in 
the buffer. 
 Three different class II PDZ target-displaying phage were used; one (-
WQGRCEVCVCOOH) was selected by PDZ3 from the library and represents the 
CxxCVCOOH-type targets (Table 1), whereas the other two (-SGSMLILFFCOOH) 
and (-RQENSQVYVCOOH) represent classical type II peptides that lack cysteines 
but demonstrated similar afﬁnities for PDZ3 (Figure 3A). In addition, a CxxCV-
COOH-type target belonging to peptide class I (-VQERCASCVCOOH) was included. 
A micropanning assay was performed by incubating immobilized GST–PDZ3 with 
a ﬁxed amount (109) of the respective phage. Subsequently, the number of phage 
that remained attached to the PDZ domain after multiple washes was determined. 
Microtitre wells containing GST alone were included as negative controls, which set 
background levels at ~103 bound phage. The addition of increasing amounts of DTT 
(up to 0.1 mm) resulted in a ﬁrm decrease, up to over 100-fold, in the number of 
CxxCVCOOH-expressing phage that were bound by GST–PDZ3 (Figure 3A). In con-
trast, binding of phage displaying peptides without cysteine residues was affected 
only slightly (SQVYV) or not affected at all (LILFF). GST–PDZ2, representing a 
known class II ligand binder, and therefore predicted to have at least moderate afﬁn-
ity towards the CEVCVCOOH peptide, was included for comparison. Importantly, the 
afﬁnity of GST–PDZ2 for the CEVCV-peptide was not altered by addition of DTT 
(Figure 3B), in line with a role for disulﬁde bonds in PDZ3 target binding. 
 To extend the above ﬁndings, we investigated the role of different redox 
conditions on the interaction of PTP-BL PDZ3 with -CxxCVCOOH targets using sur-
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face plasmon resonance (SPR) measurements. An N-terminally biotinylated peptide 
(WQGRCEVCVCOOH) was immobilized on streptavidin-coated (SA) sensor chips. 
Binding of GST-tagged PDZ domains was tested under various redox conditions, 
and GST alone was used as the negative control (data not shown). As shown in 
Figure 4, binding of PDZ3 to the CxxCV peptide is observed under normal buffer 
conditions. Interestingly, the binding afﬁnity is increased using oxidative conditions 
(H2O2). Possible inﬂuences of the redox condition on PDZ3 itself can be excluded 
because binding to the PRK2 C-terminal peptide was considerably impaired under 
these conditions (data not shown). Importantly, when changing to reducing condi-
tions using DTT, the binding of PDZ3 to the CxxCV-representing peptide is attenu-
ated, again indicating that disulﬁde bridge formation is an essential determinant for 
PDZ3 binding.
Redox effect is independent of cysteine present within PDZ3
Unlike PDZ2, the PTP-BL PDZ3 domain itself contains a cysteine residue in the β6 
strand (Figure 5A). This might explain why in the previous experiments the afﬁnity 
of PDZ3 for the SQVYV peptide appeared, albeit only partially, to be DTT sensi-
tive. In addition, this potentially allows for an intermolecular disulﬁde bond between 
PDZ3 and the cysteine-containing peptides, reminiscent of the ‘dock-and-lock’ in-
teraction observed for InaD and NorpA (18). By aligning the protein sequence of 
Figure 3: Effect of redox conditions on the interaction of PTP-BL PDZ3 with CxxCV pep-
tides. (A) Micropanning experiments comparing the afﬁnity of GST-PDZ3 for -LILFF (▼), 
-SQVYV (●), -CEVCV (×) and -CASCV (■) presenting phage. On the y-axis the number 
of phage adhering to the PDZ domains in the presence of various concentrations of DTT (in 
mM; x-axis) is displayed. (B) Similar micropanning experiment, comparing the afﬁnity of 
PTP-BL PDZ2 (●) and PDZ3 (×) for -CEVCV peptide-displaying phage (y-axis) in the pres-
ence of various concentrations of DTT (x-axis).
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PDZ3 with that of the PTP-BL PDZ2 domain for which structural data are available 
(PDB code 1GM1; Figure 5A), we performed homology modelling of PDZ3 (34). 
In the predicted structure the PDZ3 cysteine residue is placed at the extremity of the 
sixth β-strand, with its side-chain located rather opposite to the binding groove in 
between the β2 strand and helix α2 (Figure 5B). 
 To investigate whether this cysteine residue is in part responsible for the 
DTT-induced effects on PDZ3 afﬁnity for the -CxxCVCOOH peptides, we mutated the 
Cys1575 residue (amino acid numbering according to Accession no. NP_035334) to 
serine and tested the binding abilities of the resulting GST–PDZ3(C1575S) fusion 
protein. Intriguingly, the Cys–Ser mutant behaved similar to the wild-type PDZ3 do-
main in both screening and panning assays. By screening the random peptide phage 
library with GST–PDZ3(C1575S), cysteine-containing peptides were selected that 
are reminiscent of the wild-type PDZ3 proﬁle (i.e. CxxCV and xCCxV peptides; 
Table 2). Also, a micropanning assay performed on the -CASCVCOOH phage clone 
selected by the PDZ3(C1575S) mutant, and on the three class II peptide-bearing 
phage clones already characterized for binding to PDZ3 corroborated this ﬁnding, 
excluding the involvement of an intermolecular disulﬁde bridge between PDZ3 and 
its cysteine-containing peptide target (Figure 5C). Moreover, because the afﬁnity 
of PDZ3(C1575S) for the SQVYV peptide is DTT-insensitive, the mild effect on 
wild-type PDZ3 binding towards this peptide (Figure 3A) reﬂects a separate phe-
nomenon.
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Figure 4: Biosensor analysis of PTP-BL PDZ3 domain binding to oxidized and reduced 
forms of a -CxxCV type peptide. Binding of 20 nM of the PTP-BL PDZ3 domain fused to 
GST to the CxxCV peptide (WQGRCEVCVCOOH) was detected by changes in resonance 
units (RU; y-axis) over time (in s; x-axis). The sensorgrams were corrected by subtraction 
of the blank sensorgram of the control nonimmobilized ﬂow cell. Measurements were per-
formed in standard running buffer (normal; indicated on the right) or under reducing (0.1 mM 
DTT in running buffer) or oxidizing (1 mM H2O2 in running buffer) conditions.
Discussion
Screening of a phage display library expressing random C-terminal nonapeptides 
was performed to get a better understanding of the binding speciﬁcity of each PDZ 
domain in PTP-BL. Among the ﬁve PTP-BL PDZ domains, the third domain (PDZ3) 
displayed a unique binding preference: two cysteine residues are almost invariably 
present at the P-1 and P-4 positions in the selected peptides (Table 1). High afﬁnity for 
-CxxCVCOOH peptides appeared characteristic for PDZ3, because none of the other 
PDZ domains in PTP-BL is able to select this kind of ligands from the phage library 
(data not shown) or bind these peptides to a similar extent (Figure 1). We were able 
to detect a weak interaction of xCxxCVCOOH peptide-displaying phage with PDZ2 
Figure 5: The cysteine residue within PTP-BL PDZ3 is not required for CxxCV peptide 
binding. (A) Sequence alignment of the second PDZ domain of PTP-BAS (1E-PDZ2) and 
domains PDZ2 (BL-PDZ2) and PDZ3 (BL-PDZ3) of PTP-BL. Secondary structure elements 
(21,24) are indicated on top. Identical residues are in bold; similarity is shown by a grey 
background. Cys1575, at the extremity of the β6 strand in PDZ3, is indicated by an arrow-
head. (B) Structural model for PTP-BL PDZ3 based on reported PTP-BL PDZ2 domain 
structure (1GM1). Side chains of ‘GLGF’ loop and Cys1575 are shown and αB helix (α2) 
and βB strand (β2) are indicated. (C) Micropanning experiments comparing the afﬁnity of 
GST-PDZ3(C1575S) for - SQVYV (●), -LILFF (▼), -CEVCV (×) and -CASCV (■) peptide-
displaying phage (y-axis) in the presence of various concentrations of DTT (x-axis).
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and PDZ4, which probably reﬂects the class I or II nature of these peptides. Indeed 
the selected phage expressed peptides that belong to either class I or class II PDZ 
target sequences, which are characterized by hydrophobic residues in P0 and either 
serine/threonine or hydrophobic residues at P-2, respectively. Although it is widely 
accepted that for the canonical type of PDZ target interaction the amino acids at the 
P0 and P-2 position are the most important, the signiﬁcance of residues at other posi-
tions, including P-1 and P-4, has been documented (4). 
 In order to extrapolate these in vitro binding data to the identiﬁcation of po-
tential in vivo interaction partners of PTP-BL, databases were searched for proteins 
carrying the CxxCV motif at the C-terminus that might be functionally linked to 
this large intracellular protein tyrosine phosphatase. In view of PTP-BL’s proposed 
role in IκBα-mediated regulation of NFκB transcriptional activity (30,37) and neu-
rite outgrowth (41-43), we tested a possible interaction of PTP-BL with HPV10 E7 
protein and mouse Slit1 isoforms, exploiting transfected mammalian cells in GST 
pull-down and coimmunoprecipitation experiments. No interaction between the 
CxxCV-bearing proteins and PTP-BL PDZ3, or any of its other PDZ domains, could 
be observed, not even when using cross-linking agents. This may indicate that within 
the context of the whole protein the C-termini of Slit1 and HPV E7 are not accessible 
for PDZ domains. Also, perhaps other residues in addition to the two cysteines and 
the C-terminal valine, such as the P-2 residue, are important. Indeed, the peptides 
selected by PDZ3 in the phage display system belonged to either class I or class II 
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Table II: PTP-BL PDZ3(C1575S)-binding peptides selected by 
phage display
Clones             Sequences           Class
  1            T Y N D E C C L V 
  7            E A D V G C C V V
  10           E E P L D C C V V 
 
  4            V Q E R C A S C V         I
  5,8          A W E D C L T C V         I
  6            M R E L N E W R V        II
Phage clone numbers, representing independent isolates are indicated on the left. 
Selected peptide sequences are depicted in single-letter amino acid code and P0 
and cysteine residues are shown in bold. The PDZ peptide binding class (11) when 
appropriate, is indicated on the right.
targets, thus containing suitable residues at the P-2 position, whereas the proteins 
selected from the database search did not fall into these classes. 
 An appealing alternative explanation for this effect is that the cytosolic en-
vironment in COS-1 cells is reducing in nature, whereas the test-tube conditions in 
the phage display panning experiments allow cysteine-cysteine disulﬁde bridges to 
be formed. Under such conditions the -CxxCVCOOH peptide may be displayed as a 
bridged cyclic peptide scaffold on the phage particles, which could enhance afﬁnity. 
Furthermore, PTP-BL PDZ3 itself carries a cysteine residue at the extremity of the 
sixth β-strand (Figure 5A), raising the possibility of the formation of an intermo-
lecular disulﬁde bridge between the PDZ domain and its target peptide, similar to 
the ‘dock-and-lock’ principle observed in the crystal structure of the ﬁrst PDZ do-
main of InaD in complex with the C-terminal tail of NorpA (18). We therefore also 
performed GST pull-down experiments on lysates of transfected COS-1 cells under 
oxidizing conditions, but again no binding of the CxxCV targets to PTP-BL PDZ 
domains could be detected (data not shown).
 These considerations led us to study the impact of the reducing agent DTT 
in micropanning phage display experiments. Indeed, this resulted in a considerable 
loss of interaction between the –CxxCVCOOH peptide-displaying phage and PDZ3, 
whereas no such effect was noted for PDZ3 afﬁnities towards non-CxxCV targets 
(Figure 3A). The addition of DTT also had no effect on binding of the class II –
CxxCVCOOH peptide to PTP-BL PDZ2 (Figure 3B). To monitor the contribution of 
Cys1575 in PDZ3 to the DTT effect, a Cys1575Ser mutant was constructed and as-
sessed for its binding speciﬁcity under normal and reducing conditions. We found 
that this mutation had no signiﬁcant effect on the PDZ3 interactions in micropanning 
experiments, with either -CxxCVCOOH peptides or other class II targets (Figure 5C). 
These ﬁndings exclude the formation of an intermolecular disulﬁde bridge between 
peptide and PDZ domain. This was further supported by phage-library screening 
results for the mutant PDZ3 domain, because substitution of Cys1575 did not impair 
speciﬁc selection of –CxxCVCOOH peptides (Table 2).
 Our ﬁndings leave the possibility that the two cysteins present in the peptide 
engage in disulﬁde bridge formation between two peptides (intermolecular) or within 
the same peptide (intramolecular), thereby enabling high-afﬁnity binding to PDZ3. 
The ﬁrst option, formation of disulﬁde bridges between two PDZ targets, seems 
less likely. Such cross-linking via P-1 and/or P-4 residues would greatly reduce the 
ﬂexibility of the combined peptides, which is needed to dock into the PDZ binding 
groove. The proper positioning of PDZ targets, e.g. through dimerization, has indeed 
been recognized as a requirement for efﬁcient binding (27). The second option, for-
mation of disulﬁde bridges within the target peptide, is supported by the notion that 
cyclization of peptides through intramolecular disulﬁde bridge formation appeared 
essential for binding to syntrophin PDZ domains (44). In addition, using synthetic 
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cyclization of peptides in order to obtain conformationally constrained macrocyclic 
ligands for PDZ domains, Li et al. (45) were able show that small cyclic peptides 
indeed can serve as ligands for PDZ domains and that apparently minor changes in 
ring size can notably inﬂuence the binding afﬁnity. 
 But does PTP-BL PDZ3 ever encounter disulﬁdebond-containing target pep-
tides inside the cell? It has become clear that reactive oxygen species (ROS) are not 
simply damaging by-products of cellular metabolism, but can play important regu-
latory roles in many cellular processes (46-48). In particular, the local production 
of ROS in response to extracellular physiological stimuli is currently viewed as an 
important mechanism for ﬁne-tuning tyrosine phosphorylation-dependent signalling 
(49-51). All protein tyrosine phosphatases (PTPs) contain an active-site cysteine res-
idue that must be in a reduced state in order to participate in catalysis. ROS-mediated 
oxidation of this residue results in inhibition of PTP activity (52), but also more indi-
rect effects are observed. For example, a conformational change in the intracellular 
domain of RPTPα induced by H2O2 treatment led to a change in the conformation of 
the extracellular domains, indicating the capacity for inside-out signalling (53). Such 
inﬂuences of oxidation on the regulation of different processes in the submembra-
nous area of the cell make it tempting to speculate that the third PDZ domain of PTP-
BL might function as a ‘redox sensor’. In such a model, PTP-BL would circumvent 
the chance of being (reversibly) inactivated itself at the site of local ROS production 
following, e.g. growth factor signalling. PTP-BL would only be recruited following 
the appearance of ROS-induced appropriate disulﬁde-bridge-containing peptide tar-
gets for PDZ3 in that area, and could then directly counterbalance the local burst in 
kinase activity. Unfortunately, the very nature of such presumed, short-lived targets 
currently precludes their identiﬁcation.
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Abstract
PDZ domains are protein-protein interaction modules that are crucial for the as-
sembly of structural and signalling complexes. PDZ domains speciﬁcally bind short 
carboxyl-terminal peptides and occasionally internal sequences that structurally re-
semble peptide termini. Previously, using yeast two-hybrid methodology, we studied 
the interaction of two PDZ domains present in the large submembranous protein ty-
rosine phosphatase PTP-BL with the C-terminal half of the LIM domain-containing 
protein RIL. Deletion of the extreme RIL C-terminus did not eliminate binding, sug-
gesting the presence of a PDZ binding site within the RIL LIM moiety. We have now 
performed experiments in mammalian cell lysates and found that the RIL C-terminus 
proper, but not the RIL LIM domain, can interact with PTP-BL, albeit very weakly. 
However, this interaction with PTP-BL PDZ domains is greatly enhanced when the 
combined RIL LIM domain and C-terminus is used, pointing to synergistic effects. 
NMR titration experiments and site-directed mutagenesis indicate that this result is 
not dependent on speciﬁc interactions that require surface exposed residues on the 
RIL LIM domain, suggesting a stabilizing role in the association with PTP-BL. 
Introduction
Orchestration of cellular signalling pathways is exerted through the tight but versa-
tile control of sequential and modular protein-protein interactions. Key players in 
the mammalian cell system are protein tyrosine kinases and protein tyrosine phos-
phatases (PTPs) that determine the phosphotyrosine content of cellular proteins and 
thereby triggering many signalling and interaction cascades (1). PDZ domain-con-
taining proteins play a critical role as well, by sorting, assembling, and anchoring 
multi-protein signalling complexes (2,3). PDZ domains are among the most com-
mon protein modules in current day organisms and, in general, they recognize and 
bind speciﬁc C-terminal sequences in target proteins. Interestingly, no tyrosine-spe-
ciﬁc protein kinases with PDZ domains have been found thus far. A small number of 
PTPs containing PDZ domains have been identiﬁed, including one that contains ﬁve 
PDZ domains in tandem; PTP-BL (for a review see (4)).
 PDZ domains consist of six antiparallel β-strands and two α-helices. The 
canonical, C-terminal peptide binding region is located in between βB strand and 
the αB helix (5). The amino and carboxyl terminal boundary of the PDZ domain 
itself are close to each other in the folded structure and are on the opposite side rela-
tive to the peptide-binding groove in the domain, an ideal arrangement for a protein 
interaction module. Multiple structures have been solved for various PDZ domains 
and in several cases while in complex with speciﬁc ligands (5-8). Peptide binding 
speciﬁcity of PDZ domains is primarily determined by the identity of residues from 
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positions “-3” to “0” relative to the carboxylate endgroup. These residues bind in 
complementary surface pockets on the PDZ domain (9).
 Although C-terminal peptides are the archetypal PDZ domain ligands, it 
has become clear that PDZ domains have a much more varied repertoire of interac-
tion surfaces (10-13). These include PDZ domain binding to spectrin-like motifs 
(14), ankyrin repeats (15), LIM domains (16-18), as yet unclassiﬁed internal pro-
tein sequences (19-23), and even phospholipids (24). Crystallographic studies have 
shown that the non-canonical interaction of the PDZ domain of syntrophin with an 
internal sequence, referred to as “pseudopeptide”, in nNOS is enabled by a unique 
conformation introduced by a β-turn structure (8). This led Harris and co-workers to 
formulate a general rule for PDZ ligand recognition (25); a ligand must contain the 
proper linear amino acid recognition motif followed by either a carboxyl-terminus 
or, alternatively, a stabilized β-turn. Whether this indeed applies to the other PDZ 
domain - internal sequence interactions remains to be investigated.
 Some PDZ domains are able to bind to both carboxylate peptide sequences 
as well as internal sequences (2). For example, the second PDZ domain in PTP-BL, 
or its human orthologue PTP-BAS, has been reported to associate with C-termini of 
APC (26), p75NTR (27) and human Fas (28-30). In addition, we previously reported 
on the basis of yeast two-hybrid experiments that PTP-BL PDZ2 can interact with 
the LIM domain in RIL (16), a protein that is down-regulated in H-Ras-transformed 
ﬁbroblasts (31) and up-regulated in v-Jun transformed cells (32). Mutations in the 
human RIL gene have been linked to low bone mineral density in adult Japanese 
women (33) and cell biological studies demonstrated a role in the modulation of 
actin stress ﬁber turnover (34). Like PDZ domains, LIM domains are protein interac-
tion modules. The LIM domain structure is very conserved, conforming to the con-
sensus sequence CX2CX16-23HX2CX2CX2CX16-21CX2-3(C/H/D), and is composed 
of two spatially discrete zinc-binding sub-domains (35,36). Initial yeast-two hybrid 
studies showed that the PDZ2 interaction with the RIL LIM domain was independent 
of RIL’s C-terminal -VELV sequence and enhanced by presence of PTP-BL PDZ4 
(16). Further structural studies by NMR have revealed that PDZ2 can interact spe-
ciﬁcally, albeit weakly, with the ﬁnal twelve amino acids of RIL (37). 
 To further investigate the PDZ domain-mediated interaction between PTP-
BL and RIL, we have performed protein association studies in mammalian cells us-
ing a related PDZ-LIM protein as a control. Our results point to synergistic effects 
of the RIL C-terminus and the LIM domain on PTP-BL binding. Furthermore, NMR 
titration experiments and site-directed mutagenesis indicate that the contribution of 
the LIM domain to the association does not reﬂect a direct binding to the second 
PDZ2 domain in PTP-BL, but rather a stabilizing role for the RIL LIM moiety.
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Materials and Methods
Mammalian expression plasmids
The expression plasmid encoding PTP-BL PDZ 1-5 has been described elsewhere 
(38). Expression plasmids pEBG RIL-LIM-C, pEBG RIL-LIM and pEBG RIL-C 
were generated by PCR using speciﬁc primers with added BamHI sites that would 
yield fragments corresponding to nucleotide regions 661-1029, 661-1014 and 958-
1029 in mRIL cDNA (acc.nr. Y08361), respectively. In the case of pEBG RIL-LIM 
a stop-codon was included in the reverse primer. Sequences of all primers used are 
available from the authors upon request. In a similar way, pEBG ALP-LIM-C was 
generated, containing nucleotides 708-1046 of rat ALP (acc.nr. NM_053650). Re-
sulting amplicons were digested with BamHI and cloned in-frame into the mam-
malian expression vector pEBG (39) to enable expression as GST-tagged fusion pro-
teins. Expression constructs encoding GFP-tagged RIL fragments were generated 
similarly, using the BamHI site at position 661 in the RIL cDNA and an EcoRI site 
provided by the downstream primer and unidirectional cloning of the BamHI-EcoRI 
cDNA fragments into pEGFP-C1.
 Chimaeric ALP-RIL and RIL-ALP constructs were generated, using fusion 
primers (5’- gactcgagccttggc gtgcgtctcacaatac – 3’ and 5’- cgtgcgggctctcgc gtgat-
tctcacagtac –3’, respectively; RIL speciﬁc parts are in bold) in combination with 
cloning primers described above, exploiting a so-called fusion PCR reaction (40). 
Resulting fusion cDNA fragments were cloned as BamHI fragments into pEBG, 
rendering expression constructs pEBG ALP-LIM/RIL-C and pEBG RIL-LIM/ALP-
C. All constructs generated by PCR were veriﬁed by automated sequence analysis to 
exclude undesired mutations.
Tissue culture and transient cell transfection
COS-1 cells were cultured in DMEM/ 10% fetal calf serum (FCS) medium (Gibco/ 
BRL, Gaithersburg, MD). Transfections were performed using the DEAE-Dextran 
method as described previously (18). Following a 24-48h incubation at 37 °C and 
7.5% CO2, cells were washed twice with ice-cold PBS and lysed with 500 μl ice-
cold lysis buffer (0.5% Triton X-100 (Merck), 1mM PMSF and protease inhibitor 
cocktail (Boehringer) in PBS). After 30-minute incubation on ice, the lysates were 
cleared by centrifugation for 20 minutes at 10.000 x g and 4 °C.
 GST pull-down experiments were performed by incubating glutathione 
sepharose 4B beads (Amersham Biosciences AB) with lysates of transfected COS-1 
cells. For the immunoprecipitation experiments αVSV antibodies covalently cou-
pled to protein G sepharose beads (Amersham Pharmacia Biotech AB) were used. 
After overnight incubation at 4 °C, beads were thoroughly washed ﬁve times with 
PBS before being transferred into a new tube and resuspended in 40 μl sample buffer 
74
Chapter 4
(100 mM Tris-HCl, pH6.8; 200m M DTT; 4% SDS; 20% glycerol, 0.2% bromophe-
nol blue).
Western Blotting
Samples were boiled for 5 minutes and loaded onto a 15% polyacrylamide gel for 
protein size separation. Following SDS-PAGE proteins were transferred to nitrocel-
lulose membranes (Hybond ECL, Amersham Pharmacia Biotech) by electroblotting. 
Blots were blocked for 30 minutes using 5% non-fat dry milk in TBS-T (10mM Tris-
HCl, pH8.0; 150mM NaCl; 0.05% Tween-20 (Sigma)). Monoclonal α-VSV antibody 
P5D4 (41) (dilution 1:5.000) in TBS-T containing 5% not-fat dry milk was used to 
detect VSV-tagged proteins on blot. Polyclonal antiserum α-GFP (dilution 1:5.000), 
raised in rabbit by immunization with a GST-EBFP fusion protein (17), was used to 
detect GST- as well as GFP-tagged proteins. Peroxidase-conjugated goat anti-mouse 
IgG or goat anti-rabbit IgG (dilution 1:20.000; Pierce) were used as secondary anti-
bodies to visualize immunoreactivity. Antibodies were incubated for at least 1 hour 
at room temperature. In between antibody incubation steps and after the secondary 
antibody incubation, blots were washed three times with TBS-T to remove unbound 
antibody. For detection, the lumi-light Western blotting substrate kit (Roche Diag-
nostics) was used. Immunoreactive bands were visualized by exposure to Kodak 
X-omat autoradiography ﬁlms.
Recombinant protein production
The production of 15N-labelled recombinant His-tagged PDZ2 protein in Escherichia 
coli BL21(DE3) cells and its puriﬁcation over Ni2+-NTA agarose and S-sepharose 
fast ﬂow cation exchange columns has been described elsewhere (37). A biotinylat-
ed peptide corresponding to the C-terminal 12 residues of the RIL protein (biotin-
VAVYPNAKVELVCOOH) was ordered from Ansynth Service BV (Roosendaal).
 The RIL C-terminal part including the LIM domain (amino acid residues 
249-330, accession number NP_062290) as well as the LIM domain lacking the 
ﬁnal 16 C-terminal amino acids (residues 249-314) were expressed as GST fusion 
proteins in Escherichia coli BL21 Codon Plus (DE3) RIL competent cells (Strata-
gene). Bacterial pellet was resuspended in 1x PBS buffer (pH 7.7) in the presence 
of 1 mM aprotinin, 1 mM PMSF and Complete protease inhibitor, soniﬁed, and then 
centrifuged twice at 10,000 rpm at 4 ºC for 30 minutes to remove cell debris. The 
supernatant was bound to glutathione agarose beads (Molecular Probes) and washed 
with 1x PBS buffer. Elution from the column was performed by 15 mM reduced 
glutathione at pH 7.7. To cleave off the GST tag, 10 units thrombin per ml was added 
for ± 18 h at 4 °C. The resulting mixture was passed over a Sephadex G75 size exclu-
sion column at room temperature and appropriate fractions were collected, dialyzed 
against excess water or an appropriate buffer overnight at 4 °C.
75
PTP-BL interacts with the LIM domain-containing RIL protein
 
NMR measurements
The differences in backbone HN and N chemical shifts in the PDZ2 domain upon 
titration with the RIL protein segments were monitored using 15N-HSQC spectra, 
recorded on the equilibrated samples at 600 MHz and 25 ºC. The RIL C-terminus 
peptide was titrated up 3.5 equivalents into a 1 mM PDZ2 sample, composing of a 
buffer of 50 mM KH2PO4/K2HPO4 and 50 mM KCl, pH 6.8, H2O/D2O (95%/5%). A 
sample of 400 μl of 0.5 mM of GST-RIL(249-330) was prepared in a pH 6.8 buffer 
of 50 mM KH2PO4/K2HPO4 and 50 mM KCl, H2O/D2O (95%/5%). Labelled PDZ2 
was added until 1.84 equivalents. A sample of 0.5 mM of GST-RIL(249-314) was 
prepared at pH 6.3, and labelled PDZ2 domain was titrated up until 1.2 equivalents.
LIM domain homology modelling
Amino acid sequences of RIL and CRP2 were analysed and aligned using Vector 
NTI Suite 5.5 software (Informax, Oxford, UK). The structure of LIM2 of the quail 
CRP2 (PDB accession code 1QLI) was used for identiﬁcation of potential residues 
with surface-extended side-chains. Solvent accessibility was calculated using the 
program MOLMOL (42), using a probe radius of 1.4Å. Buried or structurally crucial 
amino acid residues were ﬁrst excluded. Of the remaining residues, those with a 
large solvent accessible area (>50%) or those with an inherent interesting structural 
motif were selected.
Interaction trap assay
Vector DNAs and yeast strains used for the two-hybrid assay, kindly provided by 
Drs. Finley and Brent, were used as described (43). The various PTP-BL-containing 
bait plasmids and several mouse RIL prey constructs have been previously described 
(16). Alanine mutations within the mouse RIL LIM domain were introduced in prey 
plasmid pJG-mRIL(209-330) (16) by a two-step PCR protocol (40). First, PCR am-
pliﬁcation using the vector-speciﬁc primer “5’BCO” (5’-ccagcctcttgctgagtggagatg-
3’) and an antisense mutant-speciﬁc primer (primer details available upon request) 
on pJG was performed. The resulting amplicon together with a pJG mRIL-FL (16) 
Pst1 fragment, encoding the C-terminal part of RIL, were used as template in a sec-
ond PCR reaction with primers “5’BCO” and “antisense RIL” (5’-gcgaattcagacaagt-
tccacc-3’; RIL stop codon complement is in bold). The resulting PCR fragments 
were digested using BamHI (nucl. position 661 in RIL) and EcoRI (in “antisense 
RIL”) and cloned in-frame into the BglII/EcoRI digested pJG-Br2 prey vector, a 
modiﬁed pJG4-5 yeast two-hybrid prey vector (28). All constructs were veriﬁed by 
sequencing to exclude undesired mutations.
 Prey plasmids were introduced in yeast strain RFY206 (MATα), and bait 
plasmids together with the lacZ reporter plasmid pMW107 were transformed into 
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yeast strain EGY48 (MATα). A mating assay, essentially according to Finley et al. 
(44), was used to produce diploid yeast cells that contained the various bait – prey 
combinations as well as the reporter plasmid. To determine the relative strength of 
the two-hybrid bait-prey interactions, β-galactosidase activity measurements were 
performed on crude yeast protein extracts essentially as described (45). Five inde-
pendent yeast colonies were assayed for each speciﬁc prey and bait combination. 
Statistical signiﬁcance (p<0.05) was assessed using the student t-test.
Two-step puriﬁcation of protein complex
COS-1 cells were transfected as described above and lysed after 24h in 1 ml Hepes-
buffered solution (40 mM Hepes pH 7.5, 120 mM NaCl, 1 mM EDTA, 1% Tri-
ton X-100, 1 mM PMSF and protease inhibitor cocktail (Boehringer)). After a 1h 
incubation on ice, lysates were cleared by centrifugation as described above, and 
incubated for 2h at room temperature with glutathione sepharose 4B beads. Subse-
quently, beads  were washed three times with PBS and bound proteins were eluted 
using 0.5 ml of elution buffer (10 mM reduced glutathione in 50 mM Tris-HCl pH 
8.0) for 15 minutes. Next, the eluate was subjected to immunoprecipitation using the 
α-VSV monoclonal antibody covalently coupled to protein G sepharose beads (Am-
ersham Pharmacia Biotech AB). After two hours of incubation at room temperature, 
beads were washed six times with PBS and then resuspended in 40 µl sample buffer. 
Samples were boiled for 5 minutes and loaded onto a 15% polyacrylamide gel for 
protein size separation. Proteins on the gel were visualized using a silver-staining 
protocol (46).
Results
Characterization of the PTP-BL - RIL interaction in mammalian cells
To investigate the PTP-BL - RIL interaction in more detail in mammalian cells, ex-
pression constructs encoding GST-tagged mouse RIL parts were generated (Figure 
1A). In addition to cDNA segments encoding the LIM domain-containing carboxyl-
terminal half of RIL (a.a. 209-330; protein acc. no. NP_062290) also parts encoding 
solely the LIM domain or the adjacent C-terminal 23 residues were introduced in 
the pEBG vector. The single, N-terminal PDZ domain of RIL was excluded in these 
constructs since it can also interact with the RIL C-terminal half (16), and thus will 
compete with PTP-BL PDZ domains. The GST-tagged RIL constructs were trans-
fected into COS-1 cells, together with a plasmid encoding VSV-tagged PTP-BL PDZ 
domains 1-5 (a.a. 1002-2018; acc. no. NP_035334), and resulting lysates were used 
for GST pull-down assays. Previous studies had revealed that RIL binding is most 
pronounced for a PTP-BL protein segment containing all its PDZ domains (BL-
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Figure 1: The RIL C-terminus is essential for the interaction with PTP-BL PDZ domains. 
(A) Schematic representation of the protein segments used in the GST pull-down experi-
ments. Depicted are the PTP-BL, RIL and ALP full length proteins and their derived VSV 
or GST-tagged proteins. PDZ domains are represented by black circles and LIM domains 
by black diamonds. The KIND, FERM and PTP domains of PTP-BL are indicated as black, 
grey and hatched boxes respectively. White small and large boxes represent VSV and GST 
tags, respectively. Names and amino acid positions of the different constructs are indicated 
on the right. Representations of GFP-tagged RIL segments used in this study are in essence 
comparable to the depicted GST fusions. (B) Interaction of GST-tagged RIL or ALP protein 
segments with PTP-BL PDZ domains. COS-1 cells were cotransfected with indicated expres-
sion constructs and lysates were used for GST pull-down and Western blot analysis. Anti-
VSV (middle panel) or anti-GFP (a polyvalent rabbit antiserum immunoreactive towards 
GFP and GST tags; lower panel) sera were used to detect the presence of the desired proteins 
in the lysates. The multiple bands detected with anti-VSV reﬂect partial degradation of the 
PDZ-containing moiety. Following afﬁnity puriﬁcation over glutathione-sepharose beads, 
co-purifying PDZ domains were detected using Western blot analysis exploiting anti-VSV 
antibodies (upper panel). A GST-ALP fusion protein was used as negative control. (C) Inter-
action of GFP-tagged RIL protein segments with PTP-BL PDZ domains. COS-1 cells were 
transfected with indicated constructs and protein expression was veriﬁed (middle and lower 
panel) as outlined above. Following immunoprecipitation with anti-VSV, coprecipitating RIL 
segments were detected by immunoblot analysis using anti-GFP antiserum (upper panel). 
PDZ-I-V) when compared to the PDZ2 or PDZ4 domain alone (16). Tagged proteins 
could be readily detected in the corresponding cell lysates upon Western blotting 
(Figure 1B, lower and middle panel). However, the VSV-tagged BL-PDZ-I-V was 
only co-puriﬁed with GST-fusion proteins that contained the proper RIL C-terminus 
(Figure 1B; upper panel). Contrasting with the previous studies in yeast (16), BL-
PDZ-I-V did not interact detectably with the RIL LIM domain only, and the RIL C-
terminal tail by itself did associate with BL-PDZ-I-V. Importantly, this interaction is 
about ﬁve-fold stronger when in addition to the RIL C-terminus also its LIM domain 
is included (compare lanes 1 and 3 in Figure 1B). 
 The speciﬁcity of the observed interactions is underscored by observation 
that a comparable fusion protein of ALP (alpha-actinin-2 associated LIM protein; 
AF002281) does not pull down BL-PDZ-I-V (Figure 1B). Like RIL, ALP contains 
an N-terminal PDZ domain and a single, C-terminal LIM domain (Figure 2A). Over-
all, RIL and ALP bear 42% sequence identity and display a similarity of 56% at the 
amino acid level, but the PDZ and the LIM domain show an even higher homology 
(55% and 69% identical, respectively). Although the C-terminal tail in both proteins 
is highly homologous, RIL contains ﬁve additional amino acids (-KVELVCOOH) 
which act as a PDZ binding motif, explaining why ALP does not bind to PDZ do-
mains in PTP-BL (Figures 1,2) and RIL (17).
 A reverse experiment was performed, in which PTP-BL PDZ domains were 
immunoprecipitated using α-VSV antibodies covalently coupled to protein G sepha-
rose beads and co-precipitating GFP-tagged RIL parts were subsequently detected 
on Western blots using α-GFP antiserum (Figure 1C). The tagged RIL and PTP-BL 
proteins were all properly expressed (Figure 1C; lower and middle panel) but only 
the RIL construct including both the LIM domain and the C-terminus proper co-
precipitated with the VSV-tagged PDZ domains in sufﬁcient amounts (upper panel). 
Obviously, in this reverse experiment co-precipitation of the RIL C-terminus with 
PTP-BL PDZ domains ends up below detection level, which again points to an en-
hancing effect of the RIL LIM domain on the RIL C-terminus – PTP-BL PDZ do-
main interaction.
 The above ﬁnding that the LIM domain in RIL intensiﬁes the interaction 
with PTP-BL PDZ domains prompted us to study this inﬂuence by exploiting chi-
maeric ALP/RIL constructs in which the C-terminal tails have been swapped (Figure 
2B). As expected on the basis of the above experiment, a GST-tagged RIL-LIM/
ALP-C chimaeric fusion protein, like GST-ALP, is unable to interact with PTP-BL 
PDZ domains. Surprisingly, the GST-tagged ALP-LIM/RIL-C chimaeric protein 
binds BL-PDZ-I-V to a similar extent as the wild type RIL-LIM-C construct. These 
experiments corroborate the enhancing effect by the LIM domain on the BL-PDZ-
I-V - RIL C-terminal tail interaction (Figure 1), and show that the homologous ALP 
LIM domain can also exert this effect. This synergistic effect is even clearer when 
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Figure 2: Positive contribution of the RIL as well as the ALP LIM domain to the interaction 
of PTP-BL PDZ domains with the RIL C-terminus. (A) Sequence alignment of mouse RIL 
(Y08361) and rat ALP (NM_053650) proteins. The doubly underlined stretch indicates the 
PDZ domain; a single line marks the LIM domain part. Identical residues are depicted in 
bold, similar residues are on a gray background. The horizontal arrow indicates the start of 
the proteins used in the GST pull-down experiments. The vertical arrow reﬂects the point of 
domain swapping in the RIL/ALP chimaeric constructs. (B) Interaction of GST-tagged RIL/
ALP chimaeric proteins with PTP-BL PDZ domains. Following co-transfection of COS-1 
cells with the indicated constructs, production of the desired proteins was demonstrated by 
Western blot analysis of cell lysates using anti-VSV (middle panel) or anti-GFP (a polyvalent 
rabbit antiserum immunoreactive towards GFP and GST tags; lower panel) antibodies. Co-
puriﬁcation of BL-PDZ-I-V in GST pull-down experiments was assessed on Western blots 
using anti-VSV antibodies (upper panel). (C) LIM domain-enhanced interaction of the RIL 
C-terminal tail with PTP-BL PDZ domains. Lysates from transfected cells were used for 
immunoblot analyses and GST pull-down assays as described above. The multiple bands 
detected with anti-VSV reﬂect partial degradation of the PDZ-containing moiety.
the two different LIM domain-containing constructs are compared to the RIL C-ter-
minus proper concerning their capability to pull down PTP-BL PDZ domains (lane 
2 versus lanes 1 and 3 in Figure 2C). 
No evidence for RIL LIM domain multimerization
Studies suggest that the binding of PDZ domains to C-terminal targets may depend 
in part on whether and how these C-termini are grouped and displayed (47). Some 
LIM domains are capable of homo-dimerization (48) and the consequent spatial re-
cruitment and syntenic display of C-termini may well explain the observed enhanc-
ing effect that the ALP and RIL LIM domains have on the PTP-BL PDZ domain 
binding to the RIL C-terminus. To be able to investigate the dimerization capabilities 
of LIM domains, we refrained from using GST fusions in view of its intrinsic dimeri-
zation properties (49). Instead, experiments were performed on lysates of COS-1 
cells transfected with GFP and VSV epitope-tagged RIL and ALP constructs (Figure 
3). Immunoprecipitates of VSV-tagged RIL lacking its N-terminal PDZ domain, us-
ing αVSV antibodies covalently coupled to protein G sepharose beads, were checked 
on Western blots for co-precipitation of various GFP-tagged RIL or ALP protein 
parts. No proof for RIL LIM domain homo-dimerization was obtained. However, a 
weak association between RIL and ALP, dependent on the presence of the RIL LIM 
domain, was apparent (Figure 3). This hetero-dimer formation seems to be stronger 
when the C-terminal tail of RIL is absent. 
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Figure 3: The RIL LIM domain can mediate heterodimer formation with ALP. COS-1 cells 
were cotransfected with different GFP-tagged RIL deletion constructs together with either a 
VSV-tagged RIL or ALP construct. Expression of the various proteins in the lysates was veri-
ﬁed by Western blotting using anti-GFP (middle panel) or anti-VSV (lower panel) antibodies. 
Upon immunoprecipitation of VSV-tagged proteins, co-precipitating proteins were detected 
using anti-GFP antiserum (upper panel). 
 Importantly, the experiments using GFP-tagged RIL constructs in combina-
tion with VSV-tagged BL-PDZ-I-V (Figure 1C) argue against the possibility that the 
dimeric nature of the GST moiety itself may inﬂuence the ﬁnding that PDZ binding 
to the RIL C-terminus is greatly enhanced by the presence of the RIL LIM domain.
The RIL LIM domain does not bind directly to PTP-BL PDZ2
An alternative explanation for the enhancing effects of the RIL LIM domain on 
PTP-BL – RIL binding, and again reminiscent of the syndecan – syntenin interaction 
(47), may be found in possible synergistic effects of relatively weak interactions by 
the RIL LIM domain and the RIL C-terminus, respectively, with PDZ domains. To 
study this, we used NMR and characterized whether addition of the complete RIL 
C-terminal half, the LIM domain only or the RIL C-terminus proper to 15N-labelled 
PTP-BL PDZ2 samples would result in differences in HSQC spectral peak shifts. 
This would point to distinct binding interfaces for the various RIL parts on the PDZ2 
domain. Our previous work has revealed that PDZ2 forms a complex with the RIL 
C-terminal peptide that exhibits fast exchange with their free components, character-
ized by a dissociation constant in the millimolar range (37). Spectral peaks of key 
residues in the PDZ2 binding pocket shift along with increasing concentration of the 
RIL C-terminus, with the most noticeable effects for Gly-26 and Arg-86 (Figure 4A; 
amino acid numbers are according to (37)) that are involved in binding the terminal 
Val residue, through hydrogen bonding interactions with the carboxylate group and 
hydrophobic interactions with the residue’s sidechain, respectively. 
 The C-terminal 82 residues of RIL (a.a. 249-330) as well as the RIL LIM do-
main alone (a.a. 249-314) were produced as GST fusion proteins in bacteria. Follow-
ing afﬁnity puriﬁcation and speciﬁc protease cleavage the untagged LIM-containing 
RIL segments were isolated by size exclusion chromatography. We next ascertained 
that the LIM domain containing proteins were soluble and properly folded by record-
ing 2D NOESY spectra (data not shown). Subsequently, the RIL protein segments 
were titrated into 15N-labelled PDZ2 samples and HSQC spectra were recorded. The 
observed peak shifts induced by the RIL LIM domain with or without the C-terminus 
proper were compared to those observed for the C-terminal 12 residues of RIL. 
 In Figure 4B, the spectral effects of the LIM domain with the complete C-
terminus are displayed. As observed in the titration experiment with the C-terminal 
peptide alone, the peaks representing Gly-26 and Arg-86 display major changes; in 
fact they disappeared from the spectrum due to an intermediate exchange effect by 
the binding as compared to a faster time regime for the much smaller peptide. The 
overlap in affected peaks in Figures 4A and 4B, clearly demonstrate that the C-ter-
minus, and not the LIM domain itself, is the major binding determinant in the inter-
action with PDZ2. In line with this, we did not observe any peak shifts or intensity 
changes in the HSQC spectra of 15N-labelled PDZ2 over the course of titration with 
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the LIM domain in the absence of the C-terminus (Figure 4C). These NMR titration 
experiments rule out a synergistic effect due to direct binding of the RIL C-terminus 
in combination with the LIM domain to PDZ2.
Mutation analysis of the LIM domain of RIL on binding with PTP-BL
Finally, the positive inﬂuence by the LIM domain on the RIL - PTP-BL interaction 
may come from interactions with accessory molecules. We decided to mutate resi-
dues that are potentially on the RIL LIM domain surface with the aim of abrogating 
any intermolecular interactions that could inﬂuence the RIL – PTP-BL association. 
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Figure 4: The RIL LIM domain and PTP-BL PDZ2 do not physically interact. 15N-HN-
HSQC spectra were recorded for 15N isotope-labelled PTP-BL PDZ2 samples upon titration 
with the following RIL protein segments: the RIL C-terminal twelve residues (A), the com-
plete RIL-LIM domain including the entire C-terminus (B) or the RIL-LIM domain exclud-
ing its ﬁnal 16 C-terminal residues (C). Changes in backbone HN (X axis) and 15N (Y axis) 
chemical shifts of individual peaks upon titration of the RIL fragments reﬂect an interaction 
of speciﬁc PDZ2 residues with the corresponding RIL fragment. Arrows indicate peaks that 
shift and/or grow weaker in intensity with increasing RIL fragment concentrations. Circles 
indicate resonances of speciﬁc residues that disappear completely. Amino acid numbering is 
according to (37).
To this end, we ﬁrst aligned the RIL LIM protein sequence to that of the two LIM 
domains in the quail cysteine rich protein 2 (CRP2), for which ample structural data 
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is available (50-52), and performed homology alignment (Figure 5A). In the aligned 
sequences the eight β-strands, which form paired anti-parallel structures with typical 
sharp β-turns, and the α-helix are indicated. Next, we used site-directed mutagenesis 
to alter relevant amino acid positions in distinct β-strands, sharp β-turns and the so-
called loops between the β2-β3 and the β6-β7 sheets in the RIL LIM domain. Resi-
dues that expose their side-chains, and thus perhaps involved in protein interactions, 
were selected for mutation into the small neutral amino acid alanine (Figure 5A). 
Mutations were introduced in the mRIL(209-330) yeast two-hybrid prey vector (16) 
and applied in an interaction trap assay exploiting the second, the fourth, or all ﬁve 
PDZ domains of PTP-BL as baits. Empty bait vector and PTP-BL PDZ3 served as 
negative controls. Interaction strengths, as witnessed by growth capacity and LacZ 
expression level, were scored on assay plates (Figure 5B). As expected, wild type 
RIL including the LIM domain bound to PTP-BL PDZ2 and PDZ4, but not to PDZ3 
or empty bait. Removal of the last 21 amino acids of RIL severely impaired the bind-
ing to the PDZ-containing bait proteins.  The various LIM domain mutants, however, 
did not show a clear loss of interaction to the distinct PDZ domains.
 We also investigated the interaction of the various RIL mutants with PTP-
BL PDZ2 in a more quantitative way, through the analysis of β-galactosidase activ-
ity in crude yeast protein extracts (Figure 5C). Again, none of the RIL LIM domain 
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Figure 5: (facing page) Mutations in potential surface residues in the RIL LIM domain do not 
inﬂuence PDZ binding. (A) Alignment of the two LIM domains of quail cysteine rich protein 
2 (qCRP2, acc. number: Q05158) and the LIM domain of RIL (acc. number: Y08361). Ami-
no acid numberings are indicated left and right from the primary sequence. The structural 
cysteine and histidine residues involved in the positioning of the zinc ion (52) are marked 
by grey boxes. The 8 β-strands and the α-helix as present in the solution structure (PDB ac-
cession code 1QLI), are depicted as grey and black boxes respectively. Leu286 and Leu288 
are indicated by asterisks (see discussion for details). Underneath, an overview of eleven 
RIL LIM mutants used in yeast two-hybrid experiments is given. Only the relevant segment 
of the variants (names are listed on the left) is shown, in which the essential cysteine and 
histidine residues are marked by grey boxes and non-mutated amino acids are represented by 
dots. (B) Yeast two-hybrid interaction plate assay of RIL LIM domain variants with PDZ do-
main-containing parts of PTP-BL. Representative image of selection plates after yeast mat-
ing assays using wild type (wt) and mutant RIL-LIM domain-constructs in combination with 
PTP-BL PDZ domain-constructs, is shown. Baits express single or combined PDZ domains 
(PDZ II: a.a. 1352-1450, PDZ III: a.a. 1471-1601, PDZ IV: a.a. 1756-1855 and PDZ I-V: 
a.a. 1002-2018), and empty bait vector was used as a control. (C) Yeast two-hybrid reporter 
activity assay of RIL LIM domain variants with PTP-BL PDZ2. β-Galactosidase activities 
(arbitrary units) were measured in total lysates of yeast carrying a LacZ-reporter plasmid. 
Yeast contained plasmids encoding PTP-BL PDZ2 as bait and prey plasmids encoding wild 
type or mutant RIL segments as mentioned below the bars. The RIL m7 mutant (p<0.05), the 
C-terminally truncated RIL part (∆C; p<0.005) and the empty prey (ctrl; p<0.001) displayed 
signiﬁcantly reduced levels as compared to wild type RIL. SEM values (n=5) are indicated.
mutants, except for m7 (p<0.05), differed signiﬁcantly from the wild type protein 
in binding PDZ2. Removal of the carboxyl terminus signiﬁcantly reduced the in-
teraction to background levels in this set-up (p<0.005). Since no direct interaction 
between the LIM domain moiety and the PDZ2 domain was apparent in the NMR 
titration experiment, the R291A-G292A mutation in m7 thus may impair binding of 
accessory proteins to the complex. Alternatively, the m7 mutation may have affected 
the prey protein’s expression level or nuclear location in yeast. 
 To determine a possible contribution of accessory proteins to RIL – PDZ 
complexes in a direct way, we isolated the interacting proteins from transfected cell 
lysates exploiting a two-step puriﬁcation protocol. Brieﬂy, we co-expressed VSV-
BL-PDZ-I-V with either GST-RIL-LIM-C or GST-RIL-C in COS-1 cells, puriﬁed 
the complexes over glutathione beads, subjected the eluate to an immunoprecipita-
tion with anti-VSV, and looked on a silver-stained gel for stoichiometric amounts of 
copurifying proteins that could mediate the enhancing effect of the RIL LIM domain 
structure. Since the PTP-BL segment contains two PDZ domains that can interact 
with RIL (16), and the GST tagged RIL moiety may exist as a dimer, any ratio be-
tween one and four may be obtained for the two interaction partners themselves. 
Apart from the expected PTP-BL and RIL segments, and some trace amounts of 
degradation products, no relevant amounts of additional proteins were copuriﬁed 
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Figure 6: Serial afﬁnity puriﬁcation of the tagged interacting parts of RIL and PTP-BL. 
Cells were transfected with the expression plasmids indicated above each lane, and resulting 
lysates (Lys.) were incubated with glutathione sepharose beads to isolate GST-containing 
protein complexes. The latter were eluted using reduced glutathione (el. 1), and PTP-BL 
PDZ-containing protein complexes were afﬁnity-puriﬁed using anti-VSV monoclonal an-
tibodies covalently coupled to beads (el. 2). Following SDS-PAGE, the protein content of 
the samples was visualized by silver staining. The identity of the VSV-PDZ-I-V protein (◄) 
and the GST-tagged RIL parts (<) was underscored by their apparent molecular weight and 
through immunoblot analysis. 
(Figure 6). Taken together, our data argue against a role for the RIL LIM domain in 
binding directly to PDZ2 or in recruiting additional proteins that boost the interac-
tion of the RIL C-terminus with PTP-BL PDZ domains.
Discussion
PDZ domains are established binders of speciﬁc C-terminal amino acid sequence 
motifs (2,3). Occasionally, alternative targets such as internal peptide sequences have 
been reported (14,15,20,22,23). Two out of the ﬁve PDZ domains of PTP-BL (PDZ2 
and PDZ4) display a bivalent binding mode, i.e. binding to various C-termini (26-
28,30,53,54) and LIM domains (16-18). The interaction of PTP-BL PDZ domains 
with the RIL LIM domain had been detected by yeast two-hybrid methodology (16). 
We have now investigated the PTP-BL - RIL interaction properties in mammalian 
cell systems and in isolation. The results clearly show that this interaction is in es-
sence a canonical type of interaction, dominated by RIL’s C-terminal amino acids, 
and corroborate the detection of a speciﬁc but weak interaction of the second PDZ 
domain of PTP-BL with the RIL C-terminus revealed by 15N HSQC NMR studies 
(37). 
 Not only in NMR but also in surface plasmon resonance studies the bind-
ing of PTP-BL PDZ domains 2 and 4 to a RIL C-terminal peptide is detectable (our 
unpublished results). The latter two techniques represent rather sensitive methods 
that exploit proteins and peptides in isolation, thus in absence of confounding cel-
lular components, and at relatively high concentrations. RIL and PTP-BL protein 
segments produced in mammalian cells, however, display much lower concentra-
tions and will face the cell’s proteome. To detect unequivocally an interaction with 
the RIL C-terminus proper under these conditions, single PTP-BL PDZ domains did 
not sufﬁce and we therefore used the complete PDZ-containing moiety of PTP-BL. 
Synergistic effects of PTP-BL PDZ domains had been noted in the yeast interaction 
trap setup as well (16). In addition, protein expression levels appear critical since the 
tagged RIL C-terminus is not always detectable in PDZ domain immunoprecipitates 
(comp. Figure 1C, lane 3 and Figure 6, lane 6).
 Interestingly, presence of the RIL LIM domain in the tagged RIL C-terminal 
fragment greatly enhances binding to the PTP-BL PDZ-containing segment in the 
mammalian assays (Figures 1 and 2). In the original two-hybrid study, the RIL LIM 
domain even appeared essential for binding to PTP-BL because an interaction with 
the RIL C-terminus proper remained below detection levels (16). This latter apparent 
discrepancy with the current precipitation studies may not only reﬂect differences in 
sensitivity but also in cellular environment. After all, the yeast two-hybrid system is 
a karyoplasmic interaction assay whereas the mammalian precipitation studies aim 
at complexes formed in the cytoplasm. Furthermore, the protein parts fused to both 
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the RIL and PTP-BL segments differ between the yeast and mammalian assays and 
may obstruct proper comparison. 
 Although the LIM domain was found not to bind directly to the single PTP-
BL PDZ2 domain (Figure 4), it enhanced the strength of interaction between the 
PTP-BL PDZ moiety and the RIL C-terminus at least ﬁve-fold in various copuriﬁca-
tion experiments. These results could be explained by assuming that the RIL LIM 
domain interacts with a surface formed by multiple PTP-BL PDZ domains in syn-
teny. Unfortunately, the sheer size of such a multiple PDZ domain-containing PTP-
BL segment precludes the use of NMR spectroscopy to investigate this in vitro.  
 LIM domains are cysteine-rich domains composed of two special zinc 
ﬁnger-type folds that are joined by a two amino acid spacer. The primary role of 
LIM domains appears to be in protein-protein interaction, through dimer formation 
with identical or other LIM domains or by binding to distinct proteins (55). This 
dimerization potency could have explained the enhanced binding of the RIL LIM 
domain-containing protein parts to PTP-BL PDZ domains relative to that of the RIL 
C-terminus alone. For example, the clustering of syndecan C-termini is an important 
determinant for the binding strength displayed by both syntenin PDZ domains (47). 
However, both in the yeast two-hybrid setup (16) as in transfected mammalian cells 
(Figure 3) we did not observe homo-dimerization of the RIL LIM domain. In con-
trast, we could detect low levels of ALP - RIL hetero-dimers. This dimer formation 
is dependent on the LIM domain of RIL, it even seems that the RIL C-terminal has 
a negative inﬂuence on dimer formation. This can be due to structural hindrance, 
which can be investigated by performing structural analysis on such complexes. Fur-
thermore, it would have been difﬁcult to solely attribute RIL-LIM domain-mediated 
dimerization for the observed enhancing effect since all RIL constructs used in the 
pull-down experiments contain a GST moiety that has intrinsic homodimerization 
capacity (49).
 Another argument against this dimerization hypothesis is the ﬁnding that 
extensive mutational analysis of the LIM domain interaction surface had no obvious 
inﬂuence on RIL’s binding to PTP-BL PDZ domains, either singly or combined, in 
the yeast two-hybrid system (Figure 5). Actually, the RIL m7 mutant is the only mu-
tant displaying signiﬁcant loss of interaction with PDZ2 when compared to wildtype 
RIL. Since the LIM domain is not directly involved in interaction with PDZ2, as 
apparent from NMR experiments (Figure 4), this could indicate involvement of ac-
cessory proteins in the interaction. Alternatively, the reduced β-galactosidase activ-
ity as noted for the m7 mutant may reﬂect altered localization or stability of the bait 
fusion protein itself. Importantly, no reduction in interaction for the RIL m7 mutant 
is apparent when all ﬁve PDZ domains are used as baits (Figure 5B) arguing against 
a crucial role for the involved residues in the formation of the PTP-BL – RIL com-
plex.
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 To ﬁnd direct proof for possible accessory proteins that may function as 
‘stabilizers’ in the PTP-BL – RIL association, we analyzed the total protein content 
in GST-RIL – VSV-PDZ complexes isolated from transfected cells. No additional 
proteins were observed in samples in which the RIL LIM domain was included as 
compared to those exploiting only the C-terminal tail of RIL (Figure 6). Therefore 
we conclude that there are no other proteins involved in stimulating the interaction 
of the RIL C-terminus with PTP-BL PDZ domains.
 This leaves us with two other possibilities by which the LIM domain could 
enhance the canonical PDZ interaction. The ﬁrst one assumes the presence of weak 
PDZ binding sites within the LIM domain that act in synergy with the canonical 
C-terminus of RIL. PDZ-LIM interactions were noted previously using yeast two-
hybrid methodology (16) but are not detectable in our GST pull-down (Figure 1) 
and NMR titration experiments (Figure 4). Hillier et al. suggested the presence of 
such a “pseudopeptide” PDZ target site in the ﬁrst β-sheet of the second zinc ﬁnger-
like structure within the RIL LIM sequence (8). Indeed, the sequence stretch around 
amino acid residues 286 and 288 (indicated by asterisks in Figure 5A) is reminiscent 
of a class II PDZ domain binding site and is followed by turn-preferring residues. 
Likewise, a Thr-Ile-Val sequence within the ﬁrst loop of the RIL LIM domain could 
represent a class I “pseudopeptide” PDZ target site. However, corresponding mu-
tants m10 (L286A-L288A) and m11 (T265G-V267Q) demonstrated no clear loss 
of interaction strength (Figure 5 and GST pull-down experiments, data not shown), 
excluding a role as internal peptide binding site for PTP-BL PDZ domains.
 In the second alternative some intramolecular ‘stabilization’ or ‘positioning’ 
effect, that is independent of possible LIM domain-interacting factors, may increase 
the availability of the RIL C-terminus for PDZ binding. A stabilizing effect by LIM 
domains has indeed been noted for the TRIP6 interaction with PDZ2 in PTP-BAS 
(56). Furthermore, the essential contribution of a so-called “clasp”, which pins back 
the C-terminal end to the presenting domain, to the proper presentation of an internal 
pseudopeptide PDZ binding motif has been demonstrated for the nNOS – syntrophin 
interaction (25). Structure determination of the relevant RIL segments should reveal 
whether such a clasping function for the LIM domain is at stake.
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Abstract
Lats1 and Lats2 are members of the Lats serine/threonine kinase family that includes 
the Drosophila tumour suppressor lats/warts. In this study, we have identiﬁed Lats2 
as a novel PTP-BL-interacting protein. For the interaction the ﬁnal three amino ac-
ids (-VYVCOOH) of Lats2 and the fourth PDZ domain of PTP-BL were found to be 
essential. The association with PTP-BL is regulated through reversible phosphoryla-
tion of the penultimate tyrosine residue (Y1041) in the Lats2 C-terminus. PTP-BL 
is able to dephosphorylate this phosphotyrosine residue, thereby regulating its own 
binding as reﬂected by the extent of co-localization of the two proteins in transfected 
cells. Overexpression of Lats2 in HeLa cells results in the inhibition of the G1 to 
S phase transition. The use of a Lats2 Y1041F mutant demonstrated this cell cycle 
block does not require Lats2 phosphorylation of this site. Interestingly, attenuation 
of the cell cycle inhibitory effect was noted upon removal of the carboxyl terminal 
PDZ target site of Lats2. These data are in line with a synergistic role for PTP-BL 
and Lats2 in the regulation of the cell cycle.
Introduction
Disruption of mechanisms that control cell cycle regulation, cell proliferation, cell 
size and apoptosis can cause changes in animal and tissue size which can eventually 
lead to diseases such as cancer. The large-tumour-suppressor (Lats) protein family 
controls tissue size in both Drosophila and mammals by regulating cell proliferation 
(1). Lats proteins are protein serine/threonine kinases of the nuclear Dbf2-related 
(NDR) subtype (2) that are characterized by i) a unique 30-60 amino acid insert in 
the kinase domain (3), ii) a conserved but poorly characterized N-terminal regula-
tory domain of variable length, and iii) a hydrophobic phosphorylation motif in the 
C-terminal kinase domain extension by which their activity can be regulated (4). 
 In mammals, two distinct homologues of the Drosophila tumour suppres-
sor warts/lats have been identiﬁed; Lats1 (5,6) and Lats2/kpm (acronym of kinase 
phosphorylated during mitosis) (7,8). Mice deﬁcient in Lats1 spontaneously develop 
large soft tissue sarcomas and ovarian stromal cell tumours and are highly suscep-
tible to carcinogenic treatments (9). Overexpression of Lats1 in human tumour cell 
lines causes cell cycle arrest at the G2/M transition and induction of apoptosis, and 
these effects are kinase activity dependent (10,11). Lats1 also negatively modulates 
LIMK1 activity, thereby affecting cytokinesis through the regulation of actin polym-
erization (12).
 Although their overall sequence similarity is low, Lats1 and Lats2 share 
80% sequence identity in their kinase domains (7). Targeted disruption of the Lats2 
gene resulted in embryonic lethality, attributable to an arrest in proliferation at a 
critical developmental stage (13). Overexpression of Lats2 inﬂuences cell cycle pro-
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gression by arresting cells at the G1/S transition (14), or inducing G2/M arrest and 
apoptotic cell death (15). Recently, it has been shown that Lats2 can be phosphor-
ylated on Ser-83 by the Aurora-A kinase and that this phosphorylation plays a role 
in the centrosomal localization of Lats2 (16). Furthermore, Lats2 can associate with 
the androgen receptor (AR), functioning on the AR-mediated transcription pathway 
and contributing to the development of prostate cancer (17).
 The protein tyrosine phosphatase (PTP) PTP-BL is a large intracellular 
phosphotyrosine-speciﬁc enzyme that consists of an N-terminal KIND domain (18) 
followed by a FERM domain, ﬁve PDZ domains and C-terminally its catalytic phos-
phatase domain (19). During mitosis, PTP-BL localizes at the centrosomes, the spin-
dle midzone and ﬁnally the contractile ring (20). Based on this compartmentalized 
localization during the cell cycle and on the observation that overexpression of PTP-
BL results in multi-nucleated cells, it was suggested that PTP-BL plays a role in the 
regulation of cytokinesis (20). However, the mechanism by which this regulation is 
achieved remains to be elucidated.
 In our search for PTP-BL-associating proteins that have a known or suspect 
role in cell cycle regulation and cytokinesis we identiﬁed the Lats2 kinase as a can-
didate interactor using the PDZ domain moiety of PTP-BL as a bait. PDZ domains 
(acronym of PSD-95/SAP90, Discs-large and ZO-1) interact predominantly with 
short peptide sequences at the carboxyl terminus of target proteins (21). We dem-
onstrate that the penultimate tyrosine residue within the PDZ binding sequence in 
Lats2 C-terminus (PVYV) is phosphorylated in vivo and serves as a substrate for 
the PTP domain in PTP-BL. Furthermore, its phosphorylation status determines the 
PDZ-mediated interaction and colocalization with PTP-BL inside the cell. Deleting 
the Lats2 PDZ binding site slightly affected its ability to block cell cycle progression 
at the G1/S transition, suggesting that PTP-BL and Lats2 cooperate in the regulation 
of the cell cycle.
Materials and Methods
Yeast Two-Hybrid assay
Interaction-trap vector DNAs and yeast strain EGY48 were kindly provided by Dr. 
Roger Brent and colleagues (Massachusetts General Hospital, Boston, MA). The 
HeLa and the human Go ﬁbroblast libraries were generously provided by J. Gy-
uris (Massachusetts General Hospital, Boston, MA) and C. Sardet (MIT, Boston, 
MA), respectively. The construction of most of the PTP-BL PDZ domain-encod-
ing bait plasmids has been described (22). BL-PDZ-I-II was made by subcloning 
a 1.3 kbp DraI fragment from full-length PTP-BL cDNA (acc. no. NM_011204) in 
pEG202. BL-PDZ-II-III, BL-PDZ-III-V and BL-PDZ-IV-V were generated by PCR 
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using appropriate oligonucleotide primers harbouring EcoRI or XhoI restriction 
sites, and cloned in-frame in pEG202. Prey construct HG3-∆3 was made by PCR 
using clone HG3 as a template and the reverse oligonucleotide 5’-ccctcgagtcaaggct-
ggcagccttcagt-3’ (XhoI restriction site is in bold) in combination with a pJG4-5 for-
ward primer. The prey construct encoding the mouse peptide corresponding to HG3 
(mWTS-C) was made by PCR exploiting mouse EST clone W81967 as template and 
using oligonucleotide 5’-gggaattcgtggatgaagaaagcccc-3’ (EcoRI site is in bold) in 
combination with a T3 primer. The EcoRI-XhoI restriction fragment of the resulting 
amplicon was subcloned in pJG4-5. All PCR-based constructs were checked for the 
absence of mutations by DNA sequencing. 
 For two-hybrid interaction assays (23) plasmids were introduced in yeast 
strain EGY48 (MATa trp1 ura3 his3 LEU2::pLexAop6-LEU2) containing the plas-
mid pSH18-34, which includes the reporter lacZ gene, and tested for an interaction 
as detected by growth and blue coloring in HUTL- (lacking histidine, uracil, tryp-
tophan and leucine) minimal agar-plates containing 2% galactose, 1% rafﬁnose and 
80 μg/ml X-gal, buffered at pH 7.0.
Mammalian expression plasmids
The expression construct BL-PDZ-I-V (encoding the ﬁve PDZ domains of PTP-BL 
and an N-terminal VSV-tag) has been described elsewhere (22). Mammalian ex-
pression plasmid pSG8-VSV-Lats2 was constructed by subcloning a PCR-generated 
mouse Lats2 cDNA fragment (nucl. pos. 134-3262 in acc. nr. NM_015771) in-frame 
into BamHI-digested pSG8-VSV vector (22). The GST-Lats2C mammalian expres-
sion plasmid was constructed by inserting a PCR-generated fragment, spanning pos. 
2929-3262 of  mouse Lats2 cDNA, into BamHI-digested pEBG vector (24). The 
Lats2 Y1041F mutation was introduced in full-length as well as C-terminal Lats2 
constructs by performing a PCR using the antisense primer 5’- ttggatccggcttacac-
gaacaccggctggc-3’ (BamHI site and Y1041F mutation site are in bold) in combina-
tion with appropriate Lats2 sense primers. In a similar manner Lats2-∆3 constructs 
were constructed, now using 5’-ccgctcgagttacggctggcagccctc-3’ (XhoI restriction 
site is in bold) as antisense primer. In addition, the full-length Lats2 variants were 
also cloned in frame into the pEYFP-C1 vector to serve in FACS analyses. 
 All expression constructs generated by PCR were veriﬁed by automated se-
quence analysis to exclude undesired mutations. Primer sequence details are avail-
able from the authors upon request.
Tissue culture and transient cell transfections
COS-1 cells (ATCC # CRL-1650) were cultured in DMEM medium (Gibco/ BRL, 
Gaithersburg, MD) supplemented with 10% fetal calf serum (FCS). Transfections 
using DEAE-Dextran were performed as described (25). Following 24-48h incuba-
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tion at 37 °C and 7.5% CO2, cells were washed twice with ice-cold PBS and lysed 
with 500 μl ice-cold lysis buffer (0.5% Triton X-100 (Merck), 1 mM PMSF and 
protease Inhibitor cocktail (Boehringer) in PBS). After a 30-minute incubation pe-
riod on ice, lysates were cleared by centrifugation for 20 minutes at 10.000 x g and 
4 °C. Alternatively, cells were incubated with medium containing 1 mM BpV(phen) 
(26) for 20 minutes prior to lysis with 500 μl ice-cold buffer A (0.5% Triton X-100 
(Merck), 2 mM NaVO3, 50 mM NaF, 20mM Na4P2O7, 1 mM PMSF and protease 
Inhibitor cocktail (Boehringer) in PBS).
GST protein production and puriﬁcation
The pGEX-based plasmid encoding GST-BL-PTP has been described previously (22). 
A catalytically inactive mutant, GST-BL-PTP-C/S, was generated by site-directed 
mutagenesis of the cysteine-2374 (numbering according to acc.nr. NP_035334) in 
GST-BL-PTP using the QuickChange protocol (Stratagene). Following transforma-
tion with appropriate expression constructs, E.coli DH5α cultures were grown to 
mid-log phase (A600 ~ 0.7) in LB medium at 37 °C, induced with 1.0 mM IPTG, 
and grown for an additional three hours. Bacteria were pelleted by centrifugation at 
5000 rpm for 5 min and resuspended in ice-cold PBS. After three soniﬁcation steps 
of 10 sec with an interval of 1 minute on ice between each step, 1/100 volume of 
Triton-X 100 was added. Cell debris was pelleted by centrifugation at 9500 rpm for 
15 min, and the supernatant containing the GST-fusion proteins was incubated with 
Glutathione–Sepharose 4B beads (Amersham Biosciences AB) for 3 hours at room 
temperature. Subsequently, beads with adherent GST fusion proteins were washed 
extensively with PBS and stored at 4 °C until further use. For SPR purposes, GST-
fusion proteins were eluted from the beads using 10 mM of reduced glutathione in 
50 mM Tris-HCl, pH 8.0.
GST pull-down and immuno-precipitations
GST pull-down and immuno-precipitation experiments were performed by incubat-
ing Glutathione-Sepharose 4B beads with lysates of transfected COS-1 cells express-
ing GST- and VSV-tagged proteins, essentially as described (27). After overnight 
incubation at 4 °C, beads were thoroughly washed ﬁve times with PBS, through 
repeated pelleting by centrifugation, before being transferred into a new tube and 
then resuspended in 40 μl sample buffer (100 mM Tris-HCl, pH6.8, 200 mM DTT, 
4% SDS, 20% glycerol, 0.2% bromophenol blue).
Western Blotting
Protein samples were boiled for 5 minutes and loaded onto a polyacrylamide gel for 
size separation. Subsequently, proteins were transferred to nitrocellulose membranes 
(Hybond ECL, Amersham Pharmacia Biotech) by electroblotting. Blots were blocked 
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for 30 minutes using 5% non-fat dry milk in TBS-T (10 mM Tris-HCl, pH8, 150 mM 
NaCl, 0.05% Tween-20 (Sigma)). Monoclonal antibody P5D4 (28) (dilution 1:5.000 
in TBS-T containing 5% not-fat dry milk) was used to detect VSV-tagged proteins 
on blot. Polyclonal antiserum α-GFP (dilution 1:5.000) was raised in rabbits against 
a GST-EBFP fusion protein (29) and has been successfully exploited to detect GST- 
as well as GFP-tagged proteins (27). An antibody raised against the N-terminal part 
of PTP-BL, αBL-N  (dilution 1:5.000), was used to detect full-length PTP-BL (30). 
Monoclonal antibody PY-20 (Transduction Laboratories, Lexington, KY; dilution 
1:1.000 in TBS containing 1% BSA and 1% not-fat dry milk) was used to detect ty-
rosine-phosphorylated proteins on blot. Antibodies were incubated for at least 1 hour 
at room temperature. Blots were washed three times with TBS-T (or TBS for the 
PY-20 antibody) and subsequently peroxidase-conjugated goat anti-mouse IgG or 
goat anti-rabbit IgG (dilution 1:20.000; Pierce) was applied as secondary antibody. 
Following three successive washes with TBS-T (or TBS for the PY-20 antibody), the 
lumi-light Western blotting substrate kit (Roche Diagnostics) was used to visualize 
immunoreactive bands through exposure to Kodak X-omat autoradiography ﬁlms.
Tyrosine phosphorylation and dephosphorylation assay
COS-1 cells were transfected with various Lats2 constructs, treated with BpV(phen) 
(26) and ﬁnally lysed in buffer (containing phosphatase inhibitors) as described 
above. VSV-tagged full-length Lats2 proteins were immuno-precipitated using 
P5D4, and GST-tagged C-terminal Lats2 proteins were afﬁnity puriﬁed using Glu-
tathione-Sepharose 4B beads. Following ﬁve successive washes with PBS, beads 
were resuspended in incubation-buffer (25 mM HEPES pH7.5, 5 mM EDTA, 10 mM 
DTT). For the dephosphorylation assay, beads were incubated for 30 min at 37 °C 
with 1μg GST-BL-PTP or, as a control, with 1μg GST-BL-PTP-C/S. Subsequently, 
beads were washed once with incubation-buffer and adherent proteins were resus-
pended in 40 μl sample buffer and analyzed by Western blotting as described.
 For in vivo [32P]-orthophosphate labelling, transfected COS-1 cells were 
grown for 20 hours in DMEM/5% FCS, washed with phosphate-free medium and 
cultured in phosphate-free medium containing 0.2 µCi/ml [32P]-orthophosphate 
(Amersham Pharmacia Biotech, UK) for 30 min. Preparation of cell lysates and sub-
sequent immuno-precipitations were performed as described above. Proteins were 
resolved by SDS-PAGE and detected using autoradiography.
Surface Plasmon Resonance
A Biacore 2000 system (Biacore AB, Uppsala, Sweden) was used for surface plasmon 
resonance (SPR) analysis. N-terminally biotinylated peptides (Lats2: AEGCQPVY-
VCOOH, and Lats2-P: AEGCQPVpYVCOOH; Ansynth Service B.V., Roosendaal, the 
Netherlands) were bound to streptavidin-coated sensor chips (SA) at a ﬂow rate of 5 
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μl/min. Puriﬁed GST-tagged PDZ domains, or GST alone as control, were dialyzed 
against running buffer (10 mM Hepes, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% 
surfactant P20 (BR-1000–54, Biacore AB)) and diluted to the concentrations indi-
cated. Perfusion was at a ﬂow rate of 25 μl/min, ﬁrst over a control ﬂow cell (Fc1) 
and then over capture ﬂow cells coated with the biotinylated peptides (Fc2-3). After 
13 min of association, the sample solution was replaced by running buffer alone, al-
lowing the complex to dissociate. Binding was measured as the difference between 
the Fc1 and Fc2-3 curves. Experiments were performed at 25 °C. Association and 
dissociation kinetics were ﬁtted according to the two-phase exponential association 
and decay model using the software package GraphPad Prism (version 4.0, Graph-
Pad Software, Inc.).
Immunoﬂuorescence assay and FACS analysis
HeLa cells (ATCC #CCL-2) were cultured in DMEM medium (Gibco/BRL, Gaith-
ersburg, MD) supplemented with 10% fetal calf serum (FCS). Transfections were 
performed using Lipofectamine™ transfection reagent (Invitrogen, Breda). After 24 
h the cells were washed with PBS, ﬁxed for 10 min with 1% paraformaldehyde in 
PHEM buffer (60 mM Pipes, 25 mM HEPES, 10 mM EGTA, 2 mM MgCl2, pH 6.9), 
and permeabilized using 0.1% saponin and 20 mm Glycine in PBS for 30 min. Sub-
sequently, cells were incubated for 1 h with a 1:1000 dilution of monoclonal antibody 
P5D4 (28) in SPBS (0.1% saponine in PBS) at room temperature. Following three 
washes with SPBS, cells were incubated with Alexa ﬂuor® 568 goat-anti-mouse IgG 
(2 mg/ mL; Molecular probes) (1:300 dilution in SPBS) at room temperature for 1 h. 
Finally, after three washes with SPBS and methanol dehydration, cells were mounted 
on glass slides using Mowiol (Sigma) containing 2.5% sodium azide as anti-fading 
reagent. Images were examined and collected using confocal laser scanning micros-
copy (MRC 1024, Bio-Rad). The image analysis program Metamorph® (Universal 
Imaging Corporation™) was used to quantify the extent of co-localization. 
 For FACS analyses, cells were harvested by trypsinization, washed twice 
with PBS and ﬁxed overnight in ice-cold ethanol (70%) at -20 °C. Cells were then 
washed twice with PBS and incubated for 30 minutes at 37 °C in coloring-buffer 
containing 20 µg/ml propidium iodide (PI), 0.2 mg/ml RNase and 0.1% Triton X-
100 in PBS. Cells were then analyzed and sorted on a FACStar+ and DNA content 
analysis was performed using ModFitLT V2.0 software.  
Results
The Lats2 kinase interacts with PTP-BL PDZ domains
To search for proteins that bind to PTP-BL and are involved in cell cycle regula-
101
PTP-BL interacts with the Lats2 kinase
tion a yeast two-hybrid interaction trap screening (23) was performed on a human 
ﬁbroblast and a HeLa cDNA library. Using BL-PDZ-I-V as a bait, three independent 
but overlapping clones were selected that encode prey proteins fused to the 84, 71 
or 32 C-terminal amino acid residues of human Lats2/kpm (8), respectively (Figure 
1A). The interaction strength, as determined by blue colouring on X-gal assay plates, 
decreased with reducing length of the Lats2-derived peptide. Interestingly, removal 
of the ﬁnal three amino acids (HG3-∆3) completely destroyed binding to PTP-BL 
PDZ domains (Figure 1A), indicative of a canonical type of PDZ target interac-
tion. Overall, human and mouse Lats2 proteins share 80% identity and the C-termi-
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Figure 1: PTP-BL PDZ4 binds to the Lats2 C-terminus. Schematic representation of the 
Lats2 protein parts that were retrieved from the cDNA prey libraries (A) and the regions 
of PTP-BL used as baits (B) in the yeast two-hybrid interaction trap. In addition, also the 
results obtained with mouse Lats2 and with the human protein lacking the ﬁnal three amino 
acid residues (HG3-∆C3) are included. In between brackets, the corresponding ﬁrst and last 
amino acid positions of the peptides in PTP-BL and Lats2 are shown. Two hybrid interaction 
results with BL-PDZ-I-V as a bait (A) or HG3 as prey (B) are schematically indicated: ++, 
very strong interaction; +, strong interaction; -, no interaction detectable. The Lats2 serine/
threonine kinase domain is depicted as a black box. KIND, FERM, PDZ and PTP domains 
found in PTP-BL are depicted as stippled black boxes, grey boxes, black circles and hatched 
boxes, respectively. 
nal octapeptide is completely conserved. Mouse PTP-BL PDZ domains therefore 
also bound to the mouse Lats2 protein C-terminus (Figure 1A; bottom). Additional 
yeast two-hybrid assays using various PTP-BL PDZ domain combinations revealed 
that PDZ domain 4 is required and sufﬁcient for this interaction with Lats2 (Figure 
1B). To conﬁrm the observed interaction in a more physiological surrounding, we 
co-transfected COS-1 cells with expression constructs encoding VSV-tagged Lats2 
wild type and Lats2-∆3 in combination with a EGFP-tagged version of the PTP-BL 
segment encompassing its ﬁve PDZ domains. Expression of the different constructs 
was visualised on Western blot using the indicated antibodies (Figure 2; bottom two 
panels). The EGFP-tagged PDZ domains coprecipitated with Lats2 wild type, but 
not with Lats2-∆3 (Figure 2; upper panel). The reverse experiment demonstrates that 
Lats2 wild type coprecipitated with BL-PDZ-I-V, whereas Lats2-∆3 did not (Figure 
2; second panel). These ﬁndings independently conﬁrm the results obtained in the 
yeast two-hybrid interaction trap.
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Figure 2:  Lats2 coprecipitates with 
PTP-BL PDZ domains. Interaction of 
VSV-tagged Lats2 protein segments 
with GFP-tagged PTP-BL PDZ do-
mains. COS-1 cells were cotransfected 
with indicated expression constructs 
and lysates were used for immunopre-
cipitation with α-VSV or α-GFP anti-
bodies (as indicated on the left). Sera 
were also used as indicated on the left 
to detect the presence of the desired pro-
teins in the lysates (bottom two panels) 
and the immunoprecipitate (upper two 
panels) by Western blot analysis. For 
comparison, the Lats2 Y1041F mutant 
and Lats2 lacking the ﬁnal three amino 
acids were also included. IP: immuno-
precipitation, WB: Western Blot.
Lats2 is phosphorylated on tyrosine residues in vivo
In Drosophila proper Lats functioning in vivo requires tyrosine phosphorylation 
of the conserved C-terminus (-PVYVCOOH) (31). To investigate whether the cor-
responding tyrosine in the mouse Lats2 PDZ target sequence is subject to phosphor-
ylation as well, COS-1 cells expressing the GST-tagged C-terminal portion of Lats2 
were treated with the PTP inhibitor BpV(phen). Subsequently, the phosphotyrosine 
content of afﬁnity-puriﬁed GST-Lats2C fusion protein was analyzed on immunob-
lots (Figure 3A). Indeed the P-1 tyrosine was found to be strongly phosphorylated, 
whereas a GST-Lats2C fusion protein in which Tyr-1041 was mutated into phenyla-
lanine (Y1041F) was barely phosphorylated. 
 The 1042 amino acid mouse Lats2 protein of course contains many potential 
tyrosine phosphorylation sites. To reveal the contribution of the P-1 site to overall 
tyrosine phosphorylation of Lats2, VSV-tagged full-length protein was expressed in 
COS-1 cells. Following BpV(phen) treatment, VSV-LATS2 was immunoprecipitat-
ed from the lysate and its phosphotyrosine content was determined on Western blots 
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Figure 3: Lats2 is phosphorylated on tyrosine 1041 in vivo. COS-1 cells were transfected 
with constructs encoding (A) a GST-tagged C-terminal Lats2 fragment or (B) VSV-tagged 
full-length Lats2. Before being lysed, cells were either treated for 20 minutes with the phos-
phatase inhibitor BpV(phen) (+) or left untreated (-). Both wild type Lats2 (WT) and an 
Y1041F mutant of Lats2 (Y1041F) were included. Left panels in (A) and (B) show the ex-
pression levels of respective proteins using the appropriate antibodies for immunodetection 
on Western blots. Black an grey arrowheads indicate an upward shift of Lats2 proteins in 
the presence of BpV(phen). After afﬁnity-puriﬁcation of the Lats2 proteins from the lysates, 
tyrosine phosphorylation of Lats2 is demonstrated using a speciﬁc anti-phosphotyrosine anti-
body (PY-20; right panels). IP: immunoprecipitation, PD: pull-down, WB: Western Blot.
using antibody PY-20 (Figure 3B). Introducing the Y1041F mutation in full-length 
Lats2 caused a clear but not complete reduction in phosphotyrosine content when 
compared to wild type Lats2, indicating that the P-1 position is not the only major 
tyrosine phosphorylation site in Lats2. Furthermore, the shift in protein size that is 
detectable for both the wild type and mutant Lats2 C-terminal fragment (Figure 3A; 
left panel, and Figure 5A,B; upper panels (indicated by arrowheads)) indicates that 
phosphorylation on serine and threonine residues is boosted by the PTP inhibitor as 
well.
Lats2 is dephosphorylated by PTP-BL in vitro
Lats2 is phosphorylated on tyrosines and may thus function as a substrate for the 
PTP domain of PTP-BL. Beads containing immunopuriﬁed Lats2 protein parts iso-
lated from BpV(phen)-treated cells were therefore incubated with the bacterially 
produced recombinant PTP-BL PTP domain. Tyrosine-phosphorylated Lats2 was 
found to be efﬁciently dephosphorylated upon addition of puriﬁed GST-BL-PTP 
whereas the inactive GST-BL-PTP-C/S had no effect (Figure 4 A,B). This clearly 
establishes Lats2 as a speciﬁc in vitro substrate of PTP-BL. Note that in the case of 
full-length Lats2 the dephosphorylation is not complete (Figure 4B), indicating that 
certain tyrosine residues that are outside of the Lats2 C-terminal part are much less 
preferred by BL-PTP’s enzyme activity. 
 To test whether, in reverse, PTP-BL also functions as a substrate for Lats2 
kinase activity, orthophosphate incorporation experiments were performed. COS-1 
cells were cotransfected with expression constructs for PTP-BL and VSV-tagged 
full-length Lats2 or, as a negative control, with the empty pSG8-VSV vector. After 
incubation in the presence of radioactive phosphate, the cells were lysed and PTP-
BL or Lats2 proteins were immunoprecipitated using αBL-N or α-VSV antibodies, 
respectively, and monitored for radioactive content following SDS-PAGE (Figure 
4C). Under the conditions used, PTP-BL and Lats2 are both phosphorylated in vivo. 
However, the phosphorylation level of PTP-BL appears to be independent of Lats2 
overexpression. This indicates that PTP-BL is not an obvious substrate for the Lats2 
kinase or that PTP-BL phosphorylation is already efﬁciently covered by endogenous 
kinases in these cells.
Interaction of Lats2 with PTP-BL is regulated in a phosphorylation-depend-
ent manner
It has been reported that binding of PDZ domains to their ligands can be regulat-
ed through phosphorylation of residues within the PDZ binding motif (32-35). We 
therefore examined whether the binding of PTP-BL PDZ4 to the Lats2 C-terminus 
is phosphorylation-sensitive by co-expressing the VSV-tagged PTP-BL part har-
bouring the ﬁve PDZ domains (VSV-BL-PDZ-I-V) with either wild-type or mutant 
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Figure 4: Lats2 serves as a PTP-BL substrate. COS-1 cells, transfected with constructs en-
coding either wild type (WT) or mutant (Y1041F) GST-tagged C-terminal Lats2 fragments 
(A) or the corresponding VSV-tagged full-length Lats2 (B), were treated with the phosphatase 
inhibitor BpV(phen) before being lysed. Left panels in both A and B demonstrate expression 
levels of the proteins by immunodetection (as indicated below the panel). Following afﬁnity-
puriﬁcation, Lats2 proteins were incubated with either the enzymatically active (WT) or the 
phosphatase-dead (C/S) recombinant phosphatase domain of PTP-BL (PTP). Subsequently, 
remaining phosphotyrosine levels in the Lats2 proteins were monitored by Western blotting 
using the PY-20 antibody (right panels in A and B). (C) COS-1 cells, transfected with con-
structs encoding full-length PTP-BL, full-length Lats2 and/or empty vector, were incubated 
with medium containing [32P]-orthophosphate. After immunoprecipitation of the PTP-BL 
and Lats2 proteins (using the appropriate antibodies, as indicated on the bottom of each 
panel) the protein amount was visualized by immunoblot detection (left panels), while the 
amount of phosphorylated protein was determined by autoradiography (right panels). Note 
that COS-1 cells endogenously express PTP-BL. 
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(Y1041F) GST-Lats2C fusion protein. GST pull-down revealed that the Y1041F mu-
tant was more efﬁcient in co-precipitating the PDZ moiety (Figure 5A). Addition 
of BpV(phen), to induce hyperphosphorylation of proteins within the cell, had no 
visible effect other than the upward mobility shift for the GST-Lats2C fusion protein 
on gel. Also the reverse experiment was performed; i.e. VSV-tagged PTP-BL PDZ 
domains were immuno-precipitated and co-precipitating GST-Lats2C fusions were 
detected on blots (Figure 5B). Although the GST-Lats2C Y1041F fusion efﬁciently 
co-precipitated with the VSV-tagged PDZ domains, only a very small amount of 
wild-type GST-Lats2C could be co-precipitated. Importantly, addition of the phos-
phatase inhibitor to the cells totally abrogated this, indicating that the residual bind-
ing in absence of PTP inhibitor reﬂects the non-phosphorylated GST-Lats2C pool.
 Taken together, these experiments suggest that the interaction between PTP-
BL and Lats2 is attenuated by phosphorylation of Lats2 Tyr-1041. To substantiate 
this ﬁnding, the interaction of PTP-BL PDZ4 with the Lats2 C-terminus was stud-
ied using surface plasmon resonance (SPR) measurements. On a streptavidin-coated 
(SA) sensor chip different N-terminally biotinylated peptides were immobilized; one 
being the Lats2 C-terminal nonapeptide, another (Lats2-P) corresponded to the ty-
rosine-phosphorylated Lats2 C-terminus, and a third peptide served as non-binding 
control (data not shown). Bacterially produced GST-PDZ4 fusion protein was tested 
for binding at various concentrations, allowing the determination of binding con-
stants (Figure 5C). The other PTP-BL PDZ domains did not bind to the peptides dis-
played, and served as negative controls (data not shown). Although PDZ4 was able 
to bind to both the unphosphorylated and phosphorylated Lats2 peptide the afﬁnities 
differ slightly (KD value of 3.3 μM vs 8.7 μM, respectively), partly explaining the 
reduced binding upon BpV(phen) administration and the superior performance of 
the Y1041F Lats2 mutant in the previous co-precipitation experiments (Figure 2). 
Lats2 and PTP-BL co-localization in HeLa cells requires the unphosphor-
ylated Lats2 C-terminus
The above results imply that colocalization of Lats2 and PTP-BL in cells will depend 
on the presence and phosphorylation status of the Lats2 C-terminus. To test this, we 
co-expressed PTP-BL and full-length Lats2 variants in HeLa cells and studied their 
subcellular localization (Figure 6). In interphase cells, VSV-tagged Lats2 gives rise 
to a punctuate staining pattern in the cytoplasm and a faint nuclear signal, in agree-
ment with previous reports (7,14). Similarly, GFP-tagged PTP-BL predominantly 
resides in the cytosol with residual staining in the nucleus. Using image analysis 
software, it was deduced that in fact ~30% of PTP-BL co-localized with VSV-tagged 
Lats2 (Figure 6A,D). Interestingly, co-expression of PTP-BL with the Lats2 Y1041F 
mutant resulted in a signiﬁcant increase (to ~80%) in the co-localization of both 
proteins within the cell (Figure 6B,D), in line with the phosphorylation status of 
107
PTP-BL interacts with the Lats2 kinase
Figure 5: Binding of PTP-BL to Lats2 is phosphorylation dependent. (A) Interaction of PTP-
BL PDZ domains with GST-tagged Lats2 C-terminal proteins. COS-1 cells were co-trans-
fection with the indicated constructs. Before being lysed, cells were either left untreated (-) 
or treated for 20 minutes with the phosphatase inhibitor BpV(phen) (+). Protein expression 
and co-puriﬁcation of BL-PDZ-I-V in GST pull-down experiments was assessed on Western 
blots. Black an grey arrowheads indicate an upward shift of Lats2 proteins in the presence 
of BpV(phen). (B) Interaction of GST-tagged Lats2 protein segments with PTP-BL PDZ do-
mains. COS-1 cells were transfected with indicated constructs and, before being lysed, cells 
were either treated for 20’ with the phosphatase inhibitor BpV(phen) (+) or left untreated (-). 
Following immuno-precipitation with P5D4, co-precipitating Lats2 segments were detected 
by immunoblot analysis. Asterisk indicates the presence of a background band. (C) SPR 
measurements using N-terminally biotinylated peptides representing the unphosphorylated 
Lats2 (Lats2; left) or the phosphorylated Lats2 (Lats2-P; right) C-terminal tail. Peptides were 
coated onto streptavidin (SA) sensorchips and screened for an interaction with GST-PDZ4. 
The response (resonance units) to the various concentrations of GST-PDZ4 (0.6, 1.2, 1.8, 2.4, 
3.0 μM) is depicted on the y-axis as a function of time (seconds) on the x-axis.
108
Chapter 5
the Lats2 P-1 tyrosine being a crucial determinant of the interaction in vivo. Upon 
co-expression of PTP-BL and Lats2-∆3, a mutant lacking the ﬁnal 3 amino acids, 
co-localization of both proteins is only ~5% (Figure 6C,D), underscoring the critical 
role of the phosphorylation-sensitive PDZ - C-terminus  interaction in this. 
Lats2-induced G1/S cell cycle arrest is independent of the PTP-BL interac-
tion
Previous studies put forward that Lats2 negatively regulates cell cycle progression 
in HeLa cells by inducing a G2/M arrest (15), and in NIH3T3/v-ras cells by inhi-
bition of the G1/S transition (14). In order to investigate whether Lats2 cell cycle 
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Figure 6: Lats2 and PTP-BL co-localize in overexpressing HeLa cells. HeLa cells were co-
transfected with GFP-PTP-BL and VSV-tagged (A) Lats2, (B) Lats2 Y1041F or (C) Lats2_
∆3. After ﬁxation, cells were stained with P5D4 antiserum which was visualized by ﬂuores-
cent microscopy. (D) Quantiﬁcation of colocalization as is shown in A, B and C. Percentages 
were scored from a total of at least six different cells. The percentage of colocalization of 
both mutant Lats2 constructs are signiﬁcantly different from wild type Lats2 (*; p<0.004).
regulation requires the potential to interact with PTP-BL, we examined the effects 
of overexpression of YFP-tagged Lats2 variants on HeLa cell proliferation by ﬂow-
cytometric analysis of the cellular DNA content. HeLa cells contain low levels of 
endogenous PTP-BL (20) and Lats2 (7). As compared to mock transfected cells the 
overexpression of Lats2 causes a 1.5-fold increase of cells in G1 phase (Figure 7A 
and D), indicative of a cell cycle arrest at the G1 to S phase transition. Although 
previous studies suggested a possible role for Lats2 in apoptotic cell death (15), we 
did not observe an increase in apoptotic cells when overexpressing Lats2. Interest-
ingly, overexpression of the Y1041F Lats2 mutant also caused this G1/S cell cycle 
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Figure 7: Cell cycle analysis of HeLa cells transfected with YFP-Lats2. Hela cells were 
transfected with (A) Lats2, (B) Lats2 Y1041F or (C) Lats2-∆3 constructs. Thereafter, the 
DNA content of 1 x 104 adherent cells was analyzed by ﬂowcytometry. The images of Lats2 
overexpressing cells and (D) mock transfected cells are representative of two separate experi-
ments. The percentages of cells in the different stages of the cell cycle are depicted on the 
right.
arrest (Figure 7B), indicating that inhibition of cell division does not require Lats2 
phosphorylation on tyrosine-1041. Finally, we also examined the effect of Lats2-∆3 
overexpression on cell cycle progression. Again, FACS analysis revealed that the 
cell cycle is inhibited at the G1/S transition, but to a somewhat lesser extent (Figure 
7C).
Discussion
In our search for proteins that interact with PTP-BL PDZ domains, we identiﬁed 
three independent clones encoding the carboxyl-terminal end of the serine/threonine 
kinase Lats2 (Figure 1), a mammalian homologue of the Drosophila tumour sup-
pressor warts (7). The ﬁnal three amino acids (-VYVCOOH) of Lats2 and the fourth 
PDZ domain of PTP-BL were found to be essential for this canonical PDZ – target 
peptide interaction. 
 In order to classify PDZ binding preferences for individual C-termini, four 
different peptide classes have been deﬁned on the basis of the residues at the P0 and 
P-2 position in the target peptides (36). Screening of oriented peptide libraries has 
shown that the fourth PDZ domain of the human orthologue of PTP-BL (PTP-BAS) 
speciﬁcally selected short C-terminal peptides that together yield the consensus (I/Y/
V)-Y-(Y/K)-(V/K/I)COOH (residues in bold are preferred ones) (37). This C-terminal 
consensus sequence belongs to peptide class II, having hydrophobic residues at the 
P0 and P-2 position (36). The Lats2 C-terminal tail (-PVYVCOOH) nicely resembles 
this consensus. Furthermore, recent screening of a phage display peptide library ex-
pressing random nonamers also revealed that mouse PTP-BL PDZ4 is capable of 
binding to class II peptides (our unpublished results). 
 Thus far, two other proteins have been reported as canonical binding targets 
for PTP-BL PDZ4: PARG1, a 150 kDa GTPase-activation protein for Rho, ends in 
-PQFVCOOH (38) and the C-terminus of the LIM domain-containing protein RIL 
reads -VELVCOOH (22,27). These target peptides fall into class III PDZ binding tar-
gets (36). The merging of these sequences with the Lats2 C-terminal tail does not 
yield a clear consensus for PDZ4 binding speciﬁcity: only valine at the P0 position 
appears conserved. This indicates that PTP-BL PDZ4 is rather promiscuous in bind-
ing C-terminal targets.
 At its N-terminus, PTP-BL contains a large domain that entails multiple 
potential serine, threonine and tyrosine phosphorylation sites. Indeed, PTP-BL is 
phosphorylated under basal conditions in vivo and PKA is amongst the responsible 
kinases (39). We tested, by means of overexpression of the kinase, whether in vivo 
also Lats2 can phosphorylate PTP-BL (Figure 4C). The data, however, do not support 
such a conclusion, perhaps due to the presence of endogenous Lats2 or other kinases 
in HeLa cells. Several substrates for the PTP domain of PTP-BL have been reported, 
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including the interacting proteins RIL, IκBα and ephrin B (22,40-42). In the current 
study we demonstrate that one of the major in vivo tyrosine phosphorylation sites in 
Lats2, Tyr-1041, is also speciﬁcally and efﬁciently dephosphorylated by PTP-BL. 
Intriguingly, in Drosophila the phosphorylation of this tyrosine residue was found to 
be an absolute prerequisite for full in vivo functioning of Lats, since introduction of a 
Y/F mutant transgene failed to rescue Lats mutant phenotypes (31). A genetic modi-
ﬁer screen revealed that the C-terminal Src kinase (CSK) is the responsible upstream 
component that speciﬁcally phosphorylates this C-terminally penultimate residue in 
Lats. In contrast, we observed that the corresponding mouse Lats2 Y1041F mutant 
appeared quite capable of exerting its cell cycle regulatory role, since overexpression 
lead to a G1/S transition block as efﬁciently as observed for wild type Lats2 (Figure 
7). This suggests that, although Lats proteins show conspicuous sequence conserva-
tion, the regulation of their activities diverged markedly during evolution.
 Importantly, Tyr-1041 resides within the PDZ binding sequence that we dis-
covered in Lats2. Evidence is accumulating that the phosphorylation of residues 
within PDZ binding motifs may inﬂuence PDZ domain binding, either negatively 
or positively (32-35). An interesting example is the tyrosine residue at position P-7 
in the ErbB2 C-terminal tail that upon phosphorylation abolishes part of the interac-
tion with the Erbin PDZ domain (43). Although this does not affect the binding of 
the four C-terminal ErbB2 residues, a ~2.5 fold reduction in afﬁnity of the Erbin 
PDZ domain for the phosphorylated ErbB2 peptide is the result. Likewise, tyrosine 
phosphorylation of the P-1 site in Lats2 did not eliminate PTP-BL PDZ4 binding but 
rather reduced the afﬁnity of the PDZ domain for the Lats2 target approximately 2.6 
fold as determined by surface plasmon resonance (Figure 5C). This phenomenon is 
also partly reﬂected in the co-precipitation (Figure 5B) and co-localization (Figure 
6) experiments that were performed. Obviously, only part of the Lats2 proteins will 
be phosphorylated on Tyr-1041, explaining the intermediate binding to and colo-
calization with PTP-BL observed for wild type Lats2 as compared to the Y1041F 
mutant.
 Studies in HeLa cells show that during interphase PTP-BL and Lats2 are 
present in the cytoplasm and, to a lesser extent, in the nucleus (Figure 6, (7,14,20)). 
In subcellular fractionation studies endogenous Lats2 was mainly encountered in a 
so-called nuclear fraction (7), but in retrospect this may reﬂect Lats2’s centrosom-
al localization (16). During mitosis the centrosomal localization of lats2 becomes 
much more apparent and eventually it becomes localized at the midbody during cy-
tokinesis (16). Intriguingly, for PTP-BL a very similar dynamic localization pattern 
during mitosis has been reported, and PTP-BL overexpression leads to an increase in 
multinucleate cells, indicative of a cytokinesis block (20). Overexpression of Lats2 
also blocks cell cycle progression, by inducing a G2/M arrest (15) and/or inhibiting 
the G1/S transition (Figure 7, (14)). Perhaps both effects may be united now that 
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studies in Lats2 deﬁcient cells revealed a role of Lats2 in centrosome duplication, 
maintenance of mitotic ﬁdelity and genomic stability (13). 
 In summary, we have demonstrated that Lats2 and PTP-BL engage in a 
PDZ-mediated interaction that is modulated through tyrosine phosphorylation. Both 
proteins are detected at centrosomes and during mitosis end up in the midbody. In 
view of PTP-BL’s suspect role in the regulation of cytoskeletal remodelling and 
cytokinesis (20), the putative tumour suppressor Lats2 and PTP-BL may well act in 
concert to regulate cell cycle progression.
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Chapter 6
Summarising Discussion
Summarising discussion
PDZ domains are globular protein interaction domains which are specialised for 
binding to C-terminal peptide motifs in target proteins, although binding to internal 
protein segments has also been described (1,2). The binding preference as displayed 
by PDZ domains reﬂects the nature of the amino acids that together form the pep-
tide-binding groove in the domain. The steadily increasing number of identiﬁed pep-
tide ligands for PDZ domains allowed the deﬁnition of four peptide classes based on 
the residues present at the P-2 position (classes I, II, III) or P0 position (class IV) in 
the C-terminal peptide targets (3), as discussed in Chapter 1. The focus of this thesis 
has been on the peptide binding preferences – and the regulation thereof – for the ﬁve 
PDZ domains as present in the protein tyrosine phosphatase PTP-BL. 
 At the start of this thesis period, several proteins that can associate with the 
PDZ domains in PTP-BL had been identiﬁed, which triggered speculations on PTP-
BL functioning in several signalling pathways (summarised in (4)). For instance, 
the second PDZ domain in the human PTP-BL orthologue, PTP-BAS, can bind to 
the extreme C-terminus of the human Fas receptor (5), implicating the protein in 
the regulation of Fas-induced cell death (6-9). The PTP-BL PDZ4 domain is able to 
bind to the ephrinB tail and PTP-BL’s catalytic phosphatase domain subsequently 
dephosphorylates this transmembrane molecule, thus regulating ephrinB transcellu-
lar signalling (10,11). And ﬁnally, multiple proteins that are bound by PTP-BL PDZ 
domains, e.g. PRK2 and PARG relate to the microﬁlament cytoskeleton (12,13). 
Combined with PTP-BL’s dynamic localization during the cell cycle and the ﬁnding 
that overexpression of PTP-BL results in an increase of multi-nucleated cells (14) 
this led to a proposed role in cytokinesis. In this concluding chapter, I will discuss 
three additional processes in which PTP-BL may be involved in (i.e. catenin/cad-
herin-based signalling, redox sensing, and cell cycle regulation; Figure 1) on the 
basis of the results described in the previous chapters. 
 Apart from triggering these novel viewpoints, the studies described in this 
thesis also strengthened the notion that PDZ domain-mediated interactions are sub-
ject to regulation (15-18), be it through inter- or intramolecular allosteric effects 
(Chapters 2 and 4), the redox condition (Chapter 3) or tyrosine phosphorylation 
(Chapter 5), which further adds to the complexity of protein-protein interaction net-
works.
Regulation of the cadherin/catenin signalling pathway
By screening a random peptide library in order to determine binding speciﬁcity of 
each PDZ domain in PTP-BL, we found that PDZ1 speciﬁcally selected class I pep-
tides that end with -[S/T]WVCOOH (Chapter 2). Surprisingly, the two reported target 
proteins for this PDZ domain, IκBα and BP75, do not match this consensus se-
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quence. Binding of PTP-BL to IκBα is non-canonical and involves the N-terminal 
ankyrin repeats within IκBα (19). Binding to BP75 does involve the C-terminal tail, 
but this ends with -PDASCOOH (20). To identify cellular proteins that do contain the 
PDZ1 binding consensus –[S/T]WVCOOH, and therefore represent possible physi-
ological binding partners of PTP-BL, a ScanProsite database search (http://www.
expasy.org/tools/scanprosite) was performed. Interestingly, only three related mouse 
proteins were selected that end with this speciﬁc sequence; δ-catenin, plakophilin 
4 and ARVCF (armadillo repeat gene deleted in velo-cardio-facial syndrome). δ-
catenin is almost exclusively expressed in the nervous system (21,22), plakophilin 
4 (23-26) and ARVCF (27) are more ubiquitously expressed. Together with p120 
catenin, they make up the p120 subfamily of the armadillo (arm) protein family, and 
like other types of catenins they associate with cadherins and thus contribute to the 
cytoplasmic plaque complex that links the cadherin-based cell-cell contact points to 
the actin cytoskeleton (28-30). 
 Could p120 subfamily members that end with -SWVCOOH indeed repre-
sent possible in vivo targets for PTP-BL? The search for optimal ligands for the 
Erbin PDZ domain provides strong indications in favour. In a phage display setting 
the Erbin PDZ domain selected clones that encoded peptides ending in -[D/E][S/
T]WVCOOH (31), very much like those selected by PTP-BL PDZ1. Furthermore, the 
Erbin PDZ domain efﬁciently bound synthetic peptides resembling the C-termini of 
ARVCF and δ-catenin (31). Independently, the PDZ domains of the unrelated pro-
tein PAPIN also demonstrated binding to the C-terminal tails of δ-catenin and plako-
philin 4 (32), underscoring that these arm proteins end with a genuine PDZ binding 
motif. Assuming that indeed PTP-BL PDZ1 enables the binding to p120 proteins, 
this would then target PTP-BL phosphatase activity towards cadherin-based cell-cell 
contact sites. Intriguingly, the structural and functional integrity of cadherin/catenin 
complexes has been shown to be positively regulated by serine/threonine phosphor-
ylation (33,34) but negatively by tyrosine phosphorylation (35,36) of β-catenin. And 
since tyrosine-phosphorylated β-catenin has been shown to serve as a PTP-BL sub-
strate in vitro (37), the above puts forward a stabilizing role for PTP-BL at cell-cell 
junctions (Figure 1A) and urges for experiments addressing this possibility.
 β-catenin not only serves in cadherin-mediated cell-cell adhesion but is a 
critical component in the Wnt signalling pathway as well (38). In the absence of Wnt 
signals, cytosolic β-catenin is targeted for degradation by paired phosphorylation 
through the serine/threonine kinases casein kinase I (CKI) and glycogen synthase-3β 
(GSK-3β) bound to a scaffolding complex of axin and adenomatous polyposis coli 
(APC) protein (39,40). In the presence of exogenous Wnt signals, GSK-3β becomes 
inactivated and consequently β-catenin concentrations will rise, not only in the cyto-
plasm but also into the nucleus. There it will bind to TCF/LEF transcription factors 
and alter the cells’ transcriptome. The APC tumour suppressor is instrumental in se-
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questering β-catenin from the nucleus through nucleocytoplasmic shuttling and de-
livering β-catenin to the GSK-3β - axin complex for degradation (41). Interestingly, 
PTP-BL also travels in and out of the nucleus (M. van Ham, personal communica-
tion) and binds with high afﬁnity to the APC protein C-terminus via its second PDZ2 
domain (37). And although APC itself is not phosphorylated on tyrosine residues, its 
cargo β-catenin does serve as a substrate for PTP-BL (37). Taken together, the above 
observations imply that PTP-BL may regulate β-catenin phosphorylation and protein 
levels as a result of PDZ-mediated binding to APC and p120 catenin type proteins, 
and thus may play a role in Wnt signalling and the regulation of cell division, migra-
tion and cell adhesion.
Sensing redox conditions
Binding of PDZ domains to C-terminal targets can be regulated at different levels, 
thereby adding to the complexity of PDZ interactions (15-18). The search for PTP-
BL PDZ3 target peptides (Chapter 3) revealed that this PDZ domain displays a clear 
preference for cysteine-containing peptides, and that binding is redox condition-de-
pendent. PTP-BL, being a nucleocytoplasmic protein (42), resides in a cellular envi-
ronment where reducing redox conditions govern. Many cellular stimuli, however, 
induce a transient, local shift in the cellular redox state towards oxidation through 
the conﬁned production of reactive oxygen species (ROS). Over the past decade it 
has become clear that these are in fact not necessarily undesired by-products that 
cause sometimes irreversible damage to cellular components, but may also repre-
sent powerful short-range signalling molecules that regulate multiple cellular proc-
esses (43-45). For example, during growth factor signalling the limited enzymatic 
Figure 1: (facing page) Three novel viewpoints on PTP-BL functioning. (A) Regulation of 
cadherin/catenin and wnt signalling. In the cell, β-catenin (β) is bound to various interact-
ing partners. Its distribution is therefore dictated by i) associations at the plasma membrane 
with the cadherin/catenin complex, ii) regulated degradation in the cytoplasm through an 
association with the APC/axin/GSK-3β complex, or iii) recruitment to the nucleus to act 
as a transcription factor. PTP-BL is able to bind to cytosolic (2) and nuclear (3) APC, and 
probably to cell cortical catenins (1), and is thus in the right position to dephosphorylate the 
close-by β-catenin protein. (B) PTP-BL as a redox sensor. Signalling by growth factor recep-
tors at the cell membrane leads to the activation of NAD(P)H oxidase and the production 
of reactive oxygen species (ROS) like superoxide and hydrogen peroxide. This leads very 
locally to an oxidizing cellular environment in which cysteine residues tend to form disulﬁde 
bridges (■). The latter may recruit PTP-BL to these parts of the cell. (C) Cell cycle control. 
APC is implicated in the control of cell proliferation through several signalling pathways, 
including the β-catenin- and hDLG-dependent pathways, and its overexpression results in 
G1/S cell cycle arrest. Lats2 overexpression also inhibits G1/S transition, by downregulating 
CyclinE/CDK2 activity, and it can lead to cell cycle arrest at G2/M probably by inactivating 
Cdc2 kinase. PTP-BL overexpression inhibits the cell cycle at the stage of cytokinesis (1). In 
addition, PTP-BL may contribute to other cell cycle events as well, through its interactions 
with APC and Lats2 (2). 
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turnover by receptor tyrosine kinases only stands a chance against the overwhelming 
dephosphorylating activity of PTPs if these latter enzymes are temporary taken out 
of business. Indeed, PTPs have been shown to be transiently inactivated during cell 
signalling and/or oxidative stress through the local production of ROS, indicating 
that PTPs are important sensors of the cellular redox state (46-48). For the proper 
termination of phosphotyrosine-based signals, the cell then relies on the reversal of 
inactivated PTPs into the active, reduced state but as an alternative strategy it might 
also attract unharmed, fully active PTPs from the surrounding to the site where ROS 
exerted their effect. The ability of PDZ3 in PTP-BL to ‘sense’ oxidising conditions, 
as witnessed by its enhanced afﬁnity for disulﬁde bond-containing cysteine-rich pep-
tide targets as compared to the reduced counterparts, make it tempting to speculate 
that PTP-BL recruitment is in part guided by its redox-sensor PDZ3 (Figure 1B).
 As pointed out in Chapter 3, the PDZ3 preference for binding to disulﬁde-
bridge containing CxxCV carboxyl terminal peptides is reminiscent of the noted 
enhanced afﬁnity of PSD-95 PDZ domain 1 for a cyclic peptide target relative to 
the linear version (49). Interestingly, the rigidity encountered within the structure 
of such cyclic peptides is resembling the ﬁxed positions of the four stretches of (H/
C)xx(H/C) that are surrounding the co-ordinately bound zinc ions within so-called 
LIM domains. LIM  (acronym of Lin-11, Isl-1 and Mec-3) domains are composed 
of two tandemly repeated zinc ﬁngers that pack together via a hydrophobic interface 
formed by conservatively substituted residues (for review see (50)), and LIM do-
main-containing proteins are involved in cellular functions ranging from neuronal 
pathﬁnding (51), cytoskeletal organization (52), to cell adhesion and signalling (53). 
PTP-BL PDZ domains interact with the LIM domain-containing proteins CRIP2, 
TRIP6 and RIL (54-56). In the case of RIL, binding to PTP-BL is mediated by its 
C-terminal tail, although binding is greatly enhanced when the RIL LIM domain is 
present (Chapter 4). Interestingly, binding to TRIP6 and CRIP2 is directly dependent 
on the presence of their LIM domains and, for some combinations, apparently inde-
pendent of the C-terminal tail. In view of the above, this non-canonical afﬁnity of 
PTP-BL PDZ domains for LIM domain structures may thus perhaps be explained by 
the ‘cyclic appearance’ of the CxxC/H sequences within the LIM domain core. Such 
an explanation is in line with the notion that non-canonical PDZ targets should by-
pass the requirement for a carboxylate tail through either deforming the PDZ binding 
pocket, as witnessed for the Par-6 Pals1 interaction (57), or through adopting a con-
formation that enables ﬁtting into the PDZ binding pocket, i.e. the sharp β-hairpin 
turn as in the nNOS – syntrophin complex (58) or in disulﬁde-containing ligands 
(59). 
Regulation of the cell cycle
As mentioned in the beginning of this concluding chapter, PTP-BL is engaged in 
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several protein-protein interactions that suggest a role in remodelling the cytoskele-
ton. PTP-BL interacts with the Rho GTPase-activating protein PARG1 (13) and with 
the Rho-dependent kinase PRK2 (12). This directly links PTP-BL to Rho GTPase 
signalling, the paradigm pathway for actin cytoskeleton remodelling (for reviews see 
(60,61)). Furthermore, in interphase cells PTP-BL and several of its target proteins 
display a cellular distribution that partly coincides with that of the actin cytoskeleton 
(42,54,62). In mitotic HeLa cells, however, PTP-BL is ﬁrst found at the centrosomes, 
it then accumulates at the spindle midzone, and ﬁnally it localises to the midbody 
during cytokinesis (14). Overexpression of active as well as enzymatically inactive 
PTP-BL leads to cytokinesis defects and multinucleated cells, suggesting a role for 
PTP-BL in the regulation of cytokinesis for which its phosphatase activity is not 
required (14). In agreement, mice lacking the PTP-BL tyrosine phosphatase activity 
but have retained the anchoring and scaffolding capacities, are viable and fertile and 
do not present observable morphological alterations (63).Thus PTP-BL’s role as a 
scaffolding and anchoring protein may be dominant over its role as a phosphatase.
 As yet the molecular basis for the PTP-BL-induced cytokinesis block re-
mains unclear. Two PTP-BL interacting proteins have been shown to be involved in 
cell cycle regulation; the tumour suppressors APC and Lats2 (Figure 1C). Overex-
pression of either APC or Lats2 results in the inhibition of the G1 to S phase transi-
tion (64,65), although Lats2 may also inhibit G2/M progression (66). Interestingly, 
an APC mutant that lacked the TSVCOOH PDZ domain target motif exhibited a weak-
er cell cycle blocking activity relative to the wild type protein, suggesting APC-PDZ 
complex formation to be relevant for APC-mediated cell cycle control (67). Like-
wise, in this thesis also a mild reduction in cell cycle inhibition at the G1/S transition 
was noted upon removal of the carboxyl terminal tripeptide of Lats2 (Chapter 5). 
These ﬁndings point to the critical involvement of PDZ domain-containing proteins 
in the orchestration of cell cycle regulatory complexes, and PTP-BL might represent 
one of those scaffolding proteins. A contribution as a phosphotyrosine phosphatase 
to APC- and Lats2-mediated cell cycle control, however, appears unlikely since a 
phosphatase-dead PTP-BL mutant still could block cytokinesis (14). Furthermore, 
although the PDZ target sequence in the Lats2 C-terminal tail is phosphorylated on 
tyrosine-1041 in cells (thereby inﬂuencing PTP-BL PDZ4 binding) and serves as a 
substrate for the PTP-BL phosphatase, the use of an Y1041F mutant demonstrated 
that inhibition of cell division does not require Lats2 phosphorylation (Chapter 5). It 
would be interesting to see how a phosphotyrosine-1041 mimicking mutant would 
perform in such assays. As of yet, the data are in line with a role for PTP-BL, in con-
cert with APC and Lats2, in the regulation of cell cycle progression (Figure 1C) but 
how this is exerted remains the topic of further research.
In conclusion, the many protein interaction building blocks within the large nucleo-
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cytoplasmic protein tyrosine phosphatase PTP-BL underscore its potential as scaf-
folding or anchoring protein. Its enzymatic function, therefore, is conﬁned to the 
surroundings of the large multimeric protein complexes it makes part of. The gather-
ing of knowledge on the repertoire of protein machines in which PTP-BL’s actions 
are exploited thus form the basis for understanding its physiological role. The stud-
ies presented in this thesis have added to the collection of interactions that PTP-BL 
PDZ domains are capable of. Furthermore, regulatory principles that govern these 
PDZ-mediated interactions have emerged. Based on these ﬁndings, three putative 
functions for PTP-BL were proposed that may serve in directing future experiments 
aimed at the understanding of the anchoring, scaffolding and signalling role of this 
multifaceted protein. 
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Cellulaire processen worden veelal uitgevoerd en gereguleerd door grote eiwitcom-
plexen en een juiste assemblage van dergelijke eiwitmachines is dus van groot be-
lang voor een goed verloop van de levensprocessen in de cel. De eiwit-eiwit associ-
aties die de vorming van dergelijke eiwitcomplexen mogelijk moeten maken worden 
gemedieerd door gespecialiseerde eiwit-interactie-domeinen, de zogenaamde PDZ 
domeinen zijn hier een goed voorbeeld van. De letters PDZ staan voor de eerste 
drie eiwitten waarin deze ongeveer negentig aminozuren grote, globulaire eiwitdo-
meinen werden geidentiﬁceerd: PSD95, Discs-Large A, en ZO-1. PDZ domeinen 
herkennen en binden, op een sequentie-speciﬁeke wijze, de carboxyl-terminale (C-
terminale) uiteinden van de interacterende eiwitten, waarbij met name het laatste en 
het twee-na-laatste aminozuur-residu van belang zijn. Er zijn echter ook voorbeel-
den van PDZ domeinen die interne peptidevolgordes in eiwitten herkennen. Het 
signaal-transductie-eiwit PTP-BL, de grootste cytosolische fosfotyrosine-speciﬁeke 
fosfatase, bevat maar liefst vijf van deze PDZ domeinen. In dit proefschrift heeft de 
nadruk gelegen op de PDZ-gemedieerde interactiemogelijkheden voor PTP-BL, om 
zo meer te weten te komen over de biologische functie van deze fosfatase. 
Om inzicht te krijgen in de interactiemogelijkheden van de vijf PDZ domeinen in 
PTP-BL werd de bindingsvoorkeur voor elk van de domeinen afzonderlijk bepaald 
(Hoofdstuk 2). Het bleek dat PDZ1 een zeer speciﬁeke voorkeur heeft voor pepti-
den die eindigen op [S/T]WVCOOH. Daarentegen lieten zowel PDZ2 als PDZ4 zien 
dat zij in staat zijn een grote verscheidenheid aan peptiden te binden, hetgeen ge-
staafd wordt door het grote aantal interactie-partners dat voor deze PDZ domeinen is 
beschreven. Additionele experimenten lieten zien dat de bindingspromiscuiteit van 
PDZ2 sterk wordt ingeperkt door aanwezigheid van het eerste PDZ domein. PDZ1 
blijkt namelijk, door aan de achterzijde van PDZ2 te binden, diens aan de voorzijde 
gelegen peptide-bindingsgroeve te kunnen verbuigen en zodoende de PDZ2 bin-
dingsvoorkeur te modiﬁceren. Voor het vijfde PDZ domein van PTP-BL konden 
geen interacterende peptiden gevonden worden, hetgeen suggereert dat PDZ5 een 
andere functie heeft dan het binden aan C-terminale targets. 
 In Hoofdstuk 3 wordt de bindingsvoorkeur van het derde PDZ domein van 
PTP-BL voor cysteine-bevattende C-terminale peptiden beschreven. Interessant ge-
noeg, wordt deze afﬁniteit negatief beinvloedt door de reducerende stof DTT, wat 
impliceert dat de interactie afhankelijk is van disulﬁde brug vorming. Mutatie van 
het enige cysteine residu in PDZ3 zelf bleek hierop geen invloed te hebben, en de 
van belang zijnde disulﬁde bruggen zullen dus in het target peptide gelegen zijn. Dit 
impliceert dat PTP-BL PDZ3’s voorkeur voor disulﬁde brug-bevattende C-terminale 
targets een redox-gereguleerde rol voor PTP-BL in cellen mogelijk maakt.
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 In Hoofdstuk 4 wordt de interactie tussen PTP-BL en RIL in detail beschre-
ven. Experimenten in gist hadden laten zien dat het LIM eiwitinteractiedomein in 
RIL belangrijk was voor de binding aan de PTP-BL PDZ domeinen 2 en 4. Door 
nu experimenten in zoogdiercellen uit te voeren bleek dat de RIL C-terminus alleen 
voldoende is voor een zwakke interactie met PDZ domeinen van PTP-BL. Deze in-
teractie werd enorm versterkt door de aanwezigheid van het RIL LIM domein. NMR 
experimenten en mutagenese studies lieten zien dat het LIM domein niet direct bindt 
aan de PTP-BL PDZ domeinen, waardoor het vooralsnog onduidelijk blijft hoe pre-
cies het RIL LIM domein  de complex-vorming stimuleert. 
 In Hoofdstuk 5 wordt de identiﬁcatie van het Lats2 eiwit, een serine/threo-
nine kinase, als een nieuwe bindingspartner van PTP-BL beschreven. Voor deze in-
teractie zijn de laatste drie aminozuren (-VYVCOOH) van Lats2 en het vierde PDZ 
domein van PTP-BL noodzakelijk. De binding van PTP-BL aan Lats2 wordt geregu-
leerd door reversibele fosforylering van het tyrosine (Y1041) residu in de Lats2 C-
terminus. Doordat PTP-BL dit residu kan defosforyleren heeft het de mogelijkheid 
zijn eigen binding aan de Lats2 C-terminus te reguleren. Dit wordt ook weerspiegeld 
in de associatie-afhankelijke co-localisatie van beide eiwitten in getransfecteerde 
HeLa cellen. Overexpressie van Lats2 in HeLa cellen resulteert in een blokkade van 
de overgang van G1 naar S fase. Het gebruik van een Lats2 Y1041F mutant laat zien 
dat deze cel cyclus blokkade onafhankelijk is van tyrosine fosforylering op deze 
plaats. Interessant genoeg worden minder cellen geblokkeerd in de overgang van G1 
naar S fase wanneer de C-terminale PDZ bindingsplek in Lats2 verwijderd wordt. 
Deze data suggereren dat PTP-BL en Lats2 een gezamelijke functie in de regulatie 
van de cel cyclus hebben.
 In Hoofdstuk 6, tenslotte, wordt alle informatie met betrekking tot PTP-BL 
en haar moleculaire omgeving die vergaard is tijdens deze onderzoeksperiode, ge-
plaatst naast reeds bekende gegevens. Op grond hiervan kunnen drie nieuwe sugges-
ties voor mogelijk functies van PTP-BL worden gegeven. De voorkeur van PTP-BL 
PDZ1 voor eiwitten eindigend op [S/T]WVCOOH wijst in de richting van de cateni-
ne/cadherine-gebaseerde signaaltransductie bij cel-cel interacties. De afﬁniteit van 
PDZ3 voor disulﬁdebrug-bevattende targets maakt het mogelijk dat de localisatie en 
dus de signaaltransducerende rol van PTP-BL wordt gestuurd middels locale redox 
condities. En tenslotte kan deze grote fosfotyrosine-speciﬁeke fosfatase door de fos-
forylerings-gevoelige associatie met de tumor suppressor Lats2 een rol spelen bij de 
regulatie van de cel cyclus. 
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Dankwoord
Dit is waarschijnlijk één van de kortere hoofdstukken uit mijn boekje maar zeker 
niet het minst belangrijke. Ondanks dat interne motivatie en doorzettingsvermogen 
een belangrijke eigenschap is waarover elke promovendus, naar mijn idee, moet 
beschikken, is de steun van mensen om hen heen onmisbaar. Daarom wil ik in dit 
hoofdstuk stilstaan bij de mensen die met mij deze leuke, frustrerende, gezellige, 
frustrerende, schitterende periode gedeeld hebben. 
Op de eerste plaats mijn familie natuurlijk, zonder hen was ik nooit zover gekomen. 
Pap, mam jullie zijn fantastische ouders. Ik ben blij dat jullie me naar de grote stad 
hebben laten gaan, al kostte dat ons allebei in het begin wat moeite. Bedankt dat 
jullie mij alle kansen gegeven hebben om te doen wat ik wil. Jullie hebben ons alle 
drie geweldig opgevoed, ik had het niet beter kunnen treffen! Ing, zus, we hebben 
soms wel eens ruzie maar toch geef ik veel om je. Je hebt al een tijdje je eigen kap-
perszaak en dat je kapster bent is wel eens terug te zien aan de kleur van mijn haar 
:). Zus, ik ben trots op je! René, rinus, kleintje, broertje, je bent een prachtkerel! Je 
staat niet alleen voor mij altijd klaar maar voor iedereen en dat vind ik geweldig. Net 
afgestudeerd, klaar voor het werkende leven. En voor de goede orde, ik denk wel dat 
jij ‘normaal’ denkt, denk ik :). Opa Wintelre en Oma Casteren, ik hoop echt dat jullie 
deze mooie dag nog mee mogen maken. Oma Wintelre en Opa Casteren, ondanks 
dat jullie er niet meer bij kunnen zijn, zijn jullie altijd in mijn gedachten! 
Op de tweede plaats wil ik Bé en Wiljan bedanken dat ik op hun afdeling mijn 
promotie onderzoek heb mogen doen. De zesde verdieping is zeker één van de ge-
zelligste afdelingen van de hele toren (we hebben er niet voor niets een prijs voor 
gewonnen), en ik denk dat jullie daar als hoofd een terechte pluim voor verdienen. 
Wiljan, jou wil ik in het bijzonder bedanken voor je onuitputtende energie in het 
aandragen van nieuwe experimenten en met name de oneindige lijst van controles 
:). Ik heb heel veel van je geleerd en daar zal ik in mijn verdere carrière altijd proﬁjt 
van hebben, bedankt daarvoor! Geerten, bedankt dat je mijn co-promoter wilt zijn, 
en met name bedankt voor het doornemen van dit proefschrift en het opbouwende 
commentaar daarbij.
Al met al waren vier jaren waarin ik zelf een enorme ontwikkeling doorgemaakt 
heb, zowel op wetenschappelijk als op persoonlijk gebied. Ik weet nog goed dat ik 
na een maand bij Wiljan (mijn begeleider) op gesprek moest komen omdat hij met 
mij over mijn bescheidenheid wilde praten. Volgens hem moest ik wat meer van me 
laten horen en niet over me heen laten lopen. Ik dacht toen al: “van deze woorden 
krijg je spijt, Wiljan”. Ik ben namelijk iemand die graag de kat uit de boom kijkt en 
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mensen observeert. Pas als ik mijn plekkie in de groep gevonden heb, laat ik van 
me horen. En geloof me, ik heb van me laten horen :). Gönül en ik hebben soms 
ﬂink wat herrie lopen maken. Ik denk dat het soms voor onze labgenoten erg zware 
tijden waren. Dat bleek wel toen Marloes de keuze kreeg om naar een ander U-tje 
te verhuizen. Binnen welgeteld één ochtend was ze helemaal overgehuisd en liet ze 
mij alleen achter :(. 
Om maar even bij de mensen van de zesde verdieping te blijven, wil ik iedereen 
daar bedanken voor de waanzinnige tijd die ik daar gehad heb. We begonnen nog 
in het Trigon en mijn eerste actie was het overhuizen naar de Research Toren. Daar 
bleek dat we samen gingen wonen met Moleculaire Dierfysiologie, één van de af-
delingen waar ik stage heb gelopen. Het was een leuk weerzien!! Ik vind het briljant 
om te zien dat niemand op de zesde te beroerd is om zijn steentje bij te dragen aan 
de gezellige sfeer en dat we bijna iedereen zover kregen om even gezellig mee te 
borrelen. IEDEREEN VAN DE ZESDE VERDIEPING BEDANKT! Natuurlijk zijn 
er altijd wat mensen die wat bijzondere aandacht verdienen, dus hier komen ze dan 
in willekeurige volgorde. Jan S, je was mijn BL-maatje. We hebben allebei zitten 
zwoegen aan dat enorm grote (piep)eiwit, dat vaak niet deed wat wij wilden. Ik ben 
erg blij dat je mij bijgestaan hebt op het experimentele vlak toen mijn tijd er ofﬁcieel 
op zat. Ik hoop dat we er nog een mooie publicatie uit kunnen slepen. Yvetje kro-
ketje, alias dipsaus, je bent een geweldig mens, don’t ever change. Je enthousiasme 
en optimisme zijn echt besmettelijk, geweldig. Jij bent mijn super-AIO ;). Marloes, 
jij bent waarschijnlijk de meest nuchtere persoon op het lab, maar toch zie ik dat 
je erg kunt genieten van de grappen en grollen die uitgehaald worden. Bedankt dat 
je mijn secretaresse bent geweest in onze U en heel veel succes met jouw laatste 
loodjes!! Suus, eerst analist nu AIO, super!! Ik vind het geweldig om te zien dat je 
altijd dingen roept zonder eerst even na te denken. Wat hebben wij daarom vaak in 
een deuk gelegen. Meisje met een grote mond maar een klein hartje, bedankt voor 
een hele toffe tijd!! En ik hoop vandaag 50 liter bier van je te winnen (maar die zul-
len we samen opdrinken)!! Jan K, petit Jean, altijd relaxed nooit stress. Jan the man, 
bedankt voor de leuke discussies en de begeleidende biertjes. Volgens mij kan je jou 
daarvoor zelfs wakker maken :). Ook heel veel succes met jouw laatste loodjes, en 
ik kom je zeker opzoeken in Australië, maar gelukkig hebben we ook nog altijd msn. 
Bas, de stille jongen, tenminste dat lijkt zo. Zorg ervoor dat er regelmatig een goede 
grap uitgehaald wordt hè, jij krijgt toch nooit de schuld. Rinske, we wachten nog 
steeds op een buikdansshowtje van jou :) misschien een idee voor een stukje op mijn 
promotiefeest? Mietske, toch nog een leuke foto van jou kunnen maken, zoek maar 
op de kaft, hij staat ertussen. Rinske en Mietske, allebei bedankt voor de leuke tijd 
en ik hoop jullie nog vaak te zien op de zesde verdieping. Huipie, jij bent echt uniek, 
en dat bedoel ik positief ;). Je staat altijd klaar voor jan en alleman en dat waardeer 
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ik enorm. Ik zal nog vaak bij je langskomen voor advies want nu doe ik werk wat 
precies in jouw straatje ligt. Dus je bent nog niet van me af!! Trouwens, wanneer ga 
je voor ons die rijsttafel koken? Ad, bedankt dat ik een weekje bij jou in New York 
City heb mogen logeren, ondanks dat we elkaar toen nog niet zo heel goed kenden. 
Ik heb me de hele week uitstekend vermaakt, en mocht je nog een keer naar het bui-
tenland vertrekken dan kom ik je zeker weer opzoeken ;). Edje, hopelijk gaan we nog 
een keertje apfelkorntjes drinken en wie weet, misschien ga je nog wel eens met ons 
mee naar de Skihut!! Frank Oe, bedankt voor alle gezelligheid, je bent samen met 
Huipie onze tweede papa! De X-ma’s (Wilma en Helma), jullie bedankt voor de lek-
kere dingen in de TOKO. Rick, bedankt voor de adviezen tijdens mijn AIO-periode. 
Walther, de volgende keer dat je weer in een toneelstuk meespeelt moet je het laten 
weten, dan kom ik zeker weer kijken. Ralph, houdt je laptop goed in de gaten, want 
een AIO kan niet zonder. Ineke, je laat ons altijd zien wat de nieuwste modetrends 
zijn op kledinggebied, geweldig! Mary en Magda, bedankt dat jullie het secretariaat 
zo goed draaiende houden. Jack, vrijdagmiddag om vijf uur een biertje houden we 
erin! 
Dan zijn er nog mensen die de zesde verdieping inmiddels hebben verlaten. Renaa-
tje, onze eerste ontmoeting eindigde met een biertje en dat is een traditie die gelukkig 
nog altijd voortduurt. Ik ben blij dat je voor de baan in Nijmegen gekozen hebt, zo 
blijven we elkaar nog regelmatig zien. Marco, mijn ex-overbuurman, altijd de gezel-
ligste en gekste op het lab. Bedankt dat wij in vergelijking met jou zo normaal leken 
;), grapje. We komen zeker één keer per jaar logeren bij Chez Marco in Rotterdam 
om te huppelen op de Dance Parade!! Rene, samen gestudeerd, samen AIO! Heel 
veel succes met het afronden van je boekje. Marianne en Marjon, naast Marloes de 
twee LAR dames binnen het PTP-groepje. Bedankt voor de leuke tijd! Lottie, wij 
zijn tegelijkertijd begonnen bij Celbiologie. Bedankt voor de gezellige tijd, zowel op 
het lab als met carnaval in Cuijk! Mijn studenten Jaap, Mariska (zij werkt inmiddels 
weer bij Celbiologie) en Etelka. Bedankt dat jullie mee hebben gezwoegd op mijn 
onderwerp! Jorrit, ik zal het eerlijk toegeven, je wint sporadisch wel eens ooit van 
mij met squash, al komt het nauwelijks voor :). 
Tijdens mijn AIO periode heb ik met twee groepen samengewerkt. Als eerste de 
groep van Geerten (Biofysische Chemie, RUN). Tine, jij was met mij AIO op een ge-
zamenlijk project en bent inmiddels al gepromoveerd. Bedankt voor de leuke samen-
werking. Jan A, bedankt voor de assistentie tijdens sommige proeven. Je bent de ei-
witexpert en ik heb veel van je geleerd. Verder hebben we een tweede samenwerking 
met een groep in Italië opgestart tijdens mijn AIO periode. Luciana ed Elena, grazie 
per tutto l’aiuto durante questo progetto. Sono molto felice di avervi incontrato a 
Pisa, fu una giornata molto piacevole. Spero di rivedervi in Olanda nel giorno della 
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discussione del mio dottorato e di rimanere in contatto con voi anche in futuro!
Tijdens mijn AIO periode heb ik ook veel hulp gehad van mensen van andere af-
delingen. Will, ik wil jou bedanken voor al je hulp met de BIAcore! Piet en Diana, 
jullie bedankt voor alle hulp met mijn en Jan’s FACS experimenten. 
Ad en Gerard, bedankt dat ik op jullie afdelingen stage heb mogen lopen. Het zijn 
twee hele gezellige afdelingen, waar ik met veel plezier gewerkt heb. Ook wil ik de 
begeleiders tijdens deze stages bedanken. Franci, José en Nuno BEDANKT. Helma, 
jij hebt me ook veel geholpen tijdens mijn stage en ik ben daarom heel blij dat jij in 
mijn corona plaats wilt nemen tijdens de verdediging van mijn proefschrift!
Inmiddels ben ik een verdieping afgezakt en werk ik op de vijfde verdieping bij het 
TIL (Tumor Immunologie Lab). Gelukkig is het op de vijfde (bijna) net zo gezellig 
als op de zesde verdieping! Kim en Tonnie jullie zijn twee knotsgekke analisten. 
Bedankt dat jullie me de kneepjes van het nieuwe werk leren, want voor mij is al-
les nieuw! Els, jij bent echt zo gek als een deur. We passen samen perfect in onze 
nieuwe U! Bellinda, de oudste en wijste :). Ruurd, alles op de “ruurdian way” heb ik 
al geleerd. Alessandra en Ben, toen ik nog bij Celbiologie werkte deelden we samen 
al een U-tje. Alessandra, ik denk serieus dat jij het voorbeeld bent voor iedere AIO. 
Bedankt voor de italiaanse vertaling in dit hoofdstuk. Ben, eerst middelbare school, 
toen dezelfde U en nu zelfs collega’s. It’s a small world! Verder kende ik sommige 
mensen van het TIL al van de gezellige squashavondjes of van het gezamenlijke 
kerstdiner ;) (Carl, Frank W, 10-us, Ben, Erik, Hans, Mathijs …). Frank de L, be-
dankt voor je hulp bij de analyses van mijn cel-transfectie experimenten. 
Lilian en Eveline, jullie weten niet wat jullie missen! AIO zijn is geweldig! Samen 
met mij begonnen aan de studie Biologie, maar na een jaar toch maar wat anders 
gaan doen. Bedankt voor de leuke spelletjes tijdens saaie college’s en lol tijdens de 
vele feesten die we afgestruind hebben. Laura, jij hebt het wel afgemaakt en promo-
veert ook dit jaar, toppie! Gerly, iemand die ik via via ken, maar die ik nu beschouw 
als één van mijn beste vriendinnen. Samen reizen we Europa door, stad voor stad. 
Bedankt dat je er altijd voor me bent!
Maaike, van alle mensen ken ik jou waarschijnlijkst het langst (buiten mijn familie 
om natuurlijk). Allebei in Wintelré geboren en getogen, maar daarna allebei weg-
gevlogen uit dat ‘gat’. Samen hebben we op de basischool en middelbare school 
gezeten. Uit dwang vriendinnen omdat dat handig was voor onze ouders met bren-
gen en halen tijdens schoolfeesten. Maar ondertussen ben je echt één van mijn beste 
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vriendinnen geworden. Je woont inmiddels al weer een paar jaar in Amerika en ik zie 
je dus maar zelden, maar ik kijk er altijd naar uit als je weer naar Nederland komt. 
Nu ik dit dankwoord aan het schrijven ben zit je beneden op de bank omdat je voor 3 
maanden in Nederland bent en toevallig werk hebt gevonden in Nijmegen. Ondanks 
dat ik soms zeur, vind ik het wel gezellig dat ik je nu een aantal weken kan zien :). 
Forever friends!
Waldo en Marco, jullie ken ik nog van “vroeger” toen ik net begon met squash. Sa-
men met Suzanne hebben we uren op de baan gestaan. Ben blij dat we nu weer veel 
contact hebben en we gaan nog veel leuke dingen doen samen!
Godfried, ik heb je leren kennen tijdens mijn AIO periode en daar ben ik erg blij om. 
Elke week gaan we braaf zwemmen om uiteindelijk dat topﬁtte lichaam te krijgen. 
Gaat dat nog ooit lukken, denk je? 
Gerrit, mijn huppel-maatje. Bedankt voor alle leuke herinneringen. We houden zeker 
contact!!
Marshal, jij hebt me geleerd om blij te zijn met de kleine dingen in het leven! Mi 
bosie.
Marc, je bent echt een schat! Squash, computers, je eigen promotie, je kunt het alle-
maal, de ideale man ;). Je staat altijd voor me klaar en daarvoor kan ik je niet genoeg 
bedanken. 
Danny, motormuis, stoere vent met een klein hartje. Soms ben je lief en soms ben je 
een eikel, kortom een echte man ;). Maar wil even zeggen dat ik je leuk vind :). En 
het geeft niet dat vrouwen meer dingen tegelijkertijd kunnen dan mannen, lol.
Als laatste wil ik mijn paranimfen, Gönül en Femke, bedanken. Aan allebei zou 
ik een heel apart hoofdstuk kunnen wijden, maar ik zal me proberen in te houden. 
Gönül, jij bent mijn maatje, mijn vertrouwenspersoon, mijn vriendinnetje. Ik ben 
zooo blij dat ik jou heb leren kennen. Samen AIO bij Wiljan, en gedeelte smart is in 
ons geval zeer zeker halve smart. We hebben elkaar door de laatste periode heenge-
sleept en eigenlijk ging het daardoor vanzelf. Ondanks dat we zowat in alles elkaars 
tegenpolen zijn, passen we verrassend goed bij elkaar. Ik kan niet in woorden uit-
drukken wat jij voor mij betekend, maar ik denk dat dat ook niet nodig is, je begrijpt 
wat ik bedoel. Bedankt voor de toffe tijd samen op het lab en ik ben blij dat we een 
vriendschap voor het leven opgebouwd hebben!! Femke, wijﬁe, wij zijn normaal 
niet zo klefferig, maar nu ga ik een uitzondering maken :). Je bent een ontzettende 
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geweldige en vooral unieke vriendin, kortom je bent een topwijf! Ik kan altijd met 
je lachen en we zijn vooral goed in het doen van hele stomme dingen, vooral als we 
wat gedronken hebben. Je weet wat je wilt en je gaat ervoor, al is het soms niet via 
de kortste weg ;) (speciale uitleg voor jou: ;) dit betekent een knipoog, hahahah). 
Samen gaan we wel eens toeren op de motor, stoere chickies, behalve als het regent! 
Bedankt dat je me zo goed geholpen hebt met alles, ik zal je aanbevelen bij andere 
AIOs als zijnde de perfecte paranimf. Tot slot: Eindhoven, de gekste!!! Paranimfjes, 
ik ben blij dat jullie naast me willen staan op de grote dag, en we drinken er een lek-
ker rivellaatje light en een biertje op!! Me luv you both very much!
Nu ik het dankwoord helemaal geschreven heb, blijkt dat het niet eens zo’n kort 
hoofdstuk geworden is, haha. Blijkbaar heb ik veel om dankbaar voor te zijn. Mijn 
AIO periode zit erop, eindelijk tijd om serieus te worden.... Iedereen bedankt voor 
een schitterende periode, ondanks alle frustraties heb ik er nooit een seconde spijt 
van gehad! 
It’s time to move on, time to get going 
What lies ahead I have no way of knowing 
But under my feet, baby, grass is growing 
It’s time to move on, it’s time to get going
Tom Petty – Time to move on
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Curriculum Vitae
De schrijfster van dit proefschrift werd geboren op 22 juli 1978 te Wintelré. In 1996 
behaalde zij het VWO diploma aan het Anton van Duinkerken College te Veldhoven, 
waarna zij aan de studie Medische Biologie aan de katholieke Universiteit Nijme-
gen begon. Na de propedeuse (1997) liep zij tijdens de doctoraal fase stages bij 
de vakgroep Moleculaire Dierfysiologie (Prof. dr. Gerard Martens) van de Katho-
lieke Universiteit Nijmegen en de vakgroep Antropogenetica (Prof. dr. Ad Geurts 
van Kessel) van het UMC St. Radboud te Nijmegen. In oktober 2000 ontving ze 
haar doctorale bul. In september 2000 trad zij in dienst als junior onderzoeker bij de 
afdeling Celbiologie (Prof. dr. Be Wieringa), Faculteit der Medische Wetenschappen 
van de Radboud Universiteit Nijmegen onder begeleiding van Dr. Wiljan Hendriks. 
Het onderzoek verricht op deze afdeling staat beschreven in dit proefschrift. Vanaf 
juni 2005 is zij als post-doctoraal medewerker werkzaam bij de afdeling Tumorim-
munologie (Prof. dr. C. Figdor) van het UMC St. Radboud te Nijmegen, alwaar zij 
onderzoek verricht naar de differentiatie van postnatale stamcellen. 
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